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Abstract 
S-phase kinase-associated protein 2 (SKP2) is the substrate recognition subunit 
of the SCF E3 ubiquitin ligase complex which monitors the G1/S transition of the 
cell cycle. SKP2 is a positive regulator of cell cycle progression targeting tumour 
suppressor proteins for degradation, primarily the cyclin-dependent kinase 
inhibitor p27KIP1. An oncogenic protein, SKP2 is frequently overexpressed in 
human cancers and contributes to malignant progression. SKP2 has previously 
been identified as a possible MYCN target gene in neuroblastoma and based on 
these reports it is hypothesised that SKP2 is a potential therapeutic target in 
MYCN amplified disease.  
In this study a positive correlation between MYCN expression and SKP2 mRNA 
expression was shown in the SHEP-Tet21N MYCN-regulatable cell line and in a 
panel of MYCN amplified and non-amplified neuroblastoma cell lines. In 
chromatin immunoprecipitation and reporter gene assays, MYCN bound directly 
to E-box DNA binding motifs within the SKP2 promoter, and induced 
transcriptional activity which was decreased by the removal of MYCN and 
mutation of the E-boxes.  
SKP2 knockdown induced cell cycle arrest and apoptosis in non-MYCN amplified 
neuroblastoma cell lines independent of the p53 pathway. The G1 arrest induced 
was rescued in-part by the knockdown of p27KIP1 confirming the importance of the 
SKP2/p27 axis in cell cycle progression in neuroblastoma.  
Structure-activity relationship analysis identified a sub-set of putative SKP2 
inhibitors which inhibited growth and suppressed SKP2-mediated p27 
degradation in HeLa cells. Additionally, treatment of the MYCN regulatable 
SHEP-Tet21N cell line with commercially available direct or indirect modulators 
of SKP2 activity identified a MYCN-dependent sensitivity.   
In conclusion these data show that SKP2 is a direct transcriptional target of 
MYCN and suggests that SKP2 is a potential therapeutic target in neuroblastoma.   
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NY New York 
ODC1 Ornithine decarboxylase 1 
ONPG Orhto-Nitrophenyl-β-galactosidase 
ORC1 Origin recognition complex subunit 1 
PAX3 Paired box 3 
PBS Phosphate buffered saline 
PC Polyclonal 
PCR Polymerase chain reaction 
PHOX2a/b Paired mesoderm homeobox protein 2a/b 
PI Propidium Iodide 
PI3K Phosphoinositide 3-kinase 
PPM1D Protein phosphatase Mg2+/Mn2+ dependent 1D 
pRB Retinoblastoma protein 
Pre-RC Pre-replication complex 
pTEF-β Positive transcription elongation factor 
PTEN Phosphatase and Tensin Homolog 
PTPN11 Protein tyrosine phosphatase non-receptor type 11 
PUMA p53 upregulated modulator of apoptosis  
qRT-PCR Real-time PCR 
RARα Retinoic acid receptor α 
RAG2 Recombination activating gene 2 
RBX1 RING-box protein 1 
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RhoA Rho-associated protein kinase 
RING Really Interesting New Gene 
RISC RNA-induced silencing complex 
RLT RNesy Lysis buffer 
Rn Reaction 
RNA Ribonucleic Acid 
ROX Passive reference dye for Taqman® qRT-PCR 
RPE RNesy buffer for washing membrane bound RNA 
RT-PCR Reverase transcription PCR 
RUNX3 Runt-related transcription factor 3 
RW1 RNesy buffer for washing membrane bound RNA 
SAGE Serial analysis of gene expression 
SCA Segmental chromosome alterations 
SCF Skp1-Cul1-F box protein 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-Polyacrylamide gel electrophoresis 
SEM Standard error of mean 
Ser Serine 
shRNA Small hairpin RNA 
siRNA Small interfering RNA 
SIRT3 Sirtuin-3 
SKP1 S-phase Kinase-associated protein 1 
SKP2 S-phase Kinase-associated protein 2 
SN Sense strand 
SOX9/10 SRY (sex determining region Y)-box 10 
SRB Sulforhodamine B 
SSC Side scatter 
STAT3 Signal Transducer and Activator of Transcription 3 
S-Type Substrate adherent (neuroblastoma cell type) 
TAD Transactivation domain 
TAMRA Tetramethylrhodamine  
TBI Total body irradiation 
TBP TATA-binding protein 
TBST Tris-buffered saline and Tween 20 
TCA Trichloroacetic acid 
TET Tetracycline 
TetR Tetracycline repressor 
TetO Tetracycline operator sequences 
TGF Transforming growth factor  
Thr Threonine 
THZ1 Covalent inhibitor of CDK7  
TIE TGF-β inhibitory site 
TIP60 Tat-interactive protein-60 
TOB1 Transducer of ERBB2, 1 
TP53INP1 Tumour protein p53-inducible nuclear protein 1 
TRE Tetracycline response element 
TrkA Tryosine Kinase receptor A (neurotrophic) 
TRRAP Transformation/transcription domain-associated protein 
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Tta Transcriptional activator 
UbcH5c Ubiquitin conjugating enzyme E2 D3 (Human) 
UK United Kingdom 
UPS Ubiquitin proteasome system  
USA United States of America 
VLS Virtual ligand screening 
WAF1/CIP1 Wild-type activating fragment-1 
WEE1 WEE1 G2 checkpoint kinase 
WNT Wingless/integrated  
wt Wild type 
XTT 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-
5-carboxanilide 
  
Introduction 
 Neuroblastoma 
An embryonal tumour, neuroblastoma is the most common cancer in children less 
than 1 year, and accounts for 22% of all childhood cancer diagnosed at this age 
in the UK. Accounting for approximately 6% of all childhood malignancies 
diagnosed in patients younger than 15 years, i.e. ~95 cases annually 
(www.cancerresearchuk.org), it is responsible for a disproportional percentage of 
paediatric cancer deaths, i.e. ~15% all paediatric oncology deaths (Maris, 2010).  
Neuroblastoma is a neoplasm of the neural crest of the sympathoadrenal lineage 
(sympathetic nervous system), and as such has a wide variation of presentation 
(Figure 1.1). Often arising in the adrenal medulla, primary tumours are commonly 
found as mass lesions in the neck, chest, abdomen or pelvis. An extremely 
heterogeneous disease, the clinical presentation ranges from asymptomatic 
tumours which spontaneously regress without therapy, to extremely aggressive 
malignant tumours which are non-responsive to current intensive therapeutic 
options (Maris, 2010; Davidoff, 2012).  
Understanding the heterogeneity of neuroblastoma is of great interest, and 
although a number of key genetic and biological features have been identified, 
due to the complex nature of the disease it is proving difficult to identify which 
markers are of independent prognostic value and warrant additional investigation 
(Riley et al., 2004).  
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Figure 1.1 Clinical presentation of neuroblastoma (Maris, 2010). Originating 
from sympathetic nervous tissue, neuroblastoma typically presents in the adrenal 
medullar or paraspinal nerve tissue between the neck and pelvis. Common sites 
of disease include the neck, chest and pelvis with thoracic tumours capable of 
extending the neck to produce Horner’s syndrome. Over half of patients present 
with advanced disease with metastasis to distant sites such as cortical bone, 
bone marrow and liver.  
 Neural crest development of neuroblastoma 
Due to the frequency of tumours presenting in the paraspinal ganglia and adrenal 
medulla in the abdomen, neuroblastoma is identified as a tumour of 
sympathoadrenal lineage neural crest cells. The neural crest arises from the 
dorsal-most portion of the closing neural tube beneath the overlying ectoderm 
(Gilbert, 2000). During development of the neural crest multipotent progenitor 
cells are able to migrate and differentiate into a variety of lineages depending on 
regulation by intrinsic and extrinsic factors. Lineage studies have identified the 
sympathetic nervous system as arising from the trunk region of neural crest cells 
which, following the expression of PAX3, SOX9 and SOX10 transcription factors, 
undergo epithelial to mesenchymal transition (EMT) and migrate ventrally from 
the neural tube to the dorsal aorta. Here they are exposed to signals for Bone 
morphogenetic proteins (BMPs) which initiate the differentiation programme 
directing the cells to the sympathoadrenal lineage (Huber et al., 2002; Betters et 
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al., 2010). Following BMP expression, differentiation into sympathetic neurones 
is regulated by the transient expression of basic helix-loop-helix (B-HLH) 
transcription factors which include MASH1, HES1, MYCN, HIF1α and HuD, in 
addition to homeobox genes such as PHOX2A and PHOX2B, and the p53 
paralogue p73. The upregulation or amplification of some of these genes has 
been identified in aggressive neuroblastoma linking the molecular development 
of sympathetic neurones to that of neuroblastoma biology (Figure 1.2) 
(Nakagawara and Ohira, 2004). 
Although the precise mechanism of neuroblastoma development is still largely 
elusive, advancements in genomic analyses have mapped genetic abnormalities 
and gene expression changes in neuroblastoma to specific regions involved in 
neurone development and differentiation. An improved understanding of the 
development of normal sympathetic neurones has also allowed the transcript 
profiles of these differentially expressed genes to be determined, identifying 
important groups of genes which drive neuroblastoma development. The use of 
functional analysis can further define their biological characteristics, potentially 
identifying therapeutic targets (Nakagawara and Ohira, 2004).       
 
Figure 1.2 The differentiation pathway of sympathetic neurones 
(Nakagawara and Ohira, 2004). During formation of the neural tube the original 
ectoderm is organised into somite pairs either side of the forming neural tube, 
which will eventually provide cells for skin, muscle and skeletal formation, the 
externally positioned epidermis of the skin and the transient neural crest. Neural 
crest cells migrate in both a ventrolateral direction (between somites and neural 
tube), and dorsolateral direction (between somites and epidermis), during which 
they receive signals which initiate differentiation processes.   
Somite cells
Epidermis
Neural crest 
cells
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 Tumour cell biology 
Neuroblastoma belongs to the peripheral neuroblastic tumour subgroup of 
childhood solid tumours. Histologically mature tumours are comprised of two 
main cell populations, neuroblastic/ganglion cells and non-neuronal stromal cells, 
which include Schwann, perineurial and satellite cells (Figure 1.3). 
Schwann cells are derived from the neural crest and form a myelin sheath around 
axons of the peripheral nervous system to provide support and insulation (Gilbert, 
2000). Schwann cells in neuroblastoma are not considered to be neoplastic, and 
unlike the neuroblastic/ganglion cell population have a diploid DNA content and 
in mature variants of neuroblastoma cannot be distinguished from normal 
Schwann cells (Ambros et al., 1996). Consequently, alongside the grade of 
differentiation of the neuroblastic component and nuclear pathology i.e. the 
mitosis-karyorrhexis index, the number of Schwann cells is related to disease 
outcome and applied along with age at diagnosis as prognostic indicators used 
to assign treatment in subtypes of neuroblastoma (Shimada et al., 1984).       
 
Figure 1.3 Hematoxylin and eosin stain of neuroblastoma tumour cells with 
varying degrees of differentiation. a) Schwann cells (large arrow) and ganglion 
cells (small arrows) which are prominent in stroma-rich differentiated 
neuroblastoma. b) Undifferentiated neuroblastoma with densely packed small 
round blue cells and little cytoplasm or Schwannian stroma (Maris et al., 2007)   
 Cell type 
Consistent with its origins from the multi-potent neural crest cells, neuroblastoma 
cell lines have been categorised into three cell subtypes depending on their 
morphological and biological characteristics (Biedler et al., 1973); N-type 
(neuroblastic), S-type (substrate adherent) and the intermediate I-type (Table 
1.2). Each cell type can differentiate predictably along specific neural crest 
a) b) 
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lineages in response to particular morphogens, and are therefore useful models 
for understanding the cellular heterogeneity of neuroblastoma (Ross et al., 2003). 
Cell Type Description 
I-Type  Stem cells with morphological features of both N- and S-type 
 Prominent nuclei, like N-type but with more cytoplasm and 
occasional neurites 
 Attach equally well to substrate and other cells forming focal 
aggregates 
N-Type  Neuroblastic / immature neuroblasts with small refractile cell bodies 
 High nucleur-to-cytoplasmic ratio and short neurites 
 High saturation density which form cell aggregates 
 Present at various differentiation states 
S-Type  Schwannian precursors / non-neuronal 
 Large flattened cells with prominent oval nuclei, abundant 
cytoplasm and no neurites 
 Adhere tightly to substrate, form monolayers and have contact 
inhibition 
 May be tumour-derived in vitro but not in vivo  
  Table 1.1 Neuroblastoma cell line subtypes (Ross et al., 2003)  
 Genetic predisposition to neuroblastoma 
Accounting for 1-1.5% of cases, familial neuroblastoma is thought to follow an 
autosomal dominant pattern of inheritance arising from a germline mutation 
consistent with Knudsons two-hit hypothesis (Knudson and Strong, 1972). 
Familial neuroblastoma is diagnosed at an early age, and until recently the 
genetic aetiology of the disease was largely unknown.   
The paired-like homeobox 2B (PHOX2B) gene plays a vital role in the 
differentiation and development of the sympathoadrenal phenotype (Huber, 
2006). Mutations are often found in neuroblastoma cases associated with other 
disorders of neural crest-derived tissues such as congenital central 
hypoventilation syndrome and/or Hirschsprung disease (Mosse et al., 2004; 
Trochet et al., 2004), although somatic mutations of this gene are rare. Activating 
ALK mutations are found in the majority of familial cases and ~8% of sporadic 
neuroblastoma across all subtypes and risk groups (Maris, 2010), and the 
aggressive ALK(F1174L) variant has been described as a key driver in 
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neuroblastoma development from neural crest cells (Schulte et al., 2013a). A 
receptor tyrosine kinase, ALK is thought to participate in the regulation of 
neuronal differentiation (Iwahara et al., 1997) and is generally accepted as the 
main cause of familial susceptibility to neuroblastoma in healthy families (Mosse 
et al., 2008).  
 Genetics of sporadic neuroblastoma 
A number of genetic aberrations occur in sporadic cases of neuroblastoma, some 
of which influence disease severity. Genome wide association studies have 
shown enrichment of a common genetic variation at chromosomes 6p22 and 
2q35 as well as a copy-number variation at 1q21 with the development of 
neuroblastoma. However, individually, these variations are thought to have a 
relatively modest effect on susceptibility (Maris et al., 2008; Diskin et al., 2009; 
Pugh et al., 2013).  
 MYCN amplification    
A member of the MYC family of proto-oncogenes, MYCN maps to the short arm 
of chromosome 2p24 and is found to be amplified (˃10 copies per cell) in ~20% 
of primary tumours (Schwab et al., 1983). Corresponding with high MYCN protein 
levels, MYCN amplification contributes to neoplastic transformation (Schwab et 
al., 1985a) and is sufficient to drive neuroblastoma tumorigenesis in mice (Weiss 
et al., 1997).    
The most common focal genetic lesion in sporadic neuroblastoma, MYCN 
amplification strongly correlates with high-risk, advanced stage disease and is 
used as a genetic marker of poor prognosis and for treatment stratification 
(Brodeur et al., 1984). The biological significance of MYCN amplification is 
supported further by the poor outcome seen in otherwise favourable disease 
patients, e.g. those with localised tumours, supporting its central role in 
neuroblastoma tumour progression (Cohn et al., 1995).  
The amplification of MYCN is suggested to follow the episome model where the 
DNA segment is excised, circularised, and amplified by mutual recombination, to 
produce double minute chromosomes which can integrate into somatic 
chromosomes to form homogeneously staining regions (hsr) (Storlazzi et al., 
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2010). Amplification is often associated with other genetic abnormalities such as 
allelic loss of 1p or 17q gain (Bown, 2001), and fluorescence in situ hybridisation 
studies (FISH), have shown that 17q genetic material frequently flanks integration 
sites for MYCN, suggesting it is an area for preferential MYCN recombination 
(O'Neill et al., 2001).      
 
Figure 1.4 MYCN amplification as double minutes detected in a 
neuroblastoma tumours  by fluorescence in situ hybridisation (FISH). 
 Segmental chromosome alterations (SCA) 
A number of segmental chromosome alterations have been reported in 
neuroblastoma, with deletions thought to harbour tumour suppressor genes and 
gains harbouring putative oncogenes. Although these alterations have been 
shown to be of prognostic impact individually, multivariate analysis has identified 
combinations of genetic alterations which define specific clinical and prognostic 
characteristics independently of MYCN amplification (Schleiermacher et al., 
2011). Consequently these SCA genomic profiles are used for risk stratification, 
particularly in non-MYCN amplified disease (Schleiermacher et al., 2012) 
1.3.2.1. 1p deletion  
Deletions and chromosomal rearrangements of the short arm of chromosome 1 
are found in 25 - 35% of neuroblastoma and are associated with aggressive 
metastatic disease (Caron et al., 1996). The most common deletion is at 1p36 
following the unbalanced translocation of 17q: t(1:17)(p36;q11-12), suggesting 
the region contains tumour suppressor genes (Bown et al., 2001). Although in 
multivariate analysis 1p loss of heterozygosity (LOH) is a predictor of poor event 
free survival, it has been shown to have no effect on overall survival, especially 
Normal Amplified
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in high risk groups where it is often associated with MYCN amplification (Fong et 
al., 1989; Maris et al., 2000).  
1.3.2.2. Gain of 17q 
Occurring in over 50% of neuroblastoma, gain of 17q is often the consequence 
of unbalanced translocations between chromosomes 1 and 11, and is thus 
frequently associated with the loss of 1p or 11q (Lastowska et al., 1997; Bown et 
al., 2001). Although 17q gains often correlate with a more aggressive disease, 
due to the involvement of these translocation partners, the independent 
prognostic significance is not strong. However, when combined with MYCN status 
17q gain does provide a reliable prediction of patient outcome (Spitz et al., 
2003b). Although cytogenetic analysis of 17q translocations has identified 
breakpoint heterogeneity, the gain of a region from 17q22-qter suggests that 
several candidate genes map to the region and are possibly overexpressed by a 
gene dose effect (Van Roy et al., 1997). For example, the amplification of PPM1D 
on 17q23 results in overexpression of the p53-inducible phosphatase which 
reduces p53 phosphorylation, attenuating apoptotic cell death (Saito-Ohara et al., 
2003).  
1.3.2.3. Loss of 11q 
Allelic loss of 11q most frequently occurs at 11q23 and is found in 22 - 44% of 
neuroblastoma. Inversely correlated with MYCN amplification, it is a poor 
prognostic indicator for non-amplified disease (Guo et al., 2000). Moreover 11q 
alterations are an independent marker of decreased event free survival in all risk 
groups, and strongly correlate with metastatic relapse (Spitz et al., 2003a; Spitz 
et al., 2006).  
 DNA Ploidy 
DNA content in neuroblastoma is used as a prognostic marker for disease 
behaviour. Hyperdiploidy of tumour cells is significantly more frequent in lower 
risk tumours and is associated with Schwann and ganglion cell differentiation,  a 
better response to chemotherapy, and a more favourable prognosis (Look et al., 
1984; Gansler et al., 1986; Brenner et al., 1989). DNA diploid tumours on the 
other hand are more common in metastatic, high-risk tumours and have been 
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found to act as a poor prognostic indicator when combined with MYCN 
amplification status (Muraji et al., 1993). However, DNA aneuploidy has been 
shown to not correlate with age and stage of disease but has been found to 
associate with decreased long-term survival in patients older than 24 months 
post-operation, and with advanced disease (Nakazawa, 1993).       
 ALK mutations 
Missense mutations of anaplastic lymphoma kinase, ALK, are found in 6 -10% of 
sporadic neuroblastoma with an additional 3 - 4% showing high levels of ALK 
amplification (Cheung and Dyer, 2013). Activating mutations in the kinase domain 
promotes hyper-phosphorylation and increased activity, enhancing proliferation 
and tumorigenesis, especially in the presence of MYCN amplification. MYCN has 
been shown to cooperate with ALK gain-of-function mutations, and reports have 
identified ALK as a direct transcriptional target of MYCN and able to stimulate 
MYCN gene transcription thereby contributing to MYCN-mediated disease 
progression (Schonherr et al., 2012; Hasan et al., 2013). Inactivation of ALK 
induces apoptotic cell death and impairs proliferation, identifying the kinase as an 
attractive therapeutic target (Chen et al., 2008b; George et al., 2008; Janoueix-
Lerosey et al., 2008). Preclinical data have recently validated the use of the ALK 
inhibitor crizotinib in neuroblastoma, and further clinical trials are currently in 
progress with a second generation inhibitor, LDK-378 (Schulte et al., 2013b).   
 Additional genetic aberrations 
Additional genes with significant mutated frequencies in somatic high-risk 
neuroblastoma are PTPN11 (2.9%), ATRX (2.5%) and NRAS (0.83%) (Pugh et 
al., 2013). Mutations in the α-thalassaemia/mental retardation syndrome X-linked 
(ATRX gene), while not sufficient to promote neuroblastoma formation alone, are 
significantly linked with the age of diagnosis. ATRX mutations are associated with 
an absence of the ATRX protein and long telomeres due to its role as a chromatin 
remodelling protein. They are more commonly found in older patients with 44% 
of cases found in patients older than 12 years who have a poor prognosis. 
However, due to cohort size further analysis is required into the prognostic impact 
of ATRX mutations (Cheung et al., 2012).    
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 Favourable neuroblastoma genes  
Transcripts encoding certain tyrosine kinases (TrkA, p75NTR and EFNB3) and 
cell surface molecules (CD44, EFNB2 and EFNB3) are all established favourable 
markers in neuroblastoma, as their expression predicts a favourable outcome in 
tumours lacking MYCN amplification and suppresses the malignant phenotype of 
unfavourable disease in xenograft models (Tang et al., 2000a; Tang et al., 
2000b). High-level expression EPHB6, and its ligands EFNB3 and EFNB2, 
predict a favourable outcome with more precision when combined together with 
data for TrkA expression. Interestingly, there is a distinct pattern with TrkA and 
ERNB2 expression being associated with both age and stage of disease, and 
EPHB6 and EFNB3 expression with age only (Tang et al., 2000b). TrkA is often 
considered the more informative prognostic marker (Nakagawara et al., 1993; 
Suzuki et al., 1993), and has been shown to be predictive of 5-year survival when 
associated with high MYCN expression, in a non-MYCN amplified setting (Tang 
et al., 2006b). Although the role of p75NTR in neuroblastoma is less clear, TrkA 
and p75NTR expression has been shown to be repressed by MYCN, suggesting 
a role in MYCN-driven tumour progression (Schulte et al., 2009; Iraci et al., 2011).     
 Treatment stratification and risk classification 
Many factors have been found to determine heterogeneity in neuroblastoma 
outcome, such as age at diagnosis, stage of disease, as well as the other 
histopathological and genetic features described in Section 1.3 and below. 
Identifying and understanding the clinical significance of these risk-factors has 
allowed for improved pre-treatment risk and treatment stratification.  
 International Neuroblastoma Staging System (INSS)  
The International Neuroblastoma Staging System (INSS) and International 
Neuroblastoma Response Criteria (INRC) were originally developed in 1988, 
(Brodeur et al., 1988), and revised in 1993, (Brodeur et al., 1993), and are used 
to confirm diagnosis and predict response to therapy (Table 1.2). However, the 
INSS is based on the extent of tumour removal and thus its utility is strongly 
dependent on the individual surgeon. Furthermore, localised disease which is 
expected to spontaneously regress cannot be properly staged as it is not 
removed due to ‘treatment’ being observation. To address these limitations 
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adaptations have been implemented and a new clinical staging system 
developed by the International Neuroblastoma Risk Group (INRG). Based on 
rigorously defined surgical risk factors, (IDRFs: image defined risk factors), 
localised disease was divided into two subgroups (Table 1.3) removing previous 
limitations. Not intended to replace the INSS risk assessment, the two staging 
systems are used in conjunction with one another (Monclair et al., 2009).  
 International Neuroblastoma Risk Group (INRG) classification 
system 
To overcome variation in factors selected to define pre-treatment risk across the 
different international cooperative groups, the INRG developed a new 
classification system in an attempt to standardise neuroblastoma diagnosis. 
Based on INRG stage, age, histologic category, grade of tumour differentiation, 
MYCN status, presence/absence of 11q aberrations and tumour ploidy, 16 
statistically and/or clinically different pre-treatment designations were identified 
(Table 1.4). Four main prognostic groups were then defined according to 
percentage cut-offs of 5-years event-free survival (EFS). These were; very low-
risk (≥ 85%), low-risk (≥ 75% to ≤ 85%), intermediate risk (≥ 50% to ≤ 75%) and 
high risk (≤ 50%). It was hoped that using these classifications across the 
international groups would ensure that children were allocated into homogenous 
pre-treatment groups and hence allow for a better comparison of future clinical 
trials data (Cohn et al., 2009).   
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Tumour Stage Description 
1 Localised tumour with complete gross excision, with or without 
microscope residual disease; representative ipsilateral lumpy nodes 
negative for tumour microscopically. Nodes attached to and removed 
with primary tumour may be positive  
2A Localised tumour with incomplete gross excision; representative 
ipsilateral non-adherent lymph nodes negative for tumour 
microscopically  
2B Localised tumour with or without complete gross excision, with 
ipsilateral non-adherent lymph nodes positive for tumour; enlarged 
contralateral lymph nodes negative microscopically 
3 Unresectable unilateral tumour infiltrating across the midline (beyond 
the opposite side of the vertebral column) with or without regional 
lymph node involvement, or midline tumour with bilateral extension via 
infiltration (unresectable) or lymph node involvement 
4 Any primary tumour with dissemination to distant lymph nodes, bone, 
bone marrow, liver, skin, and/or other organs (except as defined for 
stage 4S disease). Distant metastatic disease 
4s Localised primary tumour (as defined for stage 1, 2A or 2B disease) 
with dissemination limited to skin, liver, and/or bone marrow (limited to 
infants younger than 1 year, marrow involvement of less 10% of total 
nucleated cells, and MIBG scan negative in the marrow). Favourable 
outcome over stage 4 disease when in absence of MYCN amplification 
Table 1.2 Original description of INSS tumour stages (Brodeur et al., 1993). 
MIBG: Metaidobenzylguanidine 
 
 
Tumour Stage Description 
L1 Localised tumour not involving vital structures, as defined by the list of 
IDRFs, and confined to one body compartment  
L2 Local-regional tumour with presence of one or more IDRFs 
M Distant metastatic disease (except stage MS tumour) 
MS Metastatic disease in children younger than 18 months, with 
metastases confined to skin, liver and/or bone marrow 
Table 1.3 Descriptions of INRG pre-treatment classification (Monclair et al., 
2009). L: localised, M: metastatic, S: Special, and 1: with and 2: without surgical 
risk factors.  
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INRG 
stage 
Age in 
months 
Histological 
category 
Grade of 
tumour 
differentiation 
MYCN 11q 
abberations 
Ploidy Pretreatment 
risk group 
L1/2  GN maturing; 
GNB 
intermixed 
    Very Low 
L1  Any, except 
GN maturing 
or GNB 
intermixed 
 Not Amp   Very Low 
Amp   High 
L2 ≤ 18 Any, except 
GN maturing 
or GNB 
intermixed 
 Not Amp No  Low 
Yes  Intermediate 
≥ 18 GNB nodular;  Differentiating Not Amp No  Low 
Yes  Intermediate 
Poorly 
differentiated or 
undifferentiated 
Not Amp   
 Amp   High 
M ≤ 18   Not Amp  Hyper-
Diploid 
Low 
≤ 12   Not Amp  Diploid Intermediate 
12 to ≤ 
18 
  Not Amp  Diploid Intermediate 
≤ 18   Amp   High 
≥ 18      High 
MS ≤ 18   Non Amp No  Very Low 
Yes  High 
Amp   High 
Table 1.4 The INRG classification system. (GN – ganglioneuroma, GNB – 
ganglioneuroblastoma. (Cohn et al., 2009). 
 
 Current Treatment (as reviewed by (Ora and Eggert, 2011)) 
Following the tumour profiling of molecular markers and risk assessment, the 
appropriate treatment plan can be initiated based on the clinical classification.  
 Observation 
As most of INSS 4s neuroblastomas spontaneously regress, patients without 
symptoms or unfavourable prognostic markers are closely observed without 
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active treatment. A clinical trial randomising a ‘wait-and-see’ approach vs. surgery 
for INSS stage 1 and 2 (with no unfavourable prognostic markers) showed 47% 
of tumours regress spontaneously while a second found only 17 out of 53 
required treatment (Hero et al., 2008; Tanaka et al., 2010).  
 Surgery  
As a solid tumour, neuroblastoma surgery provides local control, helps confirm 
diagnosis and allows tissue acquisition for histological and molecular 
classification. Although surgery is the treatment of choice for localised disease, 
chemotherapy is sometimes required initially to shrink the tumour before surgery.   
 Chemotherapy 
A large proportion of neuroblastoma patients present with metastatic or advanced 
disease and require chemotherapy. Treatment options include alkylating agents 
(cyclophosphamide, busulfan and melphalan), platinum analogues (cisplatin and 
carboplatin), vinca-alkoids (vincristine), epipodophyllotoxins (etoposide and 
VP16-213), and anthracyclines (doxorubicin) as all have well established activity 
against neuroblastoma. Combinations of existing drugs and novel agents are also 
being investigated in ongoing Phase II trials for relapsed, refractory and chemo-
resistant neuroblastoma (Kushner et al., 2010; Bagatell et al., 2011). Treatment 
for high-risk neuroblastoma (MYCN amplified disease and INSS stage 4 ≥ 12 
months) is as follows: 
1. Dose intensive therapy to reduce tumour burden: Combinations of 
chemotherapeutic drugs at high doses, e.g. cisplatin, carboplatin, etoposide or 
doxorubicin. Topetecan is also used if initial treatment is insufficient. 
2. Consolidation treatment to removal residual tumour and metastases: Following 
surgical resection of the primary tumour, high dose myeloablative chemotherapy 
with combinations of busulfan, melphalan, carboplatin and etoposide and 
autologous stem cell rescue.  
3. Maintenance treatment to eliminate minimal residual disease: As local or 
systemic relapse of high-risk disease is often due to minimal residual disease 
(MRD), maintenance treatment focusses on biological therapies to induce 
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terminal differentiation, such as retinoid derivatives (13-cis retinoic acid), or 
cytocidal immunotherapy. Specifically, monoclonal antibodies against the surface 
glycolipid GD2, which have recently been assessed in Phase I and II trials. GD2 
is a target for immunotherapy due to its high level of expression on 
neuroblastoma, and the protection of healthy neurones in the CNS by the blood-
brain barrier. In an attempt to enhance response rates cytokines have also been 
combined with anti-GD2 therapy to increase cytotoxicity. Clinical trials have 
shown an increase in 2-year EFS for anti-GD2 therapy when combined with IL-2, 
GM-CSF and isotretinoin (Yu et al., 2010).   
 Radiation treatment  
Neuroblastoma is a radiosensitive disease, although external beam treatment is 
usually only given for high risk disease during the consolidation phase, or for a 
palliative treatment to sites of relapse. Radiation is often given at the site of the 
primary tumour using external beam radiotherapy (EBRT) with total body 
irradiation (TBI) being replaced by effective chemotherapeutic methods. A 
second approach includes iodine131-labelled metaiodobenylguanidine (131I-
MIBG). A norepinephrine analogue selectively taken up by neuroblastoma 
tumours, haematological toxicity has restricted its use, although certain regimes 
use it prior to hematopoietic stem cell rescue/transplant (HSCT) conditioning 
regimens (French et al., 2013) .  
 Treatment of recurrent disease 
Patients with low- and intermediate-risk disease can benefit from conventional 
treatment such as surgery with or without moderately intensive chemotherapy. 
Unfortunately recurrence of high-risk disease is extremely difficult to treat and no 
treatment options are currently available which offer long term cure.  
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 The MYC family of transcription factors 
The MYC proto-oncogene family is a group of basic-helix-loop-helix-leucine 
zipper (b-HLHZ) transcription factors which arise from five distinct gene family 
members, c-MYC, MYCN, L-MYC, B-MYC and s-MYC. Although, only c-MYC, L-
MYC and MYCN are expressed in mammalian cells and reported to have 
neoplastic potential (Nesbit et al., 1999). B-MYC and s-MYC are both members 
of the rat MYC gene family yet share extensive homology with the amino termini 
of the MYC family, however, B-MYC shares more similarities with c-MYC 
(Ingvarsson et al., 1988), and s-MYC shows a greater resemblance to murine 
MYCN (Sugiyama et al., 1989). 
Although c-MYC, L-MYC and MYCN all function in a similar manner though 
association with the HLH-LZ phosphoprotein MAX, as discussed in Section 1.6.2, 
the presence of three distinct gene sequences suggests each has unique 
functional roles. This is supported by findings of differential expression of MYC 
proteins in a stage and tissue-specific manner during human and murine 
differentiation, in addition to the specific cancer types in which they are 
overexpressed (Zimmerman et al., 1986).  
MYC expression is tightly regulated with each step of protein synthesis being 
intensely controlled by positive and negative inputs which respond to appropriate 
growth factor signalling as reviewed by (Tansey, 2014). All MYC proteins are 
broadly expressed at high levels during early embryogenesis, and given their 
conservation have been found to overlap in gene targets resulting in a certain 
level of functional redundancy in early embryonic development (Malynn et al., 
2000). As development continues their distribution becomes more spatial and 
restricted to specific cell types. During midgestation c-MYC expression is the 
most broadly distributed, although is most abundant in areas of high proliferative 
activity and following full development is found at low levels in adult tissues with 
a high proliferative capacity (e.g. skin epidermis and gut, (Schmid et al., 1989)). 
MYCN expression is more prominent in postmitotic cells undergoing neuronal 
differentiation (Galderisi et al., 1999; Edsjo et al., 2004) and is found in low levels 
in many neuronal tissues following its downregulation during differentiation. L-
MYC has a similar tissue distribution to MYCN and is found in both proliferative 
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and differentiative compartments on the brain and neural tube and has also been 
shown to be present in the developing kidney and lungs (Schmid et al., 1989). 
However, no unique role in development has yet to be determined for L-MYC, 
with homozygous null L-MYC mice found to be viable (Hatton et al., 1996). 
Conversely, homozygous deletion of either c-MYC or MYCN results in embryonic 
lethality, with c-MYC knockouts showing abnormalities in the heart and a delay in 
embryonic turning (Davis et al., 1993), and MYCN knockouts showing 
developmental deformities in the lungs and central and peripheral nervous tissue 
(Stanton et al., 1992).  
The importance of the spatio-temporal expression of c-MYC and MYCN is notable 
in their association with tumour development. Deregulated c-MYC expression is 
recognised as an essential aspect of human Burkitt’s lymphoma (Spencer and 
Groudine, 1991), yet has been found to be broadly overexpressed in both blood 
and solid tumours. MYCN on the other hand is more frequently overexpressed in 
solid cancers of neural origin, such as neuroblastoma, and L-MYC most 
commonly found overexpressed in small cell lung carcinoma (Tansey, 2014). 
Although overexpression of the MYC family is recognised as a key oncogenic 
event, with gain-of-function experiments identifying them capable of promoting 
transformation (Adams et al., 1985; Rosenbaum et al., 1989), it is still not fully 
understood to what level they contribute to oncogenic activity due to the plethora 
of genes which they both activate and repress. Known to play critical roles in 
proliferation, differentiation and apoptosis the oncogenic behaviour of the MYC 
family could potentially be a result of their enhanced expression, although it is still 
not fully understood how MYC behaviour is different in cancer versus normal 
cells.  
 MYC protein structure 
As with all MYC members the N-terminal transcriptional activation domain (Figure 
1.5, TAD) is essential for Myc-induced transcriptional activation following its 
fusion with a DNA binding domain (Kato et al., 1990). The TAD region is also 
accepted to be where MYC contacts RNA polymerase II-associated proteins 
(Tansey, 2014) and is responsible for signalling the ubiquitin-mediated 
degradation of MYC proteins (Salghetti et al., 1999). The amino-terminus also 
contains the Myc-boxes (MB), of which MB1 and MB2 are conserved across all 
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3 family members indicating they are critical for MYC biology. The C-terminus 
contains a basic DNA binding region (Figure 1.5, B), alongside a helix-loop-helix 
and leucine zipper region (Figure 1.5, HLH-LZ), which mediates the interaction 
with the smaller BHLH-LZ protein MAX, and the physiological recognition of the 
DNA target sequences (Wenzel et al., 1991). Dimerization of MYCN/MAX is 
essential for transcriptional activation, and mediates the DNA affinity of MYCN. 
The resultant MYCN/MAX heterodimer binds to canonical 5’ CACGTG or non-
canonical 5’ CANNNG E-box sequences upstream of the target promoter where 
MYCN is able to activate transcription (Adhikary and Eilers, 2005) (Schwab et al., 
1983; Wenzel and Schwab, 1995). Less is understood about the central portion 
of the MYC proteins with deletion mutants failing to identify regions critical for 
MYC activity (Heaney et al., 1986; Biegalke et al., 1987). 
As MYC family members have a shorter half-life than the constitutively expressed 
MAX proteins, the regulation of MYC family genes is limited to the control of MYC 
levels as reviewed by (Grandori et al., 2000). This greater stability of MAX 
proteins aids their role as MYC antagonists. Thus, along with cofactors MAD, 
MNT and MXI1, MAX forms homodimers that represses MYC-regulated genes 
by binding to the E-boxes. This repression is then lost following formation of 
MYC/MAX heterodimers on cell cycle entry and the increase in MYC expression, 
as reviewed by (Adhikary and Eilers, 2005).  
 
Figure 1.5 Schematic representation of the protein structure of the MYC 
family and Max. Transactivation domain (TAD) and conserved Myc boxes (MBI 
and MBII) at the N-terminus, central portion and basic region (B) / helix-loop-helix 
/ leucine-zipper (HLH-LZ) at the C-terminus. Proteins vary in size due to 
differences in the length of nonconserved sequences but are drawn to highlight 
the relative location of the Myc boxes (Tansey, 2014).    
Transcriptional 
activation 
domain (TAD) Central portion DNA binding
HLH-LZBI II IIIa IV CN IIIb
C-MYC 
439 amino acids
HLH-LZBI II IIIa IV CN IIIb
MYCN
464 amino acids
HLH-LZBI II IV CN IIIb
L-MYC
364 amino acids
HLH-LZB CN MAX
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 Transcriptional regulation by MYC  
MYC proteins can transcriptionally activate and repress numerous target genes. 
Although many c-MYC target genes have been identified, as listed at 
http://mycancergene.org/sit/mycTargetDB.asp (Zeller et al., 2003), fewer MYCN-
regulated genes are known. However, due to the homology between the two 
transcription factors, progress is being made in identifying the direct and indirect 
downstream targets of MYCN, (http://medgen.ugent.be/MYCNot) (Kumps et al., 
2013). Transcriptional regulation by MYC proteins relies on their dimerization with 
MAX. The MYC/MAX heterodimer interacts with a large number of proteins, 
suggesting that DNA recognition by the C-terminal domain and transcriptional 
regulation by the N-terminal domain is not solely reliant on MAX. Although both 
BHLH-LZ and transactivation domains (TAD) are known to be required for MYCN 
activity, how these activate transcription is still poorly understood (Sakamuro and 
Prendergast, 1999). Binding of the nuclear cofactor TRRAP to N-terminal domain 
MBII of MYCN is essential for its transactivation activity, and promotes the 
recruitment of histone acetyl transferases (HAT) such as GCN5 and TIP60 and 
the CBP component (cAMP-response element binding protein) of the p300/CBP 
complex, to form large multiprotein complexes (McMahon et al., 1998; McMahon 
et al., 2000; Vervoorts et al., 2003; Martínez-Cerdeño et al., 2012). These HATs 
have been shown to promote histone acetylation and chromatin remodelling, 
creating a euchromatin conformation. This conformation allows the docking of 
transcriptional machinery such as the TATA-binding protein (TBP), a member of 
the transcriptional pre-initiation complex, implying MYC/MYCN is able to recruit 
pol II machinery to activate transcription (Barrett et al., 2005). As all HATs 
mentioned are able to acetylate MYCN, and thus enhance its stability and 
transcriptional latency, it is argued that MYCN may play a more generic role in 
the maintenance of an open nucleosomal landscape, in addition to the 
transcriptional activation of specific genes (Cotterman et al., 2008).  
MYC/MYCN have also been shown to promote transcript elongation by 
recruitment of the positive transcription elongation factor b (PTEFb). A complex 
consisting of CDK9 and its regulatory subunit cyclin T1 (Peng et al., 1998), P-
TEFb phosphorylates the Ser2 residue at the carboxyl-terminal-domain of RNA 
polymerase II, stimulating transcription (Majello et al., 1999; Gargano et al., 
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2007). Using the target gene CAD as an experimental model Eberhardy et al 
showed that P-TEFb mediated MYC-mediated transcriptional activation through 
the binding of cyclin T1 to the conserved Myc Box I (MBI) domain (Eberhardy and 
Farnham, 2002). Argued to be the rate limiting step in MYC/MYCN 
transactivation, MYCN is predicted to participate in this functional interaction due 
its homology with c-MYC 
Although most genes that are regulated by the MYC family are activated, the N-
terminal TAD has been implicated in transcriptional repression through its 
interaction with the two zinc-finger transcription factors; MYC-associated 
transcription factor (MIZ-1) (Staller et al., 2001), and basal transcription factor 1 
(SP1). MYCN has since been shown to require the formation of a 
MYCN/MIZ1/SP1 complex to silence gene expression, which promotes a 
hetrochromatin conformation by recruiting histone deacetylases (e.g. HDAC1) 
and switching off gene expression (Iraci et al., 2011). Alternatively MYCN has 
been found to bind to the EZH2 component of the polycomb repressive complex 
2 (PRC2) (Corvetta et al., 2013). A histone methyltransferase, EZH2 expression 
has been associated with epigenetic silencing in neuroblastoma and its 
upregulation able to suppress the expression of several tumour suppressors 
including CLU, NGFR and RUNX3 (Wang et al., 2012a).  
In addition to the presence of an E-box motif, MYC binding has been shown to 
be influenced by the chromatin characteristics showing a stronger preference 
towards areas with a high density of CpG islands which often define regions of 
open, active chromatin (Kundu and Rao, 1999). MYC binding is also heavily 
influenced by epigenetic marks as E-boxes buried in tightly compacted chromatin 
will be overlooked for those which are associated with histone modifications 
identifying as transcriptionally ‘active’ e.g. methylation on histone H3 at lysine 4 
and 79 (Guccione et al., 2006).  
MYC has been shown to regulate gene transcription independent of the E-box 
and act as a transcriptional facilitator by directly interacting with other 
transcription factors. This has recently been shown for retinoic acid responsive 
genes where the MYC/MAX dimer is able to transcriptionally repress genes 
required for differentiation in leukaemia cells by interacting with the retinoic acid 
receptor-α (RARα). Concomitantly, during retinoic acid induced differentiation 
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phosphorylation of c-MYC in the C-terminal helix-loop-helix domain results in 
MAX being displaced and co-activators being recruited. MYC can therefore act 
as a switch from promoting to supressing leukaemia tumorigenesis (Uribesalgo 
et al., 2011).   
An alternative approach to the transcriptional role of the MYC family is that they 
work as universal amplifiers of already expressed genes rather than acting as 
sequence-specific transcriptional activators. In a model recently described for c-
MYC, tumour cells expressing low levels were found to have the transcription 
factor almost exclusively bound to the E-boxes in core promoters. However, in 
tumour cells with elevated levels of c-MYC it was found to occupy both the core 
promoters and large regulatory elements, termed enhancers, of these genes at 
additional low affinity E-box like sequences (Nie et al.; Lin et al., 2012). 
Furthermore, clusters of enhancers densely packed with transcription factors, 
cofactors and chromatin regulators (Hnisz et al.), have been recently identified 
as a feature of deregulated MYCN. These ‘super enhancers’ facilitate the high-
level expression of genes and have been found to sensitise MYCN amplified cells 
to the CDK7 inhibitor THZ1. A covalent inhibitor it prevents the phosphorylation 
and activation of RNA polymerase II thus reducing the expression of MYCN-
driven super enhancer-associated oncogenic drivers (Chipumuro et al., 2014). 
By amplifying the tumour cell’s gene expression program this enhancer model 
helps to explain the diverse effects of overexpressed MYC on gene expression, 
and the lack of a common MYC transcriptional signature. However, this model 
requires further refinement as it is not clear whether the increases in 
transcriptional output are through direct or indirect transcriptional activities of c-
MYC, additionally the model does not account for the ability of c-MYC to repress 
the transcription of select genes.         
 The MYCN oncogene in neuroblastoma 
MYCN encodes a 60-64kDa nuclear phosphoprotein which has been found to 
play an important role in the differentiation pathways of neuronal progenitor cells 
and the development of tissues of the nervous system (Knoepfler et al., 2002). 
MYCN has been repeatedly demonstrated to have a crucial role in 
neuroblastoma. MYCN over-expression studies highlighted the requirement for 
MYCN down-regulation to allow terminal differentiation of neurones (Wakamatsu 
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et al., 1997), while conditional MYCN expression was found to promote the 
transformation of neuroblasts in transgenic mice, and enhance the proliferation 
and metastatic ability of tumour-derived cell lines (Lutz et al., 1996; Weiss et al., 
1997). However, MYCN expression also sensitises cells to apoptotic cell death, 
providing a pathway which can be exploited therapeutically by inducing a p53 
response (Gamble et al., 2012; Petroni et al., 2012). The defects in the apoptotic 
pathways seen in MYCN-amplified neuroblastoma may therefore be a 
mechanism of evading MYCN-induced apoptosis (Hogarty, 2003).  
As a consequence of the ability of MYCN to both drive cellular proliferation and 
induce apoptosis, the impact of MYCN amplification is dependent on the net 
integration of the two signalling pathways. This paradox is observed histologically 
by the high mitosis-karyorrhexis index (MKI) in human MYCN amplified tumours. 
MKI is a combined measure of proliferation (mitoses) and apoptosis 
(karyorrhexis; degeneration of the nucleus) and is hence used in the cellular 
classification of neuroblastoma (Shimada et al., 1995; Shimada et al., 1999).   
Regulation of genes associated with cell cycle progression 
MYCN promotes the G1/S cell cycle transition, and in an attempt to identify 
potential MYCN target genes involved in this process microarray analysis 
following MYCN siRNA knockdown was previously performed, and the results 
confirmed in a regulatable MYCN expression system (Bell et al., 2007).  
ODC1: Ornithine decarboxylase (ODC) is the rate-limiting enzyme in polyamide 
biosynthesis and has been found to be co-amplified with 19% of MYCN-amplified 
neuroblastoma due to its position ~5.5 Mb from the MYCN locus on chromosome 
2p24 (Hogarty et al., 2008). A direct transcriptional target of MYCN, ODC is also 
required for the degradation of p27KIP1 by promoting the MYC-induction of CKS1 
(Keller et al., 2007), an accessory protein of the E3 ligase complex which targets 
p27KIP1 for degradation. However, interestingly, treatment with the ODC inhibitor 
alpha-difluoromethylornithine (DFMO) impairs cell proliferation by increasing 
levels of p21CIP1/WAF1, not p27KIP1, which enhances the G1 population of tumour 
cells and survival of TH-MYCN transgenic mice (Hogarty et al., 2008; Rounbehler 
et al., 2009). The efficacy and safety of DMFO as a single agent and in 
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combination with etoposide has since been evaluated in patients with relapsed 
and high-risk disease (Sholler et al., 2013)    
E2F: Central regulators of cell cycle progression, E2F transcription factors are 
negatively controlled by the retinoblastoma protein (pRB) pathway and target a 
variety of genes including those required for S-phase transition. E2F proteins are 
known to regulate MYCN expression in neuroblastoma (Strieder and Lutz, 2003), 
and E2F genes are direct transcriptional targets of c-MYC. However, although 
E2F1 expression has been shown to decrease after MYCN knockdown, it 
remains yet to be confirmed as a direct MYCN target gene (Woo et al., 2008).  
MDM2: The negative regulator of p53, MDM2 is a direct MYCN target gene (Slack 
et al., 2005). By binding to the P2 region of the MDM2 promoter, MYCN up-
regulates MDM2 expression providing a mechanism for the evasion of p53-
induced apoptosis in MYCN-amplified neuroblastoma (Slack et al., 2005). MDM2 
expression has also been found to have a functional role in the MYCN-mediated 
centrosome amplification observed following DNA damage in the SHEP-Tet21N 
MYCN expression system (Slack et al., 2007).      
DKK3: Dickkopf-3 (DKK3) is a member of the DKK family of secreted WNT 
antagonists, and is a candidate tumour suppressor gene due to its down-
regulation in a variety of malignancies (Kuphal et al., 2006; Katase et al., 2013; 
Lin et al., 2013). Ectopic expression of DKK3 has been shown to inhibit cell 
proliferation in neuroblastoma cell lines (Koppen et al., 2007), with MYCN 
suggested to indirectly supress DKK3 expression by directly up-regulating the 
microRNA miR-17-92 cluster (De Brouwer et al., 2012). 
ID2: An inhibitor of differentiation, DNA-binding protein inhibitor 2 (ID2) promotes 
the G1/S transition by binding to hypo-phosphorylated pRB, promoting the release 
of the E2F transcription factors, and antagonising the growth-suppressive 
activities of p16INK4A and p21CIP1/WAF1 (Lasorella et al., 1996). The clinical 
relationship between MYCN and ID2 expression remains unclear as some 
reports observe no correlation between the two oncogenes (Wang et al., 2003), 
while others identify ID2 as a potential MYCN target gene (Woo et al., 2008).       
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SKP2: S-phase kinase-associated protein 2 (SKP2) is the F-box protein for the 
SCF E3 ubiquitin ligase complex which monitors the G1/S transition (Carrano et 
al., 1999; Nakayama et al., 2004). MYCN siRNA knockdown studies decreased 
SKP2 expression at the transcript and protein level identifying it as a potential 
MYCN transcriptional target (Bell et al., 2007). 
Regulation of genes associated with apoptosis 
The ability of MYCN to enhance apoptosis following cellular stress, while not fully 
understood, involves the upregulation of multiple pro-apoptotic proteins.  
p53: The ‘guardian of the genome’ (Lane, 1992), p53 plays a crucial role in the 
maintenance of genomic stability and tumour suppression by monitoring several 
mechanisms, including the G1/S transition and induction of apoptosis. MYCN 
directly regulates p53 transcription (Westermann et al., 2008; Chen et al., 2010b), 
and this relationship is thought to play an important role in the mechanism by 
which MYCN sensitises cells to apoptosis.  
p14ARF: A central component of the p53 pathway, p14ARF antagonises MDM2 and 
thus activates and stabilises p53. Homozygous deletions of p14ARF have been 
reported in neuroblastoma indicating that it promotes the progression of MYCN 
amplified disease (Caren et al., 2008; Carr-Wilkinson et al., 2010a). Although 
there are no reports showing MYCN sensitising cells to p14ARF driven apoptosis, 
p14ARF is reported to inhibit the transcriptional activity of c-MYC/MYCN by directly 
binding to the proteins promoting their nucleolar sequestration (Qi et al., 2004; 
Amente et al., 2007). 
H-TWIST: Human Twist-related protein 1 (H-TWIST) is an embryonic 
transcription factor of the B-HLH family that is essential for neural crest 
development (Chen and Behringer, 1995). H-TWIST proteins inhibit apoptosis by 
directly interacting with p53, suppressing its DNA-binding activity (Maestro et al., 
1999; Shiota et al., 2008). Although not identified as a direct MYCN transcriptional 
target, high levels of H-TWIST are observed in MYCN-amplified tumours 
suggesting oncogenic cooperation between the two proteins, and that H-TWIST 
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is a MYCN-derived mechanism which disrupts the ARF/p53 pathway in 
neuroblastoma (Valsesia-Wittmann et al., 2004).    
PUMA: The p53 upregulated modulator of apoptosis (PUMA) is a member of the 
BCL-2 protein family which activates the BH3-only pro-apoptotic protein, inducing 
the canonical mitochondrial apoptotic pathway (Yu and Zhang, 2008). PUMA 
plays an essential role in p53-dependent and -independent apoptosis, triggering 
cell death in in vivo and in vitro models (Jeffers et al., 2003; Villunger et al., 2003; 
Yu et al., 2003), and its expression has been shown to be reduced following 
MYCN knockdown by siRNA (Chen et al., 2010b).     
BCL2 and BAX:  Overexpression of the anti-apoptotic proteins BCL-2 and BCL-
XL has been shown to inhibit apoptosis by preventing mitochondrial permeability 
(Kroemer et al., 1997). In contrast, overexpression of the pro-apoptotic protein 
BAX can induce mitochondrial permeability releasing pro-apoptotic proteins such 
as cytochrome C, thereby activating the caspase cascade (Pastorino et al., 
1998). MYCN has also been shown to cooperate with cytotoxic drug treatment to 
increase BAX protein levels, while not affecting BCL-2 levels, to alter the ratio of 
the opposing proteins in favour of apoptosis (Fulda et al., 1999).  
MYCN regulation of noncoding RNAs 
The noncoding portion of the genome, noncoding RNA (ncRNA), identifies 
functional RNA molecules which are not translated into proteins yet still play an 
important role in cellular processes. Split into the 2 classes of small ncRNAs (i.e. 
miRNAs and siRNAs ≤200 nt) and long ncRNAs (lncRNA ≥ 200 nt) their 
deregulation has been found to be involved in several diseases including cancer 
(Esteller, 2011). MicroRNAs are an abundant ncRNA which negatively regulate 
protein expression and whose expressional changes profoundly affect the protein 
composition of a cell (Baek et al., 2008). Although their precise mechanism of 
action is still elusive, the miRNA-mRNA regulatory network is highly complex. 
Given the ability of single miRNAs to target several different mRNAs they have 
been found to regulate a broad spectrum of cellular processes including 
proliferation, differentiation, and apoptosis (reviewed by (Huang et al., 2011)). 
MYCN has been reported to upregulate and repress miRNA expression. The 
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MYCN-induced miRNAs, (mir17-92 cluster, mir-9 and mir-421) have been 
identified to target genes involved in proliferation and the inhibition of apoptosis 
and differentiation, while the miRNAs which inversely correlate with MYCN 
expression (mir-184 and mir-542-5p) are identified as tumour suppressor 
miRNAs (reviewed by (Buechner and Einvik, 2012)). Interestingly ncRNAs are 
also reported to target MYCN expression and the overexpression of mir-34a has 
been shown to directly target MYCN resulting in growth inhibition and increased 
apoptosis (Wei et al., 2008). Conversely MYCN expression is stabilised by the 
MYCN cis-antisense RNA NCYM. Initially thought to be a lncRNA it has since 
been identified as a de novo evolved protein which inhibits the GSK3β-mediated 
degradation of MYCN resulting in a positive feedback loop and aggressive 
phenotype in MYCN/NCYM-amplified tumours (Suenaga et al., 2014).  
 The clinical significance of MYCN expression in neuroblastoma 
Although MYCN amplification is a strong poor prognostic indicator, high levels of 
MYCN expression in a non-amplified setting, although not an independent 
prognostic factor, is associated with a favourable outcome (Cohn et al., 1995; 
Tanaka et al., 2004; Tang et al., 2006b). Often a result of increased protein 
stabilisation, it is speculated that in the absence of MYCN amplification the 
apoptosis-inducing function of MYCN is dominant over proliferation-inducing 
effects and vice versa in amplified disease.  
MYCN protein has a short half-life (~2hrs) and is targeted for proteasomal 
degradation by the SCFFBXW7 E3 ubiquitin ligase complex (Yada et al., 2004), 
which is dependent on the phosphorylation of Thr58 by glycogen synthase kinase 
3β (GSK3β), following phosphorylation at Ser62 by the cyclin B/CDK1 complex 
which acts as a priming site for GSK3β (Sjostrom et al., 2005). As GSK3β is 
negatively regulated by the PI3K/AKT pathway, PI3K inhibitors have been 
exploited as an approach to target MYCN therapeutically by promoting its 
degradation (Chesler et al., 2006). Conversely high levels of Aurora A kinase 
(AURKA), have been shown to uncouple MYCN degradation from PI3-kinase-
dependent signalling in neuroblastoma, stabilising the protein (Otto et al., 2009). 
The expression of AURKA has also been shown to be elevated in MYCN-
amplified neuroblastoma potentially creating a positive feedback loop (Berwanger 
et al., 2002).      
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The clinical significance of high levels of MYCN expression in low-risk, non-
amplified disease requires further definition. One such study defined a functional 
MYCN signature by integrating the in vitro regulation by MYCN protein with the 
in vivo correlation to MYCN mRNA levels. Following the silencing of MYCN in a 
MYCN amplified neuroblastoma cell line, 422 up- and 463 down-regulated genes 
were identified. The selected genes were then compared to the MYCN 
expression profile in a series of 88 neuroblastoma tumours resulting in the 
identification of 157 genes which showed an expression profile which correlated 
with MYCN mRNA levels. Acting as a prognostic signature, this MYCN-157 
signature marked the influence of stabilisation of MYCN at the protein level 
separating itself from the amplified/non-amplified classifications, and 
consequently was found to predict poor outcome in neuroblastoma with and 
without MYCN-amplification (Valentijn et al., 2012).  
 The cell cycle  
The eukaryotic cell cycle is an intricate and carefully regulated sequence of 
events which culminates in mitosis. Central to this process is the sequential 
activation of the cyclin-dependent kinases (CDKs) which when in a complex with 
their activating cyclins regulate the progression towards cell division (van den 
Heuvel and Harlow, 1993; Pines, 1994; Malumbres and Barbacid, 2005; 
Malumbres et al., 2009). The cell cycle is divided into four successive stages; M 
phase (mitosis) where the parental cell divides to give two daughter cells; S phase 
(DNA synthesis), where the DNA is replicated; and the two gap phases G1 and 
G2 during which there are crucial checkpoints to ensure genomic structure and 
integrity before the cell is committed to DNA replication and mitotic division, 
respectively (Figure 1.6) 
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Figure 1.6 Cell cycle control and regulation. Progression through the cell cycle 
is regulated by different cyclin-CDK complexes which are in turn controlled by a 
combination of processes, including transcriptional activation of cyclin 
expression, post-translational modifications and inhibition by specific cyclin 
dependent kinase inhibitors (CKDI).(Dehay and Kennedy, 2007) 
 The G1 to S transition  
Progression through the G1 phase requires constant stimulation by mitogenic 
signals and a high rate of protein synthesis, interruption of either resulting in the 
rapid exit from the cell cycle into G0 (cellular quiescence) (Bertoli et al., 2013). 
The G1 to S phase transition is primarily regulated by the retinoblastoma protein 
(pRB) which in its hypo-phosphorylated form sequesters the E2F family of 
transcription factors thereby repressing E2F-responsive genes. Following 
mitogenic stimulation, pRB is initially phosphorylated by cyclin D-CDK4/6 
complexes in early G1 releasing the cell from a quiescent state. Phosphorylation 
partially inactivates pRB resulting in E2F-induced expression of cyclin E, which 
following the activation of CDK2 drives the cells though the G1 phase by 
promoting the sequential phosphorylation of pRB, liberation of E2F proteins, and 
activation of a plethora of genes required for S phase (Lundberg and Weinberg, 
1998; Ezhevsky et al., 2001). The positive feedback loop created by the cyclin E-
CDK2 complex increases levels of the complex above that of the CDK inhibitors 
p27KIP1 and p21WAF1/CIP1, and this shift in complex equilibrium plays an important 
role in the commitment of the cell to mitotic division as once past the restriction 
point cell cycle progression is independent of mitogenic and inhibitory signals 
(Zetterberg et al., 1995).  
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 Inhibitors of the G1 to S transition 
Two main families of cyclin-CDK inhibitors have been characterised, the INK4 
protein family (inhibitors of CDK4), and the CIP/KIP family. The INK4 class 
specifically inhibit CDK4 and CDK6 and include; p16INK4a, p15INK4b, p18INK4c and 
p19INK4d, while the CIP/KIP family affect a broader spectrum of cyclin-CDKs and 
include p27KIP1 (p27 hereafter) and p21WAF1/CIP1 (p21 hereafter), as reviewed by 
(Sherr and Roberts, 1999). The periodic expression of cyclins and CDK inhibitors 
thereby acts as the driving force of the cell cycle and loss of CDK inhibitors 
provides a selective advantage to tumour development. Although p27 is a 
recognised CDK2 inhibitor, it has also been demonstrated to help trigger 
replication origins and promote the assembly and activation of cyclin D-CDK4. 
High levels of p27 and p21 in early G1 have also been shown to be sequestered 
by cyclin D-CDK4 complexes preventing the inhibition of cyclin E-CDK2 (Cheng 
et al., 1999; Larrea et al., 2008). In addition to ubiquitin-mediated proteasomal 
degradation of CDK inhibitors, CDK activity is regulated by a variety of positive 
phosphorylation events by CDK-activating kinases (CAK) and negative 
phosphorylation events catalysed by kinases such as Wee1 (Perry and 
Kornbluth, 2007). Further regulation is also brought by the removal of inhibitory 
phosphates from cyclin A/E-CDK2 complexes by the phosphatase Cdc25, thus 
promoting entry into S phase (Bertoli et al., 2013).  
 S phase to M phase transition 
DNA replication is confined to the S phase of the cell cycle. Initiated by the 
assembly of the pre-replicative complexes (pre-RC) on multiple DNA origins, 
origin firing, formation of replication forks, and DNA synthesis is tightly regulated 
by CDK activity. Regulation includes inhibition of pre-RC assembly so to ensure 
that origins only fire once per S phase (Takeda and Dutta, 2005). The S to G2 
phase transition is regulated by cyclin A-CDK1/2 complexes and CDK1 which, 
thought to monitor the firing of pre-RC, is regulated by the phosphatase Cdc25 
which in turn is controlled by cyclin A-CDK2 activity (Mitra and Enders, 2004). 
Cyclin A-CDK2 has also been reported to phosphorylate E2F1 inhibiting its DNA-
binding activity and creating a negative feedback loop which switches cyclin A 
transcription off, allowing progression into S phase (Xu et al., 1994; Kitagawa et 
al., 1995). The regulation of mitotic progression by CDK1 and CDK2 is not fully 
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understood and a large number of substrates have been identified as targets, 
implicating CDK1 and CDK2 in a variety of different signalling pathways such as 
DNA replication, chromatin packaging and remodelling, spindle assembly and 
DNA damage signalling and repair (Ubersax et al., 2003; Chi et al., 2008). CDK1 
activity is best understood in budding yeast where CDK1 singularly drives the cell 
cycle progression. The current model for CDK driven cell cycle progression is 
based upon the substrates wide range of efficiencies for kinase-mediated 
phosphorylation, with the better substrates being phosphorylated at low CDK 
activity, and vice versa (Koivomagi et al., 2013). This is further complicated by 
the multisite nature of the majority of the substrates resulting in several 
phosphorylation events being required. Recently CKS1 has been identified as a 
phosphor-adaptor subunit of CDK1 able to facilitate multisite phosphorylation by 
binding to specific priming sites (Koivomagi et al., 2011), However, the role of 
CKS1 on CDK1-activity has been shown to depend on the kinetics of the CKS1 
consensus sites phosphorylation in the multisite reaction. If the CKS-binding site 
is phosphorylated early, binding to the remaining sites is triggered followed by 
enhanced CDK1-activity. However, phosphorylation late in the multisite reaction 
leaves CKS1 priming non-essential (McGrath et al., 2013). Based on these 
findings that net phosphorylation is not a singular event and relies on the 
substrates specificity towards CKS1. Additional substrate parameters have also 
been identified including the distance between phosphorylation sites, their 
distribution and the ratio of serine to threonine residues contributing to the 
understanding of CDK-controlled cell cycle progression.  
 The Ubiquitin Proteasome System  
The periodic expression of CDK inhibitors acts as a driving force for the cycle and 
is controlled by ubiquitin-mediated proteolysis. The ubiquitin-proteasome system 
(UPS) covalently attaches multiple ubiquitin molecules (Ub) to a lysine residue 
on specific protein substrates. Several rounds of ubiquitination can occur and 
different lengths of ubiquitin chains have been found to direct the substrate down 
a particular pathway with polyubiquitination, via lysine 48 or lysine 11, being 
associated with targeting substrates for degradation by the 26S proteasome 
(Clague and Urbe, 2010). Ubiquitin ligation is mediated by 3 enzymes; a ubiquitin-
activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin 
ligase (E3). While few reports have linked E1 and E2 to cancer development, the 
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deregulation of E3 has been implicated in numerous human pathologies including 
malignancy (Nakayama and Nakayama, 2006a). As uncontrolled cell proliferation 
and insensitivity to growth inhibitory signals are recognised as key ‘hallmarks’ of 
cancer development (Hanahan and Weinberg, 2011), alterations in the 
expression or activity of the UPS regulatory subunits have become of particular 
interest. 
 Ubiquitin ligases and cell cycle control 
E3 ligases are primarily responsible for the recognition of the target protein, 
specificity and versatility being achieved by the large number of different E3 
ligases available with ~600 putative E3s shown to be encoded by the human 
genome (Li et al., 2008). The E3s are divided into 2 major classes based on their 
domain structure and substrate recognition; the HECT (homologous to E6-
associated protein C-terminus) family, and the largest type the RING (Really 
Interesting New Gene) family, which can be further subdivided depending on the 
structure of the RING finger motif (Sun, 2003). The two main E3 ligases involved 
in cell cycle progression are members of the cullin-based subfamily, a further 
division of the RING-finger type E3s. The anaphase-promoting complex or 
cyclosome (APC/C), and SKP1-CUL1-F-box protein (SCF) both share similar 
core structural components including a scaffold complex, a RING protein and a 
substrate binding subunit (Figure 1.7). However, APC/C and SCF complexes 
differ in their cellular functions and substrates which are highlighted by the timing 
of their activity in the cell cycle.  
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Figure 1.7 Schematic representation of the structure of SCF and APC/C 
ubiquitin ligases. Members of the cullin-RING ligase superfamily, both 
complexes have cullin protein scaffolds (APC2) and (CUL1) (Zheng et al., 2002; 
Barford, 2011). The RING-finger component APC11/RBX1 binds to the N-
terminal end and recruits the E2 conjugating enzyme (E2), and the substrate 
specific subunit attaches to the C-terminal end via an adaptor protein. In the SCF 
complex the F-box SKP2 binds to the SKP1 adaptor. The APC/C complex has 
two specificity factors CDC20 and CDH1 which work alongside the 13 different 
core component subunits (Penas et al., 2011; Bassermann et al., 2014).     
APC/C is active from mid M-phase (anaphase), allowing the passage of the cell 
through G1, and recognises substrates by a degradation motif or degron (D-box) 
in the target protein primary sequence. In contrast SCF complexes, although 
originally thought to primarily regulate the G1-S transition, are active from late G1 
to early M-phase and utilize F-box subunits to recognise substrates which have 
often been post-transcriptionally modified though phosphorylation at specific 
residues (Nakayama and Nakayama, 2006a; Frescas and Pagano, 2008). 
Although involved in distinct phases of the cell cycle, SCF and APC/C complexes 
share common substrates and regulate each other by ubiquitin-mediated 
degradation. This crossover produces a network of positive and negative 
feedback loops which ultimately control CDK1 and CDK2 activity, allowing mitotic 
division and the controlled passage though the cell cycle as summarised in Figure 
1.8, (Bashir et al., 2004; Wei et al., 2004). Several different SCF complexes 
regulate the cell cycle and unlike SCFSKP2, which positively regulates cell cycle 
by targeting CDK inhibitors for degradation, SCFβ-TrCP can promote and inhibit 
proliferation by promoting the degradation the mitotic APC/C activator CDC20, as 
well as the CDH1 inhibitor EMI1 (Guardavaccaro et al., 2003) and CDK1 
inhibitory kinase WEE1 (Watanabe et al., 2004).  
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Figure 1.8 Schematic representation of the interplay between the APC and 
SCF E3 ubiquitin ligase complexes during cell cycle. During early G1 phase 
the APC/CCDH1 complex promotes the degradation of SKP2, its own activator 
CDC20, and cyclins A and B, which decreases CDK1/2 activity. During the G1 
phase levels of SKP2 protein increase, overcome APC/CCDH1 degradation and 
the SCFSKP2 complex targets the CDK inhibitors p27 and p21 for degradation, 
thereby activating CDK1 and CDK2 and promoting progression into S phase. 
Active cyclin A-CDK complexes in S-phase phosphorylate CDH1 targeting it for 
degradation by a second SCF complex allowing the formation of APC/CCDC20. In 
G2 the APC/CCDC20 complex is inhibited by the F-box protein EMI1; however, 
EMI1 alongside the CDK1 inhibitor WEE1 are targeted for destruction by SCFβ-
TRCP allowing the onset of mitosis. CDC20 is then targeted in a self-catalytic 
mechanism during anaphase at the spindle-associated checkpoint allowing 
mitotic progression (Kurland and Tansey, 2004; de Bie and Ciechanover, 2011). 
 The SCFSKP2 Complex 
 SCFSKP2 Structure 
SCF complexes consist of the constant components RBX1, CUL1 and SKP1, and 
a variable component known as the F-box protein. Acting as a rigid scaffold, the 
cullin protein (CUL1) organises this elongated structure. The RING-box protein 
(RBX1), which contains the RING zinc-finger domain, binds to the CUL1 protein 
C-terminal globular α/β domain and forms the catalytic core capable of recruiting 
the E2 ubiquitin-conjugating enzyme. Two E2 enzymes are associated with the 
SCFSKP2 complex, UbcH5c (Brzovic et al., 2006) and CDC34 (Lisztwan et al., 
1998), which are interchangeable and paired with particular targeted proteins 
bound to the substrate receptor F-box protein such as SKP2.  
SKP2 is bound to the N-terminal domain of the CUL1 scaffold protein by the SKP1 
adaptor protein. Prior to SKP1-SKP2 docking on CUL1, it is first released from 
the negative regulator p120CAND1 which holds the CUL1-RBX1 structure in a 
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functionally-immature state. A rate limiting step in SCF assembly, CUL1 is 
covalently modified by the attachment of the ubiquitin-like protein NEDD8. 
Termed neddylation, this process dissociates the p120CAND1 inhibitor from CUL1 
thus promoting SKP1 attachment (Liu et al., 2002).  
Early modelling studies revealed that CUL1 adopted a long stalk-like structure,  
as shown in Figure 1.9, which separated the substrate binding from the catalytic 
E2 cysteine by approximately 50 Å, implying that the substrates are placed to 
bridge the gap (Zheng et al., 2002). Neddylation has since been shown to play 
an important role in both steering RING E3 ligases towards their specific targets 
and modulating the position of the E2 catalytic centre, although presentation of 
the acceptor Lysine to the E2 active site has been shown to require further 
guidance by the substrate itself (Lydeard et al., 2013; Scott et al., 2014). 
  
 
Figure 1.9 The crystal structure of SCFSKP2 (Protein Data Bank File 1LDK) 
Following the attachment of NEDD8, the F-box protein SKP2 binds to the adaptor 
protein SKP1 and determines the substrate specificity. A 50-Å gap separates the 
tip of the SKP2 leucine rich repeat domain and the active-site cysteine of the E2 
which is docked on the RING protein within the catalytic core. The yellow spheres 
represent the zinc molecules within the RBX protein (Petroski and Deshaies, 
2005).   
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 The SKP2 F-box protein 
Attached to the SCF complex by the SKP1 adaptor protein, F-box proteins are 
characterized by a 40 amino acid F-box motif which binds to SKP1, as well as a 
protein-interaction domain which specifically interacts with target substrates (Bai 
et al., 1996). F-box proteins are classified into three categories: FBWs containing 
WD-40 domains, FBLs containing leucine-rich repeats and FBXs which either 
contain different protein-protein interaction modules or no recognisable motif 
(Cenciarelli et al., 1999). One of the better characterised mammalian F-box 
proteins is SKP2 (S-phase kinase-associated protein 2) which belongs to the 
FBX1 class. First discovered as a complex with cyclin A-CDK2 (Zhang et al., 
1995), SKP2 is now known to play an essential role in cell cycle progression 
through the controlled degradation of S-phase inhibitors.  Although SKP2 activity 
is primarily associated with degradation of the CDK inhibitor p27 (discussed 
further in Section 1.9.3), it is responsible for promoting the degradation of a 
number of tumour suppressor proteins (Table 1.5). Recognition of substrates by 
SKP2 requires the phosphorylation of specific residues and in some cases an 
accessory protein which enhances the affinity of the substrate for the SCFSKP2 
complex.    
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Cellular Role Reported 
Substrate 
Function Refs 
Cell Cycle 
Control 
p27KIP1 CDK2 and 4 inhibitor (Carrano et al., 1999; 
Sutterluty et al., 1999; 
Tsvetkov et al., 1999) 
p21WAF1/CIP1 CDK1/2/and 4/6 Inhibitor (Yu et al., 1998; 
Bornstein et al., 2003) 
p57KIP2 CDK Inhibitor (Kamura et al., 2003) 
Free Cyclin E Binds to CDK2 and drives G1 
progression 
(Nakayama et al., 
2000) 
Cyclin D1 Binds to CDK4/6 and drives G1 
progression 
(Yu et al., 1998) 
DNA 
Replication 
CDT1 DNA replication factor: helps 
from pre-RC 
(Li et al., 2003) 
ORC1 Origin recognition complex: 
forms platform for pre-RC 
(Mendez et al., 2002) 
DNA Repair 
(double-
strand 
breaks) 
BRCA2 Involved in repair of 
homologous recombinational 
repair  
(Moro et al., 2006) 
RAG2 Cleaves DNA producing signal 
ends for non-homologous end 
joining 
(Jiang et al., 2005b) 
Gene 
Transcription 
TOB1 Transcriptional corepressor  
and suppressor of cyclin D1 
promoter activity 
(Hiramatsu et al., 
2006) 
p130  pRb pocket protein: activates 
E2F family of transcription 
factors 
(Tedesco et al., 2002; 
Bhattacharya et al., 
2003) 
FOXO1 Member of the Forkhead box 
protein family: multi-functional 
transcription factor  
(Huang et al., 2005) 
MEF/ETS An ETS transcription factor 
driving G1/S transition   
(Liu et al., 2006) 
c-MYC Member of the MYC family of 
TF: Multi-functional 
(Kim et al., 2003; von 
der Lehr et al., 2003) 
E2F1 Multi-functional transcription 
factor suppressed by pRb 
(Marti et al., 1999) 
ING3 Subunit of a Nu4A histone 
acetyltransferase complex and 
multi-functional TF 
(Chen et al., 2010a) 
Table 1.5 Examples of reported substrates of SKP2, summarised from 
(Frescas and Pagano, 2008).  
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 Ubiquitin mediated degradation of CIP/KIP family of CDK inhibitors  
The most established SKP2 substrate is the CDK inhibitor p27 which 
accumulates in SKP2-/- knockout mice and is held responsible for the over-
replication phenotypes observed, including nuclear enlargement, polyploidy and 
multiple centromeres (Nakayama et al., 2000; Nakayama et al., 2001). The 
absence of these abnormalities in SKP2-/-p27-/- double-knockout mice not only 
identified p27 as a bona fide SKP2 substrate, yet also implied that p27 
degradation plays a crucial role in the regulation of the G1 phase by SKP2. 
However, as not all phenotypes of SKP2-/-p27-/- and SKP2-/- mice were found to 
be identical, additional important protein substrates are targeted for SKP2-
mediated ubiquitination (Nakayama et al., 2004).     
Recognition of p27 by SKP2 is dependent on the CDK inhibitor being 
phosphorylated on a threonine residue (Thr187) by the cyclin E-CDK2 complex 
(Müller et al., 1997; Sheaff et al., 1997; Vlach et al., 1997), and the SKP2 
accessory protein cyclin-kinase-subunit 1 (CKS1) (Ganoth et al., 2001). A cell 
cycle regulatory protein, CKS1 enhances the affinity of the SCFSKP2 complex for 
p27. Binding to the leucine-rich repeat domain and C-terminal end of SKP2, the 
interaction does not induce any conformational change in the F-box protein, but 
provides a substrate-binding site where p27 can dock (Hao et al., 2005). The 
Glu185 side-chain of p27 inserts between SKP2 and CKS1 which allows the N-
terminal end of p27 to interact with SKP2, and the C-terminal end which contains 
the phosphorylated T187 residue, with CKS1 (Figure 1.10).  
In addition to the recruitment of CKS1, SKP2-mediated turnover of p27 has been 
shown to require the assembly of p27-cyclin A/E-CDK2 complexes. In a non-
catalytic role, cyclin A (Montagnoli et al., 1999a) and cyclin E (Ungermannova et 
al., 2005) have been shown to directly bind un-phosphorylated p27, which is 
thought to be a necessary step for the recruitment of p27 to the catalytic subunits 
of the SCFSKP2 complex (Zhu et al., 2004; Ungermannova et al., 2005). In addition 
to presenting p27 to the SKP2-CKS1 binding pocket and phosphorylating Thr187, 
interactions observed between CKS1 and CDK2 (Bourne et al., 1996) and 
between SKP2 and cyclin A (Zhang et al., 1995), suggest that the p27-cyclin A/E-
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CDK2 trimeric complex may enhance binding within the SKP1-SKP2-CKS1-p27 
final configuration (Figure 1.11) (Hao et al., 2005). 
 
 
 
Figure 1.10 Crystal structure of SKP1-SKP2-CKS1-p27 complex. Ribbon 
diagrams of the complex are shown in views related by a 90° rotation. SKP1, 
SKP2 CKS1 and p27 are shown in blue, red, cyan and yellow, respectively. (Hao 
et al., 2005) 
 
 
 
Figure 1.11 Model of SCFSKP2 -CKS1-CDK2-cyclin A complex showing that 
the hypothesised interactions, which have been structurally characterised, 
can coexist in one complex. SKP1, SKP2 CKS1 and p27 are shown in blue, 
magenta, cyan and yellow, respectively. The middle region of p27 (yellow) where 
no structural information exists is shown as a dotted line. Also shown is the 
docked E2 (orange) and its active site cysteine (cyan) (Hao et al., 2005).  
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The other members of the CIP/KIP family of CDK inhibitors, p57 and p21, share 
the conserved N-terminal CDK2-cyclin A/E inhibitory domain with p27, and have 
also been shown to be targeted for degradation by the SKP1-SKP2-CKS1 
complex (Bornstein et al., 2003; Kamura et al., 2003). Extensive homology at the 
C-terminal end has been described between p27 and p57, suggesting that the 
mechanism for recognition by SKP2 and recruitment to the SCFSKP2 complex are 
analogous following the phosphorylation of p57 on a threonine residue (Thr310) 
(Kamura et al., 2003; Hao et al., 2005). In contrast, p21 does not show clear C-
terminal domain homology with p27, although similarities have been shown 
including the requirement for CKS1 and for cyclin E-CDK2 presentation and 
phosphorylation of a specific residue (Ser130) (Bornstein et al., 2003). The anion-
binding site of CKS1 has also been shown to be necessary for p21 ubiquitination, 
which interacts with a negatively charged glutamine residue in an analogous 
manner to p27. Interestingly, additional charged residues on p21 have been 
found to interact with CKS1, and promote ubiquitination in the absence of 
substrate phosphorylation, implying that p21 Ser130 phosphorylation is not 
absolutely required for SKP2-mediated degradation. A final difference between 
p27 and p21 observed was the specificity of E2 enzymes. As discussed in Section 
1.9.1, the CUL1 scaffold protein dictates the distance between the SKP2-protein 
substrate and the catalytically active E2 enzymes CDC34 and UbcH5c. While the 
SCFSKP2-mediated ubiquitination of p27 was shown to be similar with CDC34 and 
UbcH5c, a much lower ubiquitination was observed for UbcH5c in the targeting 
of p21, suggesting that the identity of the SKP2 substrate influences E2 enzyme 
selected (Bornstein et al., 2003).  
 Regulation of SKP2 gene expression 
Isolation and characterisation of the human SKP2 promoter has identified binding 
sites for a number of transcription factors suggesting that SKP2 expression is 
regulated at a transcriptional as well as post-translational level. The cell cycle 
dependent oscillations of SKP2 mRNA are often cell context dependent, and both 
active and repressive regions have been identified in the SKP2 promoter 
(reviewed by (Chan et al., 2010b)).  
The identification of binding regions for GA-binding protein (GABP), Notch-1 
activated CBF1, and SP1/ELK-1 regulatory elements, supports the concept of 
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cell cycle SKP2 regulation as these factors are all known to mediate mitogenic 
signalling. However, as neither GABP or Notch-1 alone were able to bypass 
mitogen-dependent SKP2 induction, the accumulation of SKP2 protein during the 
G1 cell cycle phase must involve the cooperation of several signalling pathways 
(Imaki et al., 2003; Sarmento et al., 2005). Interleukin-6 (IL-6) activated signal 
transducer and activator of transcription 3 (STAT3) mediates the expression of a 
variety of genes and was found to promote SKP2 transcription in cervical 
carcinoma cells by recruiting the co-activator p300 to the SKP2 promoter region 
(Huang et al., 2012). Furthermore, regulation of SKP2 gene expression by the 
PI3K/AKT signalling pathway is implicated by the decrease in SKP2 mRNA levels 
following PI3K inhibition or AKT1 knockdown (Auld et al., 2007; Gao et al., 2009). 
The PI3K/PTEN/AKT signalling pathway modulates many aspects of cell growth 
and survival, and has been shown to positively (Andreu et al., 2005) and 
negatively (Mamillapalli et al., 2001) regulate SKP2 transcription in cancer cell 
models, depending on the levels of AKT activation or PTEN suppression. 
Moreover, the transcription factors c-MYC and NF-кB are downstream targets of 
PI3K signalling and have both been shown to bind to the SKP2 promoter; c-MYC 
binding to high affinity E-boxes capable of promoting SKP2 mRNA expression 
(Bretones et al., 2011). However, the contribution of SKP2-mediated p27 
degradation towards c-MYC-driven proliferation was found to be modest when 
compared to the effect of CKS1 loss, suggesting that other CKS1 targets not 
linked to the SCFSKP2 complex are critical for MYC-driven tumorigenesis (Old et 
al., 2010).    
NF-кB is a family of transcription factors and consists of two structural classes, 
Class I/NF-кB subfamily (p50/p105 and p52/p100) and Class II/Rel subfamily 
(RelA and RelB) which bind as homo- or hetero-dimers, and are held in an 
inactive state by the inhibitory IкB subfamily (IкBα and IкBβ). Following 
stimulation by extracellular signals, and a series of proximal events, an IкB-
inducing kinase (IKKα or IKKβ), is activated which phosphorylates the IкB 
proteins, allowing their dissociation and the activation of gene transcription 
(Gilmore, 2006). There are two key pathways leading to NF-кB-mediated 
transcription, however only the non-canonical pathway is reported to regulate 
SKP2 gene expression (Figure 1.12). The IKK catalytic subunits are linked to the 
cell cycle, and the IKKα subunit has been shown to induce SKP2 transcription, 
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and thereby decrease p27 stability, by phosphorylating the p52 precursor p100 
leading to its processing to p52, nuclear translocation as a RelB/p52 heterodimer, 
and exchange with the repressive p50/RelB dimer on the SKP2 promoter 
(Schneider et al., 2006). This model is supported by findings of Barré et al who 
observed p52/RelA dimer binding to the SKP2 promoter during G1 and S phases 
following release of the IKKβ subunit by AKT-mediated phosphorylation (Barre 
and Perkins, 2007). The difference in composition of the activating dimers reflects 
the complexity of NF-кB pathways. Regulated by a large number of stimuli in a 
cell context-dependent manner, functional differences are widely observed 
between the activator and repressor roles of the same NF-кB subunits.  
IKKβ has also been shown to negatively regulate the Forkhead FOXO 
transcription factor FOXO3a, which inhibits SKP2-mediated cell cycle 
progression by transcriptional repression and disruption of the SCFSKP2 complex 
formation. This again links the PI3K/AKT pathway to SKP2 expression, which has 
been shown to target FOXO3a for inactivation (Hu et al., 2004; Santo et al., 2013; 
Wu et al., 2013). Additionally the transcriptional repressor of the HER2/ERBB2 
oncogene in breast cancer Forkhead box P3, FOXP3, is a SKP2 transcriptional 
repressor (Zuo et al., 2007).  
 
 
Figure 1.12 Schematic representation of transcription factors reported to 
regulate SKP2 gene expression.  
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 SKP2 and pRB-mediated cell cycle progression 
The identification of functional E2F responsive elements in the SKP2 promoter 
implicates pRB in the regulation of SKP2 at the transcriptional level (Zhang and 
Wang, 2006). Given that the primary SKP2 target, p27, is a recognised negative 
regulator of cyclin E/A-CDK2 complexes, and that pRB phosphorylation by CDK2 
is required for the E2F release, a positive feedback loop exists between the four 
components (Figure 1.13).  
This interplay between SKP2 and pRB at both the transcriptional and protein 
levels emphasises the central role of SKP2 in the response to proliferative 
signals, and progression through the cell cycle towards mitogen independence.   
 
Figure 1.13. The SKP2 autoinduction loop. A positive feedback loop, upon 
mitogenic stimulation, cyclin D/CDK4/CDK6 complexes perform the initial 
phosphorylation of pRB allowing E2F1 dissociation and expression of E2F1-
dependent genes such as SKP2 and cyclin E. SKP2 and cyclin E/CDK2 
phosphorylate and ubiquitinate p27 promoting its degradation and allowing full 
activation of cyclin E/CDK2 complexes which further phosphorylate pRB 
enhancing E2F1-dependent gene induction (Ji et al., 2004). 
While E2F1 promotes SKP2 activity, two consecutive E2F sites have been 
located in tandem with a TGF-β inhibitory site (TIE) on the SKP2 promoter. This 
tandem E2F/TIE element is a known transcriptional repressor of c-MYC promoter 
function and has been shown to have a similar role in suppressing SKP2 gene 
expression (Appleman et al., 2006; Muth et al., 2010). The pRB-E2F regulation 
of cell cycle dependent genes occurs by three modes: active induction, de-
repression and active repression (reviewed by (Cobrinik, 2005), and the net 
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impact on SKP2 expression is dependent on the combination of E2F-binding sites 
used, as well as the cell type and level of cell differentiation (Chong et al., 2009).   
Although pRB is capable of both activating and repressing SKP2 activity, kinetic 
studies have demonstrated that the p27 accumulation observed during pRB-
mediated G1 arrest is independent of the repression of E2F targets (Ji et al., 
2004). As the outcome of gene regulation depends on the final protein expression 
levels, and pRB-E2F plays a crucial role in cell cycle progression, it is not 
surprising that pRB functions at a post-translational level. Direct interaction 
between pRB and the N-terminus of SKP2 has been demonstrated and found to 
disrupt SKP2-targeted degradation of p27 (Ji et al., 2004), and the ability of pRB 
to cooperate with APC/CCDH1 in targeting SKP2 for proteasomal degradation 
(Binne et al., 2007). Additionally the pRB pocket protein p107 has been found to 
regulate SKP2 proteolysis by a mechanism only partly reliant on the APC/CCDH1 
complex (Rodier et al., 2005). Together these additional faces of the pRB-SKP2 
model highlight a functional cooperation between the two E3 ligases and pRB 
which contributes to pRB-mediated cell cycle progression, independent of E2F 
binding.  
 Post translational modifications of SKP2  
As discussed in Section 1.8.1, SKP2 is periodically expressed throughout the cell 
cycle and targeted for proteasomal degradation by the APC/CCDH1 complex. 
Targeted by CDH1, which recognises the D-box in the SKP2 N-terminal domain 
(Bashir et al., 2004; Wei et al., 2004), post-translational modifications of SKP2 
have been shown to disrupt this interaction increasing SKP2 stabilisation. Current 
literature has identified the phosphorylation of Ser72 by activated AKT as an 
important mechanism for the regulation of SKP2 stability and activity. Induced by 
a direct interaction between AKT and the N-terminus of SKP2 (Gao et al., 2009; 
Lin et al., 2009), Ser72 phosphorylation acts as a molecular switch which, in 
addition to its ability to increase SKP2 transcription, (Section 1.9.4), identifies 
PI3K/AKT signalling as a major regulatory pathway of SKP2 activity.  
Ser72 phosphorylation has been shown to play a central role in the re-localisation 
of SKP2 to the cytoplasm and two mechanisms have been described. Firstly, 
SKP2 phosphorylation promotes binding to the 14-3-3 protein family member 14-
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3-3β which regulates AKT-mediated trafficking across the nuclear membrane, 
and secondly phosphorylation disrupts the nuclear localisation sequence (NLS), 
inhibiting binding to the nuclear import receptors, importin α5 and α7 (Gao et al., 
2009; Lin et al., 2009). Interestingly, restricting SKP2 to the cytoplasm has been 
found to promote cell migration, identifying an oncogenic role for overexpressed 
SKP2 independent of its E3 ligase activity as discussed in Section 1.10.3 (Lin et 
al., 2009).    
Contrasting molecular consequences of SKP2 phosphorylation by AKT have 
been observed. While Lin et al proposed that Ser72 phosphorylation is required 
for efficient SCFSKP2 complex formation (Lin et al., 2009), Gao et al confirmed the 
previous observations that Ser72 modification primes SKP2 for phosphorylation 
on flanking sites Ser64 (by CDK2) and Ser75 (by casein kinase 1), (Rodier et al., 
2008). Phosphorylation of these residues was shown to stabilise SKP2 by 
disrupting its interaction with CDH1, and thus preventing its degradation by the 
APC/CCDH1 complex. However, the dual phosphorylation at Ser74 and Ser75 was 
more effective in inhibiting CDH1 binding, while Ser64 phosphorylation was found 
able to stabilise SKP2 in a CDH1 independent mechanism (Gao et al., 2009).  
Rodier et al did not find Ser72 phosphorylation a requirement for SCFSKP2 
assembly and activity, however as the authors overexpressed all components of 
the SCF complex including CKS1, this may have favoured SCFSKP2 complex 
formation (Rodier et al., 2008). Interestingly, although the N-terminal region of 
SKP2 is dispensable for the assembly of the SCFSKP2 complex (Schulman et al., 
2000), a SKP2 mutant lacking the N-terminal 90 amino acids was found to form 
the SCF complex more efficiently than full-length SKP2 (Lin et al., 2009). Based 
on the model that Ser72 phosphorylation promotes a conformational change of 
the N-terminus to promote the interaction between SKP2 with SKP1, the 
phosphorylation of Ser72 may identify a mechanism to which the overexpression 
of SKP2, seen in human tumours, promotes aggressive proliferation following 
AKT-mediated phosphorylation (Ecker and Hengst, 2009; Lin et al., 2009). 
Nonetheless, as CDH1 is more prevalent in the nucleus, the cytoplasmic re-
localisation may ultimately play a larger role in SKP2 stabilisation than post-
translational modification and structural inhibition.   
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A second post-translational modification of SKP2 which produces a similar 
outcome is acetylation. Building upon the known interaction between SKP2 and 
the transcriptional co-activator/acetyl-transferase p300, SKP2 has been shown 
to be acetylated at K68 and K71 within the NLS region (Inuzuka et al., 2012). 
Negatively regulated by the deacetylase SIRT3, the sites are adjacent to Ser72 
and acetylation has been shown to prevent the SKP2-CDH1 interaction and 
promote SKP2 translocation into the cytoplasm, independently of AKT-mediated 
phosphorylation (Inuzuka et al., 2012).  
 SKP2 the proto-oncogene   
SKP2 protein overexpression has been identified in a variety of human cancers 
and found to contribute to the malignant phenotype both as an E3 ligase and 
through molecular mechanisms independent of its F-box (Figure 1.14).   
 Targeting p27 for degradation 
The majority of reports of SKP2 as an oncogenic protein are related to the 
negative regulation of the CDK inhibitor p27. In the absence of p27, mice have 
organ hyperplasia and grow ~20%-30% larger than wild-type animals. However, 
p27-/- mice rarely develop malignancies with exception of the thymus and pituitary 
glands, which have high endogenous levels of p27 (Blain et al., 2003).  A ‘dose-
dependent’ or ‘haploinsufficient’ tumour suppressor, the loss of a single allele of 
p27 (CDKN1B) increases susceptibility to tumorigenesis in mice when challenged 
with either carcinogens or paired with oncogenes (Blain et al., 2003; Bloom and 
Pagano, 2003). The contribution of p27 deficiency to tumorigenesis through 
enhancing proliferation or reducing apoptosis when p27-/+ mice are crossed with 
PTEN+/- or RB+/- mice, respectively, in addition to the desensitisation to anti-
mitogenic stimuli seen in p27 deficient human tumours, highlights the potential 
clinical benefits of restoring p27 levels (Park et al., 1999; Di Cristofano et al., 
2001; Blain et al., 2003). However, although low levels of p27 profoundly impact 
tumour progression and are associated with a poor prognosis, mutations and 
deletions of CDKN1B are seldom found and mRNA levels often stay constant, 
implying that the low levels are a result of decreased protein stability and 
increased degradation (Bloom and Pagano, 2003).  
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 SKP2 overexpression  
Amplification of the 5p13 locus containing the SKP2 gene or increased 
expression of SKP2 mRNA are only occasionally seen and are often associated 
with an advanced metastatic state, while increased SKP2 expression is often 
detected in early oncogenesis (Dowen et al.; Yokoi et al., 2004). As previously 
discussed, a multitude of molecular pathways regulate SKP2 expression at the 
transcriptional and post-translational level, many of which are found to be 
constitutively active in human cancers (e.g. PTEN/PI3K/AKT, c-MYC, IL-
6/STAT3). Consequently the overexpression of SKP2 is often due to a 
combination of enhanced SKP2 gene activation and decreased CDH1- targeted 
degradation.  
SKP2 overexpression has been detected in various types of cancers and directly 
correlates with tumour aggressiveness and poor prognosis (Hershko, 2008). 
There is often an inverse relationship between SKP2 and p27 levels, and SKP2 
cooperation with H-RasG12V to promote neoplastic transformation is associated 
with reduced levels of p27, implying that it is the loss of the CDK inhibitor that 
promotes malignancy (Gstaiger et al., 2001). Although promoting the 
accumulation of p27 forms the objective of the majority of inhibitor development 
programmes targeting SKP2, the importance of the SKP2-p27 axis has been 
shown to be cell type specific. As SKP2 regulates p27 levels to promote S phase 
transition and mitogen independence, a point of control that is regulated by 
multiple pathways, the importance of SKP2 and the impact of SKP2 inhibition is 
heavily dependent on the significance of p27 degradation on tumour incidence, 
progression and aggressiveness in each tumour type (Timmerbeul et al., 2006).  
Importantly, not all the over-replication characteristics in the SKP2-/-mice were 
corrected by the dual knockout of p27, implying that secondary SKP2 targets 
could also contribute to its oncogenic function (Kossatz et al., 2004).  
 SKP2 cytosolic localisation and cell migration 
SKP2 overexpression has been linked to metastatic behaviour in several cancer 
types including prostate (Drobnjak et al., 2003), breast (Signoretti et al., 2002), 
melanoma (Rose et al., 2011) and lymphoma (Yokoi et al., 2004), which often 
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also correlates with increased SKP2 cytoplasmic immunostaining. Although the 
mechanism is not fully elucidated, the impaired migratory capacity of SKP2-/- 
MEFs compared to their wild-type counterparts suggests that SKP2 is involved in 
the migratory response (Lin et al., 2009).  
SKP2 cytoplasmic localisation induced by Ser72 phosphorylation and K68/K71 
acetylation, as discussed in Section 1.9.6, has been shown to contribute to 
tumour cell migration. Expression of the KLKL acetylation-mimetic SKP2 mutant 
in SKP2-/- MEFs was associated with increased migration compared to wild-type 
SKP2 MEFs. Additionally, increased expression of E-cadherin was detected both 
in SKP2-/- MEFs and following the depletion of endogenous SKP2 in a range of 
epithelial carcinoma cell lines. An important protein which mediates cell-cell 
adhesion, SKP2 is reported to modulate E-cadherin stability by targeting it for 
degradation once phosphorylated by casein kinase 1 (CK1) (Inuzuka et al., 2012).  
A second model for SKP2-mediated cell migration and metastasis implicates 
SKP2 in the transcriptional activation of RhoA. A member of the Ras superfamily, 
Rho GTPases are involved in cancer cell motility by inducing the reorganisation 
of the actin cytoskeleton (Sahai and Marshall, 2002). Although RhoA transcription 
is ultimately induced by c-MYC binding to E-box motifs within the proximal 
promoter, it has been suggested that c-MYC recruits SKP2 to form a MYC-SKP2-
MIZ1 transcriptional complex which orchestrates increased RhoA expression and 
thus enhanced motility (Chan et al., 2010a). Furthermore, p27 has been shown 
to regulate cell motility by binding to RhoA thus preventing it from interacting with 
its downstream effectors (Besson et al., 2004). SKP2 overexpression would 
therefore target RhoA both at the transcriptional and post-translational level, and 
this interplay has been observed in the regulation of cell motility in gastric cancer 
cell lines by the IL-6/JAK/STAT3 pathway. Interleukin-6 (IL-6) induced STAT3 
activity regulates multiple aspects of cancer development and progression, and 
is a well-established facilitator of increased invasion and metastasis (Teng et al., 
2014). A direct transcriptional target of STAT3 (Section 1.9.4) (Huang et al., 
2012), SKP2 links the IL-6/JAK/STAT3 pathway with RhoA activity, as the 
STAT3-mediated upregulation of SKP2 results in decreased p27 and increased 
RhoA activity (Wei et al., 2013).   
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 SKP2 and apoptotic cell death 
Although the oncogenic role of SKP2 is primarily associated with its ability to 
target proteins for degradation, many of which are established tumour 
suppressors, there is a growing body of literature describing an oncogenic 
function for SKP2 independent of its E3 ligase activity. One such mechanism is 
the involvement of SKP2 in the regulation of apoptosis. The depletion of SKP2 
by siRNA or antisense oligonucleotides has been shown to induce apoptosis in 
several cancer cell lines (Cobrinik, 2005; Jiang et al., 2005a). However, only 
recently have the molecular mechanisms by which SKP2 suppresses apoptosis 
started to be understood. The evasion of apoptosis is one of the main hallmarks 
of cancer development and is often associated with the loss of function of one or 
both of the two major tumour suppressors, p53 and pRB (Hanahan and 
Weinberg, 2011), both of which have been shown to have their functional activity 
modulated by SKP2.  
The antiproliferative effects of p53 are exerted through its ability to act as a 
transcription factor. Often activated by post-translational modifications, the p53-
cofactor p300 stimulates transcriptional activity by transferring acetyl groups to 
conserved lysine residues within the C-terminus subsequently activating p53 
DNA-binding (Gu and Roeder, 1997; Gu et al., 1997; Lill et al., 1997). Kitagawa 
et al found that although SKP2 does target p300 for degradation, this role was 
secondary to the disruption of the p300-p53 interaction. SKP2 directly binds to 
p300 through the same CH1 and CH3 domain as p53, thereby antagonising the 
p53-p300 interaction and suppressing p53-mediated cell cycle arrest and 
apoptosis (Kitagawa et al., 2008). Interestingly, SKP2 deficiency has also been 
shown to induce senescence in an ARF-p53 independent manner in ARF-/- mice 
and in PTEN-deficient prostate, although the authors emphasized the 
requirement for the SKP2 inactivation to be paired with an oncogenic stress to 
induce senescence, which was found to be dependent upon the levels of 
induction of p27, p21 and the activating transcription factor Atf4 (Lin et al., 2010a). 
Additionally the SKP2 isoform SKP2B, which differs at the C-terminal domain 
(Radke et al., 2005), is reported to promote the degradation of the potential 
tumour suppressor protein prohibitin (Chander et al., 2010). Thought to be 
involved in both cell proliferation and apoptosis, depending on its cellular location, 
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nuclear prohibitin has been shown to enhance p53-mediated transcriptional 
activity while repressing E2F1 activity. 
In contrast to the p53 pathway which is activated by oncogenic stress, pRB is 
regulated by phosphorylation, and when active (i.e. hypo-phosphorylated) is often 
associated with induction of senescence or a G1 arrest rather than apoptosis. 
Recently studies have found that the ability of pRB to maintain p27 stability plays 
an important role in the capacity of pRB to both arrest cells in G1 and induce 
cellular senescence (Ji et al., 2004; Binne et al., 2007). Deleting SKP2 in pRB-
deficient cells (Rb1+/-Skp2-/-) was found to prevent pituitary tumorigenesis in mice 
by inducing apoptosis identifying a synthetically lethal interaction which could be 
targeted to treat RB-deficient tumours (Wang et al., 2010a).   
The interplay between p53 and pRB in the response to SKP2 depletion conforms 
to the existing paradigm whereby p53 is activated in response to pRB-deficiency 
(Wang et al., 2010a) and conversely, that pRB is activated by p53-deficiency (Lin 
et al., 2010a). Zhao et al demonstrated a p27 safeguarding response where 
SKP2 deletion in pRB/p53 doubly deficient tumours established a lasting mitotic 
block due to the accumulation of p27 protein which subsequently developed into 
apoptotic cell death (Zhao et al., 2013). This effect of p27 stabilisation has 
previously been observed in SKP2-/- mouse models, where chromosome over-
duplication as a result of the accumulation of cyclin E and p27 in SKP2-/- MEFs 
triggered apoptotic cell death (Nakayama et al., 2000). These data suggest that 
specifically targeting p27 degradation mechanisms would be more effective than 
targeting SKP2 alone; however, p27 is known to both promote and inhibit 
apoptosis depending on the cell type and environmental factors (Drexler, 2003). 
It would therefore be important to first determine the contribution of p27 to tumour 
progression in each tumour type.  
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Figure 1.14 Summary of key potential mechanisms by which SKP2 can be 
overexpressed and potentiate tumour development  
 SKP2 in Neuroblastoma 
The oncogenic function of SKP2 in neuroblastoma is primarily associated with its 
role in the ubiquitination and degradation of p27. The mRNA and protein level of 
p27 is of clinical relevance to the progression of neuroblastoma, and p27 levels 
have been shown to be predictive for long-term survival and decreased 
metastasis in neuroblastoma patients (Bergmann et al., 2001; Koomoa et al., 
2013). Consequently, p27 accumulation has been associated with a favourable 
response to treatment in neuroblastoma cell lines with increased p27 levels 
shown to; prevent chromosomal instability following DNA damage (Sugihara et 
al., 2006), induce retinoic acid-mediated cell cycle arrest (Nakamura et al., 2003), 
and play a key role in the potency of the ODC1 inhibitor alpha-
difluoromethylornithine (DFMO) towards G1 arrest and tumour migration 
(Koomoa et al., 2013).     
SKP2 overexpression has previously been observed at the mRNA and protein 
level in neuroblastoma clinical samples, and is related positively with tumour 
aggressiveness and inversely with p27 levels. Identifying high risk neuroblastoma 
independently of established prognostic indicators (e.g. MYCN amplification 1p 
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deletion, 17q gain), the higher levels of SKP2 mRNA and protein found in MYCN 
amplified compared to non-amplified tumours suggests that a regulatory 
relationship exists between MYCN and SKP2 (Westermann et al., 2007). This 
suggestion is supported by studies which have found higher SKP2 levels in the 
presence of ectopic MYCN expression and in MYCN amplified cell lines 
(Sugihara et al., 2006; Bell et al., 2007; Westermann et al., 2007; Muth et al., 
2010). Moreover, SKP2 has recently been characterised as a c-MYC target gene 
confirming the existence of E-box motifs within the SKP2 promoter (Bretones et 
al., 2011). Given the overlap often found between target genes of the MYC family 
members, these previous findings suggest that SKP2 is a candidate gene for 
direct MYCN regulation in neuroblastoma.       
The exact role of SKP2 overexpression in MYCN amplified neuroblastoma is not 
fully understood, yet both genes have been shown to drive uncontrolled 
proliferation and regulate p53-mediated apoptosis (Kitagawa et al., 2008; Chen 
et al., 2010b). MYCN-driven deregulated SKP2 expression may therefore 
attenuate apoptotic cell death as seen for c-MYC (Bretones et al., 2011). 
However, SKP2 protein expression levels do not correlate with MYCN expression 
in MYCN amplified or non-amplified cell lines (Westermann et al., 2007). 
Furthermore although low p27 expression has been reported to inversely 
correlate with SKP2, it is of prognostic importance in neuroblastoma independent 
of MYCN status (Bergmann et al., 2001). The role of SKP2 in neuroblastoma 
pathogenesis may therefore range from being an independent driving force to an 
essential MYCN-driven mechanism.  
 The regulation of SKP2 by c-MYC and MYCN 
Like many transcription factors both c-MYC and MYCN are rapidly turned over by 
the ubiquitin proteasome pathway. Recently, SKP2 has been shown to participate 
in the ubiquitin/proteasome-mediated degradation of c-MYC. In a yeast-based 
screen, Kim et al took advantage of the destruction of mammalian c-MYC 
expressed in Saccharomyces cerevisiae by Ub-mediated proteolysis. Through a 
series of mutations inhibiting the function of different components of the ubiquitin 
proteasome system, it was found that c-MYC was stabilised in yeast cells lacking 
Grr1, the yeast ortholog of SKP2 (Kim et al., 2003). This evidence was supported 
by similar findings from von der Lehr et al, confirming that SKP2 participates in c-
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MYC degradation. Interestingly, this interaction between c-MYC and SKP2 was 
also found to stabilise the transcription factor and enhance c-MYC regulated 
transcription and S-phase entry (von der Lehr et al., 2003). Surprisingly, the 
interaction and coactivator ability of SKP2 was observed to be dependent upon 
the presence of the SKP2 F-box motif, implying that the E3 ligase activity plays a 
role; however, the effect was shown to be independent of p27 degradation or 
phosphorylation of c-MYC (von der Lehr et al., 2003). SKP2 recruits c-MYC to 
the SCFSKP2 complex by interacting with the N-terminal MYC Box 2 (MB2) and a 
region within the C-terminal BHLH-Zip domain. As both these regions are 
required for the transcriptional regulation and oncogenic potential of c-MYC these 
results indicate that SKP2 plays a critical role in the oncogenic potential of c-MYC 
by acting a transcriptional cofactor (Kim et al., 2003; von der Lehr et al., 2003). 
Although the authors were unable to show ubiquitination and degradation of c-
MYC occurred at the promoter, the removal of the SKP2 F-box repressed c-MYC 
induced transcription. These findings therefore suggest that the E3 ligase activity 
of SKP2 is essential for its coactivator function, supporting the hypothesis that 
there is a close relationship between the activities of transcription factors and 
their ubiquitination and degradation.   
Moreover SKP2 has been identified as a direct c-MYC target gene, inducing 
SKP2 accumulation and subsequent p27 degradation in a CML model. 
Interestingly, c-MYC was also shown to promote the phosphorylation of p27 on 
the Thr187 residue required for SKP2 recognition through its ability to up-regulate 
CDK2 and cyclin A and E, therefore reinforcing the importance of c-MYC in 
controlling p27 levels (Bretones et al., 2011).   
Several studies have observed higher SKP2 expression in the presence of MYCN 
in neuroblastoma tumours and cell lines (Bell et al., 2007; Muth et al., 2010). The 
mechanism of MYCN-mediated up-regulation of SKP2 is not fully understood but 
one report identifies SKP2 as an indirect target of MYCN (Muth et al., 2010). As 
SKP2 is a confirmed E2F2 gene target the authors suggested that deregulated 
SKP2 expression is through the induction of the direct MYCN target gene product 
CDK4, which promotes the SKP2 auto-induction loop by increasing pRB 
phosphorylation and E2F1 abundance, which consequently decreases the level 
of repressive pRb-E2F1 complexes on the SKP2 promoter (Muth et al., 2010). 
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However, taking into account the recent mapping of two high affinity E-boxes on 
the SKP2 promoter to which c-MYC can bind, and the aforementioned homology 
within the MYC family, it is possible that SKP2 is in fact a direct target of MYCN. 
Transcript profiling has established SKP2 as a prognostic indicator of high risk, 
aggressive disease independent of the MYCN status and disease stage 
(Westermann et al., 2007). Nevertheless, two independent gene expression 
microarray analyses have identified an effect on SKP2 levels from differential 
MYCN expression, with both studies showing an increase in SKP2 in the 
presence of MYCN (Bell et al., 2007; Muth et al., 2010). Amongst other 
characteristics, deregulated MYCN expression is well known to accelerate cell 
proliferation by shortening the G1 phase of cell cycle (Lutz et al., 1996). Several 
studies have suggested that the enhanced transition into S phase induced by 
MYCN is in part a result of the reduced expression of cell cycle related genes 
such as p27 and p21, as their function has been reported to be antagonised by 
c-MYC (Charron et al., 1992; Wei et al., 2004; Guglielmi et al., 2014). However 
further research into the relationship between MYCN and p27/p21 implies that 
high MYCN expression alone is not responsible for their repressed levels (Bell et 
al., 2006; Guglielmi et al., 2014). As both p27 and p21 are targeted by the 
SCFSKP2 complex for degradation the hypothesised direct regulation of SKP2 by 
MYCN may contribute to the aggressive phenotype of MYCN-amplified tumours.         
  Pharmacological inactivation of SKP2 
The prognostic significance and potential oncogenic role of SKP2 in several 
human malignancies, in contrast to its restricted role in mouse development, has 
led to the classification of SKP2 as a cancer-cell specific drug target. Taken with 
the observation that SKP2 knockdown only promotes senescence, apoptosis and 
autophagy in the presence of an oncogenic event, and that SKP2 knockout mice 
are both viable and fertile, SKP2 inhibition has the potential to be tumour cell 
specific (Lin et al.; Chen et al., 2008a; Kitagawa et al., 2008). Although small 
molecules which indirectly disrupt SKP2 activity have been developed in an 
attempt to restore p27 levels, as discussed in Chapter 5, no specific SKP2 
inhibitors are currently available. The crystal structure of the SCFSKP2 complex 
identifies interfaces between p27 and SKP2-CKS1, offering the possibility of 
compounds designed to directly interact with these interfaces in order to inhibit 
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SKP2-mediated p27 degradation. Ubiquitination of p27 is prevented by 
introducing a point mutation at Glu185 or Thr187 (Hao et al., 2005), and this site 
together with clefts at the CKS1-SKP2 interface could be exploited by small 
molecular inhibitors to disrupt the SKP2-p27 interface (Hao et al., 2005).  
Protein-protein interactions are often described as ‘undruggable’; however, 
advances in drug discovery approaches and techniques have opened up new 
possibilities (as reviewed by (Nero et al., 2014)). In a recent report, Chan et al 
identified candidate compound SZL-P1-41 (compound #25) which specifically 
inhibited SKP2 activity by blocking the SKP1-SKP2 interaction (Chan et al., 
2013). By utilizing virtual high-throughput screening, clusters of residues along 
the SKP2-SKP1 interaction surface were first identified on the basis of their 
contribution to the overall binding energy. Termed ‘hot spots’, a library of potential 
small molecule inhibitors was then searched, and evaluated for their interaction 
with the drug target. A knowledge driven approach, virtual-ligand screening (VLS) 
utilises previously collected information on the 3D structure of the target to 
establish an understanding of the spatial and energetic criteria required for the 
interaction. A computational or in silico method, potential inhibitors can then be 
screened, predictions made based on their calculated binding affinities for the 
‘hot spots’, and lead compounds identified for biological screening and 
experimental validation (Klebe, 2006). A study has recently utilised this approach 
to identify inhibitors of the SKP2-CKS1 interface (Wu et al., 2012b), enhancing 
the specificity to only SKP2 targets which require CKS1 (i.e. CDK inhibitors p27, 
p21 and p57). Taken together with the small molecule inhibitors identified by 
Chan et al, these studies illustrate potential approaches to specifically target 
SKP2 activity.   
 Summary 
MYCN amplified neuroblastoma is a highly aggressive sub-type of disease which 
has proven difficult to treat successfully. Consequently, downstream effectors of 
MYCN are being investigated as potential therapeutic targets. SKP2 
overexpression is observed in several malignancies including neuroblastoma 
where it is associated with MYCN amplification, suggesting a potential 
mechanistic link. The substrate recognition factor for the SCFSKP2 E3 ligase 
complex, SKP2 is an important regulator of the G1/S cell cycle transition, primarily 
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through its ability to target the CDK inhibitor p27 for degradation. Often correlating 
directly with tumour progression and inversely with p27 stability, SKP2 is a well-
established oncoprotein whose inactivation while compatible with life, has been 
shown to trigger cell-type specific G1 arrest, senescence and apoptotic cell death. 
The present study aims to further validate SKP2 as a potential therapeutic target 
in neuroblastoma by determining whether it is directly regulated by MYCN, and 
exploring its role in cancer cell proliferation and survival to inform the discovery 
and development of SKP2 inhibitors.   
            Hypothesis and Aims 
Hypothesis: 
SKP2 promotes cancer cell proliferation and survival in neuroblastoma identifying 
it as a potential therapeutic target.    
Aims:  
1. To determine whether SKP2 is a direct transcriptional target gene of MYCN.  
2. To validate SKP2 as a therapeutic target using a panel of neuroblastoma cell 
lines, and determine whether MYCN amplification or p53 status influence 
sensitivity to SKP2 inhibition. 
3. To investigate the potency and specificity of commercially available and novel 
compounds reported or designed to directly or indirectly target SKP2.   
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Materials and Methods 
 Tissue culture 
All neuroblastoma cell lines used in this study were routinely confirmed to be 
mycoplasma negative using the Mycoalert® detection kit (Lonza, Basel, 
Switzerland). All tissue culture was carried out using aseptic technique in class II 
contamination hoods (Biomat2, MedAir® Inc. MA, USA). A list of the 
neuroblastoma cell lines used in this study is shown in Table 2.1. The conditional 
MYCN expressing SHEP Tet21N cells and SKNAS-Nmyc-ER cells are discussed 
in detail in Section 2.2.  
 Propagating neuroblastoma cell lines 
All cell lines were grown in RPMI 1640 growth medium with 10% (v/v) foetal 
bovine serum (FBS) (Sigma, St Louis, MO, USA), 100 units/ml penicillin and 100 
µg/ml streptomycin (Sigma) unless otherwise stated. All cell lines were grown at 
37°C in 5% CO2 in a humidified incubator and passaged once 60-70% confluent. 
The growing surface of the flask was washed with 10 ml sterile PBS and the cells 
detached by incubation at room temperature with 2 ml of 1x trypsin-EDTA 
(Sigma). Once the cells were dislodged the trypsin was neutralised using 8 ml of 
full media and the resulting cell suspension used to seed new flasks at the desired 
cell density. 
 Resurrecting cell lines from liquid nitrogen stocks 
Cells were removed from liquid nitrogen storage and thawed in a 37°C waterbath. 
The cell suspension was transferred to a sterile universal container and 
centrifuged at 500 x g for 5 minutes at room temperature, after which the 
supernatant containing dimethyl sulphoxide (DMSO) was removed and the cell 
pellet resuspended in 6 ml of fresh full media, previously warmed to 37°C, and 
transferred to a 25 cm2 flask (Corning Incorporated, Corning, NY, USA) and 
incubated at 37°C, 5% CO2 in a humidified incubator.  
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Table 2.1 Morphology, MYCN and MDM2 amplification and p53 status for 
the panel of neuroblastoma cell lines used in this study.  
1 Mutation from alternative splicing downstream of exon 9; leads to truncated β-
isoform. 2 Missense mutation at exon 5, codon 135; TGC (cysteine) to TCC 
(phenylalanine).3 Selected for resistance to potassium antimony tartrate (KAT) 
leading to point mutation at codon 135 (exon 5); TGC (cysteine) to TCC 
(phenylalanine). (-) non-amplified, (+) amplified and WT: wildtype.    
 Freezing down cells for storage in liquid nitrogen 
For cell stocks a 75 cm2 flask of cells at ~70% confluency were frozen down. 
Adherent cells were detached according to Section 2.1.1, centrifuged at 500 x g 
and resuspended in 10 ml freezing media containing 10% DMSO (v/v) (Sigma, 
Tissue culture grade), 10% FBS (v/v) and 80% growth media (10% FBS v/v). Cell 
suspension was aliquoted into cryogenic vials (NUNC™, Rochester, NY, USA) 
and stored at -80°C for 24 hrs prior to transfer to liquid nitrogen stores.  
 Cell counting 
The concentration of cells after detachment was determined using a 
haemocytometer (Hawksley, Sussex, UK). The cells were dispersed by passage 
Cell Line Morphology MYCN 
Status 
p53 Status Reference 
SHSY5Y N-type - WT (Biedler et al., 1973) 
GIMEN S˃N - WT (Cornaglia-Ferraris et 
al., 1990) 
SHEP S-Type - WT (Biedler et al., 1978) 
SKNAS S-Type - Mutant1 (Goldschneider et al., 
2006a) 
SKNAS-
NmycER 
N-Type - Mutant1 (Valentijn et al., 2005) 
SK-N-
BE(2c) 
I-Type + Mutant2 (Biedler et al., 1973) 
IMR-
KAT100 
N-Type + Mutant3 (Xue et al., 2007) 
IMR32 N-type + WT (Tumilowicz et al., 
1970) 
LAN5 N-type + WT (Seeger et al., 1982) 
SHEP-
TET21N 
S-type  WT (Lutz et al., 1996) 
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through a 5 ml COMBITIP® PLUS syringe (Eppendorf, Cambridge, UK) and ~10 
µl of cell suspension drawn under the coverslip of the haemocytometer by 
capillarity action. The haemocytomter has 2 grids for scoring cells, each 1 mm2 
(area) x 0.1 mm (depth). The liquid of 0.1 mm depth covering the 1 mm square 
therefore has a volume of 10-4 ml (0.1 cm x 0.1 cm x 0.01 cm). To calculate the 
number of cells/ml, the average number of cells from 2 central grids was first 
calculated and then multiplied by 104.  
48 cell in counting area = 48 cells per 10-4 ml = 48/10-4 cells per ml = 48 x 104 
cells per ml).    
 
 
Figure 2.1 Grid layout of the hemocytometer 
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 MYCN regulatable cell lines  
 SHEP Tet21N MYCN expression system 
The SHEP-Tet21N MYCN expression system allows the effect of conditional 
MYCN expression to be investigated by using a synthetic inducible expression 
system based around the tetracycline repressor of E coli. Stably transfected into 
the S-type SHEP cells which normally express low levels of MYCN mRNA and 
no detectable protein levels, the expression of MYCN can be controlled through 
the addition or removal of tetracycline (Lutz et al., 1996).  
 Principles of Tet-OFF system 
The Tet-Off system utilises the regulatory elements of the Tn10-specified 
tetracycline-resistance operon of E. coli where resistance to the antibiotic 
tetracycline is negatively regulated by the tetracycline repressor (tetR). TetR 
blocks the transcription of tetracycline resistant genes by binding to the tet 
operator sequences (tetO). Upon addition of tetracycline tetR is prevented from 
binding the tetO allowing gene activation (Gossen and Bujard, 1992).  
By fusing the tetR to the C-terminal domain (activation domain) of the VP16 
protein found in the Herpes Simplex Virus (HSV), the TetR is converted from a 
transcriptional repressor to a hybrid transcriptional activator (tTA) which can 
activate promoters fused to specific tetO sequences resulting in an increase in 
gene expression up to 105-fold (Gossen and Bujard, 1992).  
In order to express the gene of interest, several identical tetO sequences are 
placed upstream of a minimal CMV promoter (PminCMV) forming the tetracycline 
response element (TRE). Therefore, under regular culture conditions the tTA will 
bind to the specific tetO sequences within the TRE promoting the expression of 
the gene of interest. Following the addition of tetracycline the TRE-controlled 
genes are repressed as tetracycline binds to the tTA rendering it incapable of 
binding the TRE sequences, thereby preventing the transactivation of the gene 
of interest (figure 2.2).  
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Figure 2.2 The Tet-OFF system  
 
 Generation of SHEP-Tet21N MYCN regulatable cells  
The Tet-OFF SHEP Tet21N cells were originally generated by Lutz et al. (1996). 
In brief, SHEP cells were first co-transfected with the pUHD15-1 plasmid 
containing the Tet-responsive reporter units (tTA) and the pSV2neo plasmid 
which provided neomycin resistance and allowed selection by treatment with 
G418 sulphate. The clones were then co-transfected with the pUHD10-3/MYCN 
plasmid which had previously had the MYCN sequence cloned into the EcoR1 
site, and the pHMR272 plasmid allowing selection by hygromycin (Figure 2.3). 
Addition of G418 sulphate and hygromycin in the growth media therefore selected 
and maintained the growth of transfected clones which expressed MYCN only in 
the absence of tetracycline (Lutz et al., 1996).  
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Figure 2.3 Plasmid maps of a. pUHD15-1 and b. pUHD10-3 used to generate 
the Tet21N cell line (http://www.zmbh.uni-heidelberg.de) 
 Culturing of SHEP-Tet21N MYCN regulatable cells 
The SHEP-TET21N cell line was grown in RPMI 1640 growth medium with 10% 
(v/v) FBS (Sigma) and 200 µg/ml G418 sulfate (Calbiochem, Darmstadt, 
Germany) at 37°C in 5% CO2 in a humidified incubator and passaged once 60-
70% confluent. Cells were cultured in the presence of 1 µg/ml tetracycline 
(Sigma) for a minimum of 24 hrs to switch off MYCN expression.   
 SKNAS-NmycER cell line 
The SKNAS-NmycER cell line was generated by stably inserting the NmycER 
chimeric protein into the non-MYCN amplified, p53 mutant SKNAS cell line. The 
C-terminus of mouse MYCN protein is fused to the hormone binding domain 
cDNA of MYCN (lacking 
non-coding exon 1) 
inserted within the 
Multiple cloning site 
(MCS) at the EcoR1 site
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(HBD) of a transcriptionally inactive oestrogen receptor. Harbouring a point 
mutation (G525R) the receptor is unable to bind to oestrogen yet retains normal 
sensitivity to the synthetic ligand 4-hydroxytamoxifen. The ability of MYCN to 
transcriptionally activate its target genes is therefore dependent on the presence 
of 4-hydroxytamoxifen to promote the movement of MYCN from the cytoplasm 
into the nucleus (Littlewood et al., 1995).       
 Generation of the SKNAS-NmycER cell line 
The SKNAS-NmycER cell line was generated using a pBABEpuro retrovirus 
vector which contained a puromycin resistance gene and the Nmyc-ER chimeric 
protein construct. Based on the previous construction of the c-MycER construct 
a BamHI site was created using PCR at the 5’ end of a tamoxifen mutant 
oestrogen receptor to facilitate the fusion of the MYC protein. The fusion protein 
was subsequently cloned into a retroviral vector through the generation of an 
EcoRI fragment containing the MycER construct (Figure 2.4) (Littlewood et al., 
1995). The retroviral vector pBABEpuro-myc-ER was then transfected into the 
SKNAS cells by retrovirus transduction, and stable transfectants selected and 
maintained by continuous exposure to puromycin (Tang et al., 2006a).   
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Figure 2.4 Construction of the c-MycER™ chimeric protein and plasmid 
map of pBABE-puro used to generate the SKNAS-NmycER cell line. The 
mutant hormone binding domain of the oestrogen receptor containing a single 
amino acid change from glycine to arginine at position 525 was fused to the C-
terminal of human c-Myc to form the c-MycER construct (Littlewood et al., 1995). 
The EcoRI site in which the N-MycER construct is inserted is highlighted 
(www.addgene.org)    
 Culturing the SKNAS-NmycER cell line 
The SKNAS-NmycER cell line was grown in DMEM growth medium with 10% 
(v/v) FBS (Sigma) and 1 µg/ml puromycin at 37°C in 5% CO2 in a humidified 
incubator and passaged once 60-70% confluent. Cells were cultured in the 
presence of 100 ng/ml 4-hydroxytamoxifen to switch on the transcriptional activity 
of MYCN.    
 Advantages and disadvantages of the MYCN regulatable cell lines  
A number of systems can be employed to control transgene expression in 
mammalian cells. The Tet-OFF and ER system have tight control over gene 
expression which is also reversible, unlike knock-out or knock-in systems such 
as Cre-lox recombination were the effect on gene expression is irreversible. The 
Tet system and ER system are highly sensitive to their corresponding activator 
molecules and have both been used to study MYCN target genes upon MYCN 
modulation (Bell et al., 2007; Valentijn et al., 2012). Although, as the Tet-OFF 
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system represses the transcription of a gene, it will have a slower response time 
than the ER system which stabilises an already expressed protein inducing its 
activity, the mutation in the ER fused to MYCN also possesses very low affinity 
for 17β-oestradiol preventing the activation of the ER-fusion protein by 
endogenous oestrogen (Littlewood et al., 1995).  As the SKNAS cell line harbours 
a p53 mutation, the SKNAS-NmycER cell line allows further investigation of the 
role of MYCN in cell proliferation and apoptosis independent of the p53 pathway.   
The main disadvantage of SHEP-TET21N and SKNAS-NMycER cells is the 
histology of their parental cell lines. Both SHEP and SKANS cells are S-type 
subclones of the SK-N-SH cell line which have been shown to be the least 
tumorigenic and to have lower levels of MYCN expression compared to other cell 
types (Carr-Wilkinson et al., 2011). The induction of MYCN expression may 
therefore not provide data directly relevant to a MYCN amplified cell line. 
However, for the Tet21N cells, the level of MYCN mRNA and protein expression 
has been reported to be comparable to that in the MYCN amplified cell lines 
IMR32, CHLA-136 and PER-108. Furthermore the cells respond to DNA damage 
in a similar manner in the absence of tetracycline (Tet21N MYCN+) (Bell et al., 
2006). Additionally, both SHEP and SKNAS cells harbour p14ARF deletions which 
may provide a selective growth advantage (Dreidax et al., 2013).       
 Cycloheximide treatment of the SHEP-Tet21N MYCN regulatable cell 
line 
Cycloheximide is an inhibitor of protein synthesis in eukaryotes. An anti-fungal 
antibiotic, it interferes with translational elongation and can be used to study the 
stability of proteins. Cycloheximide (Calbiochem) was prepared at a 200 nM stock 
solution in 100% ethanol and stored at -20°C for a maximum of one month. 
Cycloheximide was diluted in cell culture media prior to use to a final 
concentration of 25 µM and cells treated for the time periods stated.   
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 RNA Interference 
RNA interference via small interfering RNA (siRNA) is a cellular process that can 
be used to control gene expression in eukaryotic cells. A type of post-
transcriptional gene silencing, the siRNA hybridizes to its complementary 
sequence within the target mRNA initiating its degradation, and therefore 
preventing protein expression. By exploiting this pathway, the expression of 
chosen genes can be ‘knocked down’ through use of appropriately designed 
synthetic siRNAs (Elbashir et al., 2001a).  
 The mechanism of siRNA 
siRNAs are 20-25 nucleotide-long non-translated double-stranded RNA (dsRNA) 
duplexes, with phosphorylated 5’ ends and hydroxylated 3’ ends, which have 
symmetric 2-3 nucleotide overhangs. Formed following the cleavage of long 
dsRNAs, catalysed by the RNA endonuclease Dicer enzyme, the siRNA 
molecules are then incorporated into a multiprotein RNA-inducing silencing 
complex (RISC). One essential component of the RISC is the argonaute family 
of proteins which act as the main catalytic components. Once the 3’ overhang of 
the siRNA is exposed, the RNA strand with the least thermodynamically stable 5’ 
end is selected by the argonaute protein, the siRNA is unwound, and the chosen 
strand fed into the RISC complex. With the partner strand then degraded the 
chosen ‘guide strand’ is used as a template to recognise complementary mRNA 
molecules. mRNA strands which display extensive complementarity to the guide 
strand are then fragmented by activated endonucleases, within the argonaute 
protein family, ensuring translation cannot take place and therefore preventing 
protein expression (Figure 2.5). 
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Figure 2.5 A schematic representation of the siRNA pathway 
(http://www.abcam.com/index.html?pageconfig=resource&rid=10787&#5) 
 siRNA design and synthesis  
Three siRNA duplexes were designed and synthesised by Eurogentec 
(Southampton, UK) based on the SKP2 cDNA sequence (Table 2.2) and their 
efficacy evaluated against a universal negative control (cat no. SR-CL000-005, 
Eurogentec), hereafter referred to as the negative control siRNA (NCS). p27 
siRNAs were designed and functionally verified by Qiagen using RT-PCR 
(Qiagen, Manchester, UK), and compared to AllStars negative controls (Qiagen, 
cat no. 1027280). All siRNAs were designed using siRNA design software based 
on published methods (Elbashir et al., 2001a; Elbashir et al., 2001b; Krueger et 
al., 2007).   
siRNA Target siRNA sequence (sense) 
SKP2 siRNA 1 5’GUG-AUA-GUG-UCA-UGC-UAA-A3’ 
SKP2 siRNA 2 5’GGC-CAA-CUA-UUG-GCA-ACA-A3’ 
SKP2 siRNA 3 5’UCA-UUC-UUU-AGC-AUG-ACA-C3’ 
Table 2.2 siRNA sequences targeting SKP2 
67 
 
 siRNA Transfection 
Cells were seeded at 4 x 105 cells/well into 6-well plates in RPMI 1640 medium 
containing 10% (v/v) FBS, 24 hrs prior to transfection. siRNA was transfected into 
cells using lipofectamine® 2000 in Opti-MEM® reduced serum medium 
(Invitrogen, Life Technologies, Paisley, UK). siRNA was stored at stock 
concentrations of 20 µM and the following calculations used to determine the total 
volume of siRNA and Opti-MEM (400 µl/well) required:  
siRNA volume: N x 0.12 x nM 
Opti-MEM volume: 400 µl x N 
N = no. wells, nM = final siRNA concentration 
Separately, Lipofectamine 2000 was diluted in Opti-MEM as below to give a final 
ratio of DNA : Liofectamine of 1 : 1.25 
Lipofectamine volume: N x 0.15 x nM 
Opti-MEM volume: 400 µl x N 
The two solutions were gently mixed and incubated at room temperature for 10 
minutes after which an equal volume of each solution was gently mixed together 
and incubated for a further 30 minutes again at room temperature to allow siRNA 
containing liposomes to form. Meanwhile, the medium was removed from the 
wells, the cells washed with 1 ml of Opti-MEM to remove any remaining FBS and 
1.6 ml of fresh Opti-MEM added to each well. Following the 30 minutes 
incubation, 0.8 ml of the DNA-liposome solution was added to each well and 
incubated at 37°C, 5% CO2. After 24 hrs the DNA-liposome solution was removed 
and the cells either harvested, or Opti-MEM replaced with 2 ml RPMI 1640 
containing 10% (v/v) FBS for collection at later time points.  
 Protein Expression 
Protein expression was measured using western blotting. A widely used 
technique, it allows the protein expression levels of specific proteins to be 
identified in whole cell lysates or tissue samples. There are 3 stages to western 
blotting; proteins are first denatured by boiling with the reducing agent β-
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mercaptoethanol to break disulphide bonds within the protein, and the anionic 
detergent sodium, dodecyl sulphate (SDS), which uniformly covers the protein 
with a negative charge. This creates a homogenous mass to charge ratio and 
allows for separation according to molecular weight by sodium dodecyl sulphate 
gel electrophoresis (SDS-PAGE). The proteins are then transferred to a 
nitrocellulose membrane, and finally visualised and detected by the use of 
specific antibodies, conjugated to horseradish peroxide (HRP), and 
chemiluminescence.  
 Harvesting and preparation of cell lysates  
For the collection of adherent cells from a 6-well plate, medium was removed, the 
cells washed with PBS and 20 µl of Laemmli lysis buffer (2% (w/v) SDS, 10% 
(v/v) glycerol, 62.5 mM Tris pH 6.8) added. Cells were harvested using a cell 
scraper, lysates collected in a 1.5 ml eppendorf and then sonicated for 10 
seconds (MSE Soniprep 150 Plus, Wolf Laboratories, UK) to fragment the 
viscous DNA. After a 10 minute centrifugation at 8000 x g the supernatant was 
transferred to a fresh Eppendorf and the lysates stored at -20⁰C. 
 Pierce® Protein Estimation 
To determine the total protein concentration in each sample the Pierce® BCA 
protein assay kit was used. When in an alkaline medium peptide bonds reduce 
Cu2+ ions to Cu1+. This assay utilises the colourimetric reaction seen when 
bicinchoninic acid (BCA) reacts with Cu1+. Measurable at 570 nm, the amount of 
Cu2+reduced is proportional to the protein content of the solution allowing protein 
concentrations to be determined based on a calibration curve of albumin protein 
standards.   
Lysates were vortexed and diluted 1:10 in sterile water to a total volume of 50 µl. 
Albumin protein standards at 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 µg/ml were prepared 
from the provided 200 µg/ml stock and 10 µl pipetted into 4 consecutive wells of 
a 96 well plate, followed by the samples (Figure 2.6). Sterile water was used as 
the negative control. Reagent A and B of the Pierce® BCA protein assay kit were 
mixed at a ratio of 50:1 and 190 µl added to each well. After a 30 minute 
incubation at 37°C the optical densities of the samples were measured on a 
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spectrophotometric plate reader (Model 680 Microplate Reader, Bio-Rad 
Laboratories, CA, USA) at 570 nm. After subtracting the average negative control, 
a standard curve was generated and the samples’ protein content determined 
from the equation describing the line. All values were multiplied by 10 to account 
for the 1:10 dilution factor and the volume of each sample containing 25 µg of 
protein calculated.   
 
Figure 2.6 Pierce assay set up in a 96-well plate. Sterile water was aliquoted 
into the first row as the negative control, followed by 4 wells of 10 µl of each 
prepared standard and then 4 wells of 10 µl of each sample to be measured.   
 SDS-PAGE and membrane transfer 
After determination of the protein content, the appropriate volume of lysate was 
added to 5 µl loading buffer (Laemmli lysis buffer with 5% (v/v) β-mercaptoethanol 
and 0.0025% (w/v) bromophenol blue) and denatured at 100°C. Samples 
(containing 25 µg of protein) were resoled on Novex® 4-20% Tris-glycine 
polyacrylamide gels (Invitrogen) at 150 V in 1 x electrode buffer (Appendix I) 
using SeeBlue® Plus2 pre-stained protein standard (Invitrogen) for the molecular 
weight markers. Proteins from the polyacrylamide gel were transferred to 
Hybond™-C nitrocellulose membrane (GE Healthcare, Life Sciences, 
Buckinghamshire, UK) using a 1 x transfer buffer (Appendix I) at 30 V overnight 
or 60 V for 2 hrs.   
 Protein detection 
After protein transfer, the membrane was blocked in 5% (w/v) milk powder in 
0.1% (v/v) Tween 20 in TBS (TBST, Appendix I) for 1 hr and then incubated 
water 0.2 0.6 1.0 S1 S3 S5 S7 S9 S11 S13 S15
water 0.2 0.6 1.0 S1 S3 S5 S7 S9 S11 S13 S15
water 0.2 0.6 1.0 S1 S3 S5 S7 S9 S11 S13 S15
water 0.2 0.6 1.0 S1 S3 S5 S7 S9 S11 S13 S15
water 0.4 0.8 1.2 S2 S4 S6 S8 S10 S12 S14 S16
water 0.4 0.8 1.2 S2 S4 S6 S8 S10 S12 S14 S16
water 0.4 0.8 1.2 S2 S4 S6 S8 S10 S12 S14 S16
water 0.4 0.8 1.2 S2 S4 S6 S8 S10 S12 S14 S16
Standards Samples
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overnight with the chosen primary antibody at 5°C. All primary antibodies used 
are listed in Table 2.3 and were diluted in 5% (w/v) milk powder in TBST (Table 
2.3).  
Protein Antibody Dilution Antibody Type Manufacturer 
GAPDH SC-25778 1:1000 Rabbit PC Santa-Cruz 
MDM2 OP46 1:100 Mouse MAb Calbiochem 
MYCN SC-53993 1:500 Mouse MAb Santa-Cruz 
p27KIP1 SC-528 1:200 Rabbit PC Santa-Cruz 
p21WAF1 OP64 1:200 Mouse MAb Calbiochem 
p53 DO-7 1:1000 Mouse MAb Novocastra 
SKP2 32-300 1:1000 Mouse MAb Invitrogen 
Table 2.3 Primary antibodies used in this study.  
PC: Polyclonal, MAb: Monoclonal 
After exposure to a primary antibody the blot was washed with TBST and 
incubated for 1 hour at room temperature with a stabilised peroxide conjugated 
goat anti-mouse (Dako) or goat anti-rabbit (Dako) antibody, diluted 1:1000 in 5% 
milk powder (w/v). Following 4 independent 10 minute washes with TBST the 
blots were treated with chemiluminescence reagents (ECL) (GE Healthcare) and 
exposed onto film (Kodak). 
 Densitometry  
Densitometry was performed to semi-quantitatively measure protein expression 
levels compared to the GAPDH loading control. The Fuji-Las Pro (FUJIFILM Life 
Science, Stamford, CA, USA) scanner was used to capture the image of the 
bands from the x-ray film, and the AIDA image analyser (Raytest, Straubenhardt, 
Germany) was used to estimate size and density of the bands. The densitometry 
values for each band were first corrected for the background and then normalised 
to the GAPDH control. 
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 Cell cycle analysis  
The ‘replication state’ of cell populations was analysed using fluorescence 
activated flow cytometry (FACS). In FACS analysis a sample of suspended cells 
which are fluorescently labelled are hydrodynamically focused into a single 
stream to run pass a laser light source one cell at a time. A number of detectors 
then detect the scattered light which helps to identify particular cell populations 
within the sample. The detector in front of the light beam collects forward scatter 
(FSC) which is related to the cell size, while the detectors perpendicular to the 
incident light (FL1, FL2 and FL3) collect side scatter (SSC), which is often split 
into defined wavelengths by a set of filters or mirrors and identifies the cell 
granularity.  
Propidium Iodide (PI) is a fluorescent DNA intercalating agent which binds to the 
DNA of the cell. When excited by an argon-laser DNA-bound PI emits an orange 
fluorescence which is detected by the FL2 detector and the photon energy 
converted into an electrical signal. PI binds stoichiometrically to DNA allowing the 
proportion of DNA in the cell to be measured. In this way the stage of the cell 
cycle can be determined. Cells going through S phase will have more DNA than 
those in G1, due to DNA replication, and will therefore take up proportionally more 
PI and fluoresce more brightly. This trend will continue until G2 phase where cells 
will have twice the amount of DNA and hence fluorescence than in G1, until they 
undergo mitosis.  
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Figure 2.7 FACSCalibur optical layout (www.bdbiosciences.com). 
 Preparation of samples  
Cells were seeded at 4 x 105 cells/well into 6-well plates in RPMI 1640 containing 
10% (v/v) FBS and left overnight. After treatment cells were harvested, washed 
in ice cold PBS, centrifuged at 500 x g for 5 minutes and then fixed in 70% (v/v) 
ethanol and stored at 4°C. Cells were then rehydrated, washed twice with PBS,  
treated with RNase H (0.1 mg/ml, Sigma) and stained with propidium iodide (40 
µg/ml, Sigma), and finally incubated under light-protected conditions at 37°C for 
30 minutes.  
 FACSCalibur flow cytometer 
Before running the samples through the flow cytometer, they were passed 
through a syringe to separate clumped cells. Samples were measured and the 
data acquired using the FACSCalibur™ (Becton Dickinson, Franklin Lakes, NJ, 
USA), and CellQuest software (Becton Dickinson). To optimise instrument 
settings a dot plot of FL2-Area vs. FL2-Width was set up using untreated control 
cells and a gate set around the G0/G1/G2/M population to exclude cell aggregates 
and doublet particles. The gated population was also represented in a histogram 
graph of cell counts vs. FL2-Area and the G1 peak adjusted to 200 on the linear 
axis. For each sample, 1000 events were collected and saved.  
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 Analysis 
Cells were analysed using Cyflogic analysis software (Cyflo Ltd, Finland). FL2-W 
vs. FL2-A scatter plots were generated and the cells gated to exclude 
doublets/aggregates. Using the gated data, FL2-A histograms were generated 
and the proportion of cells in G1, S, G2 and sub-G1 determined by marking the 
various phases of the cell cycle as shown in Figure 2.8. A table of statistics 
identifying the percentage of cells in each phase was generated from the 
histogram and recalculated from the total cells gated for that sample to correct 
for variation in phase size.  
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Figure 2.8 FL2-W vs. FL2-A scatter plots and corresponding histogram of 
gated population. a) Dot plot of FL2-Width (FL2-W) vs. FL2-Area (FL2-A) 
allowing discrimination between G1 doublet and G2 /M single cell. b) Histogram 
analysis of the percentage of cells in each phase of the cell cycle determined 
from the events gated in the dot plot.       
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 Caspase 3/7 activity assay 
The Caspase-Glo® 3/7 assay (Promega, Southampton, UK) measures apoptosis 
by providing a luminogenic caspase-3/7 substrate which contains the amino acid 
sequence DEVD based on the caspase-3 and 7 consensus cleavage site. Once 
added to the cells, cell lysis releases the caspase enzymes which by cleaving the 
DVED sequence, release the luciferase substrate (aminoluciferin) resulting in the 
emission of light. Luminescence is proportional to the amount of caspase-3/7 
activity. 
 
Figure 2.9 Detection of caspase 3/7 activity by the Caspase-Glo® assay 
www.promega.co.uk 
 Caspase-Glo® 3/7 assay protocol 
Cells were seeded at 5000 cells/well in a 96-well white plate in a final volume of 
50 µl prior to caspase reagent addition. Once at room temperature, 50 µl of the 
caspase reagent  was added to each well. The plate was put in light protected 
conditions and incubated for 1 hr at room temperature after which it was analysed 
on a microplate luminometer (Berthold Technologies, Herefordshire, UK). 
Luminescence readings were corrected for background (medium only), 
normalised to the untreated control and plotted relative to negative control (non-
coding siRNA). Results are the average of 3 independent wells. 
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 mRNA extraction and determination of concentration 
Extraction and purification of mRNA was performed using the RNeasy® Mini kit 
(Qiagen, Venlo, Limburg, Netherlands) according to the manufacturer’s protocol 
for the purification of total RNA from animal cells using spin technology. 
Centrifuged samples were homogenised by the addition of Buffer RLT and moved 
through a syringe 3 times. An equal volume of 70% (v/v) ethanol was then added 
to the lysate, gently pipetted to mix the sample and immediately applied to the 
RNeasy Mini spin column. Total RNA binds to the column membranes, allowing 
contaminants to be washed away by the flow-through of the washing buffers RW1 
followed by RPE. RNA was then eluted from the membrane in 40 µl of RNase-
free water, and the RNA concentration and quality determined using the 
NanoDrop™ ND-1000 Spectrophotometer (NanoDrop Technologies, INC., 
Wilmington, DE, USA). Absorbance was measured at 260 and 280 nm, and the 
purity of the RNA determined by the 260/280 ratio, which should be ~2.0 for good 
quality RNA.    
 Generation of cDNA by reverse transcription 
The synthesis of cDNA was carried out using the iScript™ cDNA synthesis kit 
(BioRad). RNA (1 µg), was added to 4 µl of 5x iScript reagent, containing 
oligo(dT) and reaction hexamer primers, and 1 µl of the iScript reverse 
transcriptase, RNase H+. The oligo d(T) primers bind to the poly-A tail of the 
mRNA ensuring RNA transcription, preventing genomic DNA contamination, 
whilst RNase H+ degrades the RNA template after cDNA synthesis. The thermal 
reaction conditions were:  
5 minutes at 25 °C 
30 minutes at 42 °C 
5 minutes at 85 °C 
Hold at 4 °C (optional) 
 Quantitative reverse-transcription polymerase chain reaction 
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) is a 
technique which adopts the amplification techniques of PCR to identify a specific 
DNA sequence, with either fluorescent dyes or fluorescently-tagged probes to 
77 
 
determine the amount of DNA formed during each cycle. As the PCR reaction 
progresses the amplification of the PCR product (amplicon) is detected and 
quantified. As the amount of fluorescence measured is proportional to the total 
amount of the amplicon, by monitoring the changes in fluorescence the amount 
produced in each cycle can be calculated. Based on this relationship the initial 
number of copies of template DNA can be determined as the higher the starting 
level of the target sequence, the fewer the PCR cycles required to generate the 
final level of DNA.  
There are 3 steps to the PCR reaction: 
1. Denaturation at 95°C, which disrupts the hydrogen bonds between the 
complementary DNA bases yielding single stranded DNA. 
2. Primer annealing at 50-68°C, which allows the hybridisation of primers 
onto the single stranded DNA promoting the attachment of the DNA 
polymerase. 
3. Elongation at the optimum temperature for the DNA polymerase, which 
synthesizes a new strand of DNA complementary to the DNA template.  
Two types of fluorescence detection method are used in qRT-PCR. SYBR-based 
chemistry uses non-specific fluorescent dyes or flurophores which intercalate 
within the DNA helix and rely on DNA primers for their sensitivity and specificity. 
Probe-based chemistry, such as the hydrolysis Taqman® probe (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA) uses fluorescently-tagged 
oligonucleotide probes which are specifically designed to target a particular DNA 
sequence. In this study Taqman chemistry was employed.  
 Taqman® gene expression assay     
Taqman® probes (Applied Biosystems) utilise energy transfer from a high to a 
low energy state, termed fluorescence resonance energy transfer (FRET). The 5’ 
end of the probe is labelled with a high energy fluorophore (e.g. 6-
carboxyfluorescein: FAM) which upon excitation by a light source transfers 
energy to the low energy quencher (e.g. tetramethylrhodamine: TAMRA) on the 
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3’ end supressing the FAM fluorescence. Specific for a particular cDNA 
sequence, the probe binds to the specific amplicon during the annealing step of 
the PCR, and is then cleaved by the 5’ to 3’ endonuclease activity of the Taq 
polymerase during the elongation phase. The release of the fluorophore from the 
quencher stops the transfer of energy between the two resulting in an increase in 
fluorescence from the fluorophore reflecting the amplification of the specific target 
sequence (Figure 2.10).  
Once the fluorescence signal is strong enough to be detected it is captured and 
displayed in an amplification plot where ∆Rn is plotted against the PCR cycle 
number (Figure 2.11). Rn is the signal from the fluorophore normalised to the 
fluorescence intensity of a passive reference dye e.g. ROX. By subtracting the 
baseline emission, where the signal is not yet strong enough to be detected, ∆Rn 
can be calculated. The amplification plot has 2 phases, an exponential phase and 
a plateau phase. During the exponential phase the amount of PCR product 
approximately doubles until the reagents begin to become limiting which slows 
the reaction down. By setting the threshold level (the point at which a reaction 
reaches a fluorescent intensity above background) in the exponential phase of 
amplification the most accurate reading can be made. The cycle number at which 
the fluorescent signal of a reaction crosses the threshold is called the threshold 
cycle (Ct). Inversely proportional to the amount of the target sequence, it allows 
for the initial amount of target DNA to be determined, which is directly proportional 
to the level of mRNA in the original sample.  
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Figure 2.10 Taqman probe-based assay. During PCR the Taqman probe 
anneals specifically to a complementary sequence between the forward and 
reverse primer sites. With the probe intact the reporter fluorescence is quenched 
until the polymerase cleaves the probe hybridised to the target. This separates 
the reporter from the quencher resulting in a fluorescent signal which is detected. 
Polymerisation then continues yet is not extended along the probe due to the 3’ 
end being blocked. Figure adapted from Taqman protocol 
(https://tools.lifetechnologies.com/content/sfs/manuals/).      
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Figure 2.11 An example of an amplification plot for MYCN in the Tet21N 
MYCN regulatable cell lines after increasing exposure to tetracycline. Each 
curve represents readings from 3 replica wells and were generated by SDS 
software, threshold levels indicated in green.  
 qRT-PCR Protocol 
qRT-PCR was carried out according to the Taqman® gene expression assay 
protocol (Applied Biosystems). Each cDNA sample was diluted 1 in 10 with 
nuclease-free water before being run in triplicate with each of the individual 
probes (Table 2.4). The total reaction volume was 10 µl: 7.5 µl of the reaction mix 
and 2.5 µl of diluted cDNA (Table 2.5).  
Gene Name Assay Reference 
MYCN Hs00232074_m1 
SKP2 Hs00180634_m1 
ODC1 Hs-00159739_m1 
p27 Hs-00153277_m1 
p21 Hs00355782_m1 
GAPDH Hs03929097_g1 
 
Table 2.4 List of Taqman® Probes (www.appliedbiosystmes.com).  
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Reaction components Per well 
2x Taqman® master mix 5 µl 
20x Taqman® Primer and Probe 0.5 µl 
Nuclease-free water 2 µl 
1 in 10 diluted cDNA 2.5 µl 
Table 2.5 qRT-PCR reaction composition  
The Taqman® gene expression master mix contains the chemically modified 
form of AmpliTaq Gold® DNA polymerase called Ultra Pure (UP). Activated only 
at high temperatures, i.e. once the DNA is fully denatured, the UP enzyme 
promotes primer extension and elongation resulting in the cleavage of the probe 
and generation of the fluorescent signal. The master mix also contains the pre-
mixed passive reference dye (ROX) which is used to normalise the fluorescence 
emission from the Taqman® probe. The qRT-PCR reactions were run on the 
7900HT Fast Real-Time PCR system (Applied Biosystems) in a 384-well plate 
format using the thermal cycling conditions shown in Figure 2.12. Fluorescence 
emissions in the range 500-600 nm wavelength were detected.  
 
Figure 2.12 Thermal cycling programmed for quantitative real-time PCR 
  Analysis of qRT-PCR results 
SDS 2.2 software (Applied Biosystems) was used to analyse the qRT-PCR 
results. Amplification plots were generated for each cDNA sample and the 
threshold automatically set (Figure 2.11). All Ct values were first normalised to 
GAPDH (∆Ct) and then analysed using the comparative Ct method where the ∆Ct 
values of each sample were compared to the ∆Ct value of a reference sample or 
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non-treated control. The normalised target gene expression level could then be 
determined by the equation:   
∆Ct = Ct (Sample) – Ct (Housekeeping gene) 
∆∆Ct = ∆Ct(Sample) - ∆CT(reference) 
Sample Gene expression = 2∆∆Ct 
 Plasmid purification and amplification  
 Transformation of competent cells 
Plasmid DNA was transformed into DH5™chemically competent E-coli 
bacterial cells for replication of plasmid DNA. Approximately 50 pg (1 µl) of DNA 
was added to 30 µl of freshly defrosted competent cells (Invitrogen) and 
incubated on ice for 30 minutes. The competent cells/DNA mixture was heat 
shocked for 45 seconds at 42°C and immediately placed on ice for 2 minutes. 
Lysogeny broth (LB, 250 µl) was added to the competent cells/DNA mixture and 
incubated at 37°C with shaking at 180 rpm for 1 hr. After incubation 100 µl was 
spread onto LB-agar plates containing 100 µg/ml ampicillin (Sigma), and 
incubated at 37°C overnight. Single colonies were selected and inoculated in 5 
ml of LB broth containing 100 µg/ml ampicillin and grown for 8 hours at 37°C, with 
shaking at 200 rpm. When competent, 500 µl of the starter culture was used to 
inoculate 500 ml LB-broth containing 100 µg/ml ampicillin, grown overnight at 
37°C, with shaking at 200 rpm and used in plasmid extraction as described in 
section 2.12.2. The remaining culture was centrifuged at 1500 x g for 15 minutes, 
the supernatant removed and the cell pellet used for plasmid extraction and 
sequencing.  
 Plasmid extraction 
Extraction of plasmid DNA was performed using a HiSpeed™ Plasmid Maxi Kit 
(Qiagen) according to the manufacturer’s protocol. Briefly, the overnight culture 
prepared as described in Section 2.12.1 was collected by centrifugation at 5000 
x g for 30 minutes at 4°C and the bacterial cells lysed by resuspending the pellet 
in 10 ml of Buffer P1 containing RNase A (100 µg/ml) and LyseBlue reagent 
(1:1000). Once fully resuspended 10 ml of Buffer P2 was added causing a colour 
change to blue as the LyseBlue precipitate dissolves in Buffer P1. The sample 
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was gently inverted to create a homogenously coloured solution and incubated 
for 5 minutes at room temperature. To precipitate genomic DNA, proteins and cell 
debris, 10 ml of pre-chilled Buffer P3 was added to the lysate and mixed 
immediately by gently inverting 4-6 times. Upon addition of the neutralisation 
buffer the LyseBlue turns colourless indicating that all SDS from the lysis buffer 
has been effectively precipitated. The lysate was immediately poured into a 
QIAfilter cartridge and incubated for 10 minutes to allow separation of the solution 
containing the plasmid DNA and the precipitate. During this latter incubation a 
HiSpeed Maxi tip was equilibrated by passing through 10 ml of Buffer QBT, after 
which the lysate was added from the QIAfilter. Once the lysate had entered the 
resin, the HiSpeed tip was washed with 60 ml of Buffer QC which passed through 
the tip by gravity flow. Plasmid DNA was eluted into a fresh 50 ml falcon tube 
using 15 ml of Buffer QF and precipitated by mixing with 10.5 ml of 70% (v/v) 
isopropanol at room-temperature for 5 minutes.   
 Reporter Gene Assay  
Reporter genes are used to study the regulation of gene expression by cis-acting 
(e.g. regulatory DNA sequences) or trans-acting (e.g. transcription factors) 
elements by attaching a DNA sequence of interest upstream of a reporter which 
is not naturally expressed in the cells being transfected, e.g. luciferase. The 
presence of the reporter gene products or, if appropriate, their enzymatic activity 
can then be quantitatively measured to determine the functional status of the DNA 
sequence of interest.  
 SKP2-promoter luciferase reporter assay 
pGL3-Basic luciferase plasmids containing a 1148bp fragment of the SKP2 
promoter were kindly donated by Professor Javier Léon (University of Cantabria, 
Spain) and have been previously described by Huang et al (Huang and Hung, 
2006; Bretones et al., 2011). An extremely sensitive system, the luciferase 
reporter gene produces an optical signal by catalysing the bioluminescent 
oxidation of luciferin to oxyluciferin in the presence of ATP, Mg2+ and O2 (Figure 
2.14).   
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Figure 2.13 Oxidation reaction of luciferin by luciferase. Figure adapted 
from www.piercenet.com 
To account for variability in the transfection efficiency the control reporter 
construct β-galactosidase was co-transfected with the reporter construct. Driven 
by the constitutively active cytomegalovirus (CMV) promoter, the control reporter 
was measured by the expression of β-galactosidase. The activity of the luciferase 
reporter was then normalised to β-galactosidase expression, measured 
colorimetrically using the substrate ONPG, to account for variability.   
 Luciferase reporter gene assay protocol  
Cells were seeded at 1 x 105 (SHSY5Y and IMR32) or 5 x 104 (Tet21N) cells/well 
into 24-well plates in RPMI 1640 medium containing 10% (v/v) FBS, 24 hrs prior 
to transfection. pGL3-Basic, pGL3-SKP2 and pGL3-SKP2-MutEB were 
transfected into cells using Lipofectamine® 2000 in Opti-MEM® reduced serum 
medium (Invitrogen) together with β-galactosidase as a transfection control. 
Plasmids were stored at -20°C in stock concentrations of 0.2 µg/µl and the 
transfection mixture made as shown in Table 2.6. 
Reaction components Per well Final Concentration/well 
Plasmid DNA (0.2 µg/µl) 4 µl 0.8 µg/µl 
β-Gal (0.2 µg/µl) 0.5 µl 0.1 µg/µl 
Lipofectamine® 2000 2 µl  
Opti-MEM® 43.5 µl  
Table 2.6 Luciferase reporter gene transfection mixture 
Plasmid DNA was first added to the Opti-MEM® media, mixed thoroughly and 
incubated at room temperature for 15 minutes. Following incubation, 
Lipofectamine® 2000 was added directly to the DNA/serum free media mixture, 
mixed thoroughly and incubated for a further 40 minutes at room temperature. 
The RPMI medium was removed from the wells, the cells rinsed with Opti-MEM® 
Luciferin
Luciferin
+
Luciferase
+
AMP
O2
CO2
Oxyluciferin
+
AMP
PPi
+ LIGHT
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to remove any remaining FBS, and then replaced with 500 µl of Opti-MEM® 
medium. After the incubation, 50 µl of the transfection mixture was added to each 
well, plates were shaken, and then incubated at 37°C for 24 hrs prior to cell lysis.  
Reporter lysis 5x buffer (Promega, Madison, WI, USA) was first diluted 1 in 5 with 
sterile water and after the cells were washed with PBS, lysis buffer (500 µl) was 
added directly to each well and the plate incubated at 37°C for 10 minutes. The 
cell lysates were then stored at -20 C overnight after which the luciferase and β-
galactosidase activity was measured using the Luciferase Assay System 
(Promega) and Ortho-nitrophenyl-β-D-galactopyranoside (ONPG) assay 
(Thermo Scientific, Waltham, MA, USA), respectively.  
Luciferase activity was measured using the BMG LABTECH FLUOstar Omega 
microplate reader (BMG LABTECH, Germany). Cell lysates (100 µl) were 
transferred in triplicate to a microplate, placed onto the plate reader and, using 
automated injectors, 50 µl of luciferase reagent was added to each well, plates 
were shaken for 5 seconds and luminescence immediately read. β-Galactosidase 
activity was measured separately using the colorimetric ONPG reagent (Thermo 
Scientific). ONPG solution (150 µl) was added to 10 µl of cell lysate in a 96 well 
plate, in triplicate, and incubated at 37°C for 15 minutes. Following the colour 
change, 5 µl of sodium carbonate was added to each well to stop the reaction 
and the plate read at 415 nm on a spectrophotometric plate reader (Model 680 
Microplate Reader, Bio-Rad Laboratories, CA, USA).  
Luciferase activity was normalised to the β-galactosidase activity to control for 
transfection efficiency and the data analysed using Prism Version 6.0. Results 
are the average of 3 independent wells.  
 Generation of pGL3-SKP2-MutEB construct 
 Site directed mutagenesis 
Site directed mutagenesis allows specific, targeted changes to be made in double 
stranded plasmid DNA either by the insertion, deletion or substitutions of bases. 
It is a technique that is used to investigate the structure and biological activity of 
DNA, RNA and proteins, especially enzymes and receptors. The technique uses 
a synthetic DNA primer which contains the desired mutation surrounded by 
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sequences complementary to the template DNA called flanking sequences. 
These sequences hybridise to the plasmid DNA and are then extended during 
the thermal cycle incorporating the mutation into the newly synthesised plasmid 
DNA. Following a PCR reaction, the product is digested with the restriction 
endonuclease DpnI, which recognises and cleaves only at the methylated 
adenine in the GATC recognition sequence. Most template plasmids are from 
E.coli strains which contain site-specific DNA methylases, such as DNA adenine 
methylase (DAM) and DNA cytosine methylase (DCM), which transfer methyl-
groups to specific sites after replication. As the newly synthesised mutant DNA 
will not be methylated, digestion by DpnI will therefore isolate the mutant product 
from the original plasmid, which can then be transformed into competent bacteria 
as described in section 2.12 (Figure 2.15).  
 
Figure 2.14 Schematic representation of single-primer site-directed 
mutagenesis.  
 Generation of pGL3-SKP2-MutEB 
The two E-box motifs (CCCGTG) and (CACCTG) were identified within the -
1148bp SKP2 promoter construct, mutated and replaced with the PstI restriction 
site CTGCAG. Using the specific primers listed in Table 2.7 plasmid DNA was 
amplified using PCR with 5x Phusion® High-Fidelity DNA polymerase (New 
England Biolabs, Ipswich, MA, USA) as indicated in Tables 2.8 and 2.9. The PCR 
products were incubated for 1 hour at 37°C with DpnI (New England Biolabs) to 
digest the parental DNA and run on a 1% agrose gel to determine whether the 
PCR was successful. Once confirmed, the remaining PCR products were purified 
using a QIAquick PCR puritifcation Kit (Qiagen) according to the manufacturer’s 
protocol and transformed into competent cells as described in Section 2.12.   
Mutagenic primer
Primer extension
Parental plasmid DNA
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E-box Sense (SN) or Antisense (ASN) 
CACCTG SN: 5’-CAGTTCGCAGCCTCTCTGCAGGCCGGCGGGCTGGGC-3’ 
ASN: 5’-GCCCAGCCCGCCGGCCTGCAGAGAGGCTGCGAACTG-3’ 
CCCGTG SN: 5’-CCGCCTCCCGCCTACCTGCAGGGCCGACCAGTCCCG-3’ 
ASN: 5’-CGCCTCCCCGCCTACCTGCAGGTAGGCGGGGAGGCG-3’ 
Table 2.7 Primers used to generate pGL3-SKP2-MutEB 
 
Component 1x 50µl Reaction Final Concentration 
Plasmid DNA 1 µl ~100 ng/µl 
DNA polymerase (5x solution) 10 µl 1x 
Deoxynucleotide (dNTP) 
solution mix 
1 µl 200 µM 
Primer Stock * 1 µl 0.5 µM 
Nuclease free Water 37 µl  
Table 2.8 Reaction mixture for site-directed mutagenesis PCR. * Primer 
stock contains 2 µl of SN and ASN primers in sterile water at a total volume of 
100 µl 
 
Step Temperature Time 
Initial Denaturation 98°C 30 seconds 
25 cycles 98°C 
55°C 
72°C 
10 seconds 
30 seconds 
30 seconds per kb 
Final Extension 72°C 7 minutes 
Hold 4°C  
Table 2.9 Thermocycling conditions for PCR 
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 Restriction enzyme digestion  
To confirm the presence of the mutated E-Box sequence CTGCAG, PGL3-SKP2-
MutEB was digested with PstI (New England Biolabs) using the reagents shown 
in Table 2.10. The plasmid was incubated with PstI for 1 hour at 37°C, and the 
products separated using 1% agarose gel electrophoresis, visualised under UV 
and the images captured by the BioRad Molecular Imager Gel Doc XR system 
(Figure 2.8). The presence of the mutation was confirmed by sequencing (Source 
BioScience, LifeSciences, Nottingham, UK). Following sequence confirmation, 
the plasmid DNA was diluted into 0.2 µg/µl stocks in sterile distilled water and 
stored at -20°C.  
Component 1x 50 µl Reaction Final Concentration 
Plasmid DNA 2 µg 2 µg 
4x NEBuffer 3.1 5 µl 1x 
PstI 1 µl 20 units 
Sterile Water *  
Table 2.10 Restriction endonuclease reaction mixtures for digestion of E 
box motifs 
 Cell proliferation assay 
Cell proliferation was measured using the sodium 3’-{1-(phenylaminocarbonyl)-
3,4-tetrazolim]-bis(4-methoxy-6-nitro)benzene sulfonic acid hydrate (XTT) assay 
(Roche applied Science, West Sussex, UK). A colorimetric assay, it determines 
the number of viable cells based on the cleavage of the tetrazolium salt (XTT) to 
the soluble formazan salt, in the presence of an electron-coupling reagent. 
Indicated by a colour change with an absorbance measured at 450 nm, this 
conversion can only occur within functioning mitochondria which reflects the 
number of viable cells. Before use, the reagents are equilibrated at room 
temperature and mixed together by adding 50 µl of XTT labelling reagent to 1 µl 
electron-coupling reagent for each individual well. The 50 µl of mixed XTT reagent 
is then added to each well containing 100 µl of medium. Wells containing growth 
medium only are also analysed to act as a negative control.   
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 Determining optimal cell density 
The optimal number of cells was determined by generating 5 day growth curves. 
In 96-well plates, cell were seeded in intervals of 1000 cells up to 5000 cells/well 
and the cell proliferation determined each day using the XTT assay. A seeding 
density was chosen such that cells were in the exponential growth phase 
throughout the experiment and not in the plateau or lag phase of growth, 
illustrated in Figure 2.16 
 XTT assay 
Cells were seeded at their optimal density and incubated at 37°C, 5% CO2 
overnight to allow attachment. Following treatment and incubation for the time 
period indicated, 50 µl of XTT reagent was added and the cells incubated for a 
further 6 hours at 37°C, before the optical density was measured at 450 nm using 
a microplate reader (Model 680 Microplate Reader, Bio-Rad Laboratories, CA, 
USA).  
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Figure 2.15  Five day growth curves for 6 neuroblastoma cell lines 
measured by the XTT assay to determine seeding densities for growth 
inhibition assay.  
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 Compound Screening  
Compounds were screened in HeLa cells to determine a GI50 value, i.e. the 
concentration at which the compound inhibits growth to 50% of the untreated cell 
population. All compounds were screened at a range of concentrations between 
0.1 and 100 µM. Compounds were suspended in 100% DMSO at 100mM, when 
solubility allowed, and stored at -20°C. Final drug concentrations added to each 
well were in 100 µl full medium, containing 0.5% (v/v) DMSO.  
 Growth Inhibition Assays 
Growth inhibition was measured using the sulforhodamine B (SRB) dye method 
which binds to basic amino acid residues in proteins allowing cell proliferation to 
be measured based on the protein content of each well (Skehan et al., 1990). 
The optimal cell density for HeLa cells was determined by using the SRB assay 
as described in section 2.16.2.    
 SRB Assay 
HeLa cells were seeded at 2 x 103 cells/well in 96-well plates and given 24 hrs  
to attach. Cells were then treated with a range of compound concentrations and 
incubated for 72 hrs. A day 0 control was plated and fixed on the day of drug 
treatment to provide a pre-treatment measure of cell number. Cells were fixed by 
adding 25µl of 50% (w/v) cold aqueous trichloroacetic Acid (TCA) to each well 
containing 100 µl of culture medium. After 1 hr at 4°C plates were washed with 
deionised water and stained with 0.4% (w/v) SRB in 1% (v/v) acetic acid for 30 
minutes at room temperature. Unbound dye was removed with 1% (v/v) acetic 
acid and plates left overnight to air dry.  Bound dye was solubilised by the addition 
of 100µl 10 mM Tris pH 9.5 and the optical density measured using a 
spectrophotometric plate reader (Model 680 Microplate Reader, Bio-Rad 
Laboratories, CA, USA) at 570 nm.   
 Analysis 
GI50 values were calculated using GraphPad Prism Version 6.0 software 
(GraphPad Software Inc). Following corrections for the pre-treatment cell 
number, the percentage cell number relative to the control (DMSO only treated) 
92 
 
was calculated for each concentration, data were plotted and GI50 values 
determined based on a standard point to point curve with 1000 segments using 
GraphPad Prism statistical software.   
 Statistical Analyses 
All statistical tests were performed using GraphPad Prism Version 6.0 software 
(GrpahPad Software Inc). Significance differences were determined by the tests 
stated and indicated as follows: * p ≥ 0.05, ** p ≥ 0.01, *** p ≥ 0.001. 
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The relationship between MYCN and SKP2 expression in 
neuroblastoma cell lines 
 Introduction 
 MYCN and neuroblastoma 
Amplification of the MYCN oncogene, first identified by Schwab et al (Schwab et 
al., 1983), occurs in 20 to 25% of neuroblastoma and is a well-established 
prognostic indicator associated with rapid tumour progression and a poor 
outcome. There is strong experimental evidence that MYCN initiates and 
promotes neuroblastoma tumorigenesis evident by the dose-dependent tumour 
formation upon targeted MYCN expression in the neuroectoderm in transgenic 
mouse models (Weiss et al., 1997). Functioning as a heterodimer with MAX, 
MYCN forms a functional transcriptional activator which exerts activity by directly 
binding to E-box motifs (CACA/GTG) located within the promoter regions of target 
genes. Implicated in multiple aspects of malignancy including the promotion of 
proliferation and metastasis and the suppression of apoptosis and differentiation, 
the diverse role of MYCN in neuroblastoma development continues to be 
investigated by attempting to identify the particular MYCN-driven genes which 
contribute to the aggressive phenotype of MYCN-amplified disease.  
 The MYC family interchange 
The MYC family of oncoproteins have been implicated in the transcriptional 
regulation of genes involved in cellular proliferation, differentiation and apoptosis 
(Henriksson and Luscher, 1996). Sharing protein structural features and DNA 
consensus core binding sites (E-Box), evidence indicates a functional 
interchangeability within the family. MYCN and c-MYC are reported to display 
homologous coding regions and show similar oncogenic potential in in vitro 
transformation assays. Along with the ability of MYCN to replace c-MYC functions 
in embryonic development, it is often assumed that the molecular mechanisms 
known for c-MYC can be extrapolated to MYCN (Schwab et al., 1985b; Kohl et 
al., 1986; Malynn et al., 2000).  
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Although greater progress has been made in the identification of c-MYC target 
genes, (http://www.myccancergene.org/site/about.asp) (Zeller et al., 2003), 
known MYCN downstream targets, including indirect and putative direct MYCN 
targets, have been summarised in an attempt to clarify the current knowledge on 
MYCN activity (http://medgen.ugent.be/MYCNot) (Kumps et al., 2013). In 
neuroblastoma there is an assumed redundancy between the two family 
members with functional interchange between c-MYC and MYCN in the 
regulation of tumorigenesis being well documented. Whilst deregulated MYCN 
expression identifies with an aggressive subtype in MYCN amplified 
neuroblastoma, the presence of MYCN in single-copy tumours correlates with a 
favourable clinical outcome (Tang et al., 2006a). In neuroblastoma derived cell 
lines, c-MYC is often expressed in favour of MYCN in the absence of MYCN 
amplification due to each repressing the other at defined promoter sites, 
indicating a regulatory interaction (Breit and Schwab, 1989; Tang et al., 2006a).  
Conversely, a subset of MYCN/c-MYC target genes have been identified which 
define malignant neuroblastoma progression independent of other established 
risk markers such as disease stage or MYCN amplification (Westermann et al., 
2008).  
As a result of the homology between MYC family members a candidate gene 
approach can be used to identify MYCN target genes by investigating those 
previously identified as c-MYC transcriptional targets. This approach can also be 
adopted to investigate genes involved in the known biological functions of MYCN 
such as cell cycle progression. However, while there is considerable overlap in 
function between the MYC family members, they do maintain a distinct 
expression pattern in normal tissue with c-MYC expression correlating with high 
proliferative activity and MYCN and L-MYC playing a more dominant role in the 
differentiation of postmitotic cells (Hirvonen et al., 1990). Therefore, while c-MYC 
is a useful candidate gene for the exploration of MYCN driven tumorigenesis, it 
is important to note that the two are not completely interchangeable.  
Alternatively a whole genome approach can be utilised to investigate target genes 
differentially expressed in the presence and absence of MYCN, for example; 
studies in MYCN amplified vs. non-MYCN amplified cell lines or tumour cohorts, 
siRNA targeted MYCN knock down and MYCN regulatable cell lines. This 
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approach often uses microarray analysis or serial analysis of gene expression 
(SAGE) and identifies a broad spectrum of genes associated with MYCN 
amplification and expression which require further investigation to distinguish 
whether they are directly or indirectly regulated (reviewed by (Bell et al., 2010)).      
A direct target gene is one where MYCN drives transcription by binding to an E-
box motif within close proximity of the transcriptional start site of the gene. An 
indirect target gene is one which shows no evidence of MYCN binding yet whose 
RNA or protein expression is altered as a result of MYCN driven mechanisms or 
pathways. Ultimately the identification of MYCN regulated genes allows for a 
further understanding of the biological role of MYCN in driving the tumorigenesis 
of neuroblastoma. As there is currently no inhibitor directly blocking MYCN, these 
downstream target genes may also provide potential therapeutic options in 
treating MYCN driven neuroblastoma.   
 Identification of direct targets of MYCN  
For gene expression to be identified as a direct transcriptional target of MYCN a 
combination of ChIP and reporter gene assays are used to determine whether 
MYCN directly binds to the gene promoter region and functionally activates gene 
expression.  
Principles of chromatin immunoprecipitation analysis  
Chromatin immunoprecipitation (ChIP) is a technique which allows for analysis of 
DNA sequences that are bound by a given protein in living cells. A well-
established technique it can be used to map the localisation of post-translationally 
modified histones, histone variants, transcription factors or chromatin modifying 
enzymes (Collas, 2010). Cells are first exposed to a crosslinking agent, such as 
formaldehyde, which covalently links nuclear proteins to the DNA sequences they 
are bound to at the moment of treatment, thereby creating stabilised DNA-protein 
complexes. The cells are then lysed and the nuclear material extracted and 
fragmented by sonication or enzymatic digestion via micrococcal nuclease. Using 
an appropriate antibody the protein of interest is immunoprecipitated and isolated 
from the remaining nuclear components creating an enriched pool of the specific 
DNA-protein complexes. To identify the bound DNA sequence, the crosslinking 
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is first reversed often by heat incubations or enzymatic digestion of the protein 
component by proteinase K. The purified DNA is then quantified using qRT-PCR 
as described in Section 2.10 to determine if the DNA from a specific promoter is 
present and whether a direct correlation exists between the amount of 
immunoprecipitated complex and bound DNA. While this technique determines 
whether a transcription factor can bind to a promoter, DNA ChIP-seq combines 
ChIP with DNA sequencing to identify the DNA binding sites of the 
immunoprecipitated proteins. Additionally ChIP-chip examines the DNA binding 
on a genome wide basis by utilising microarray analysis as described below, to 
identify further direct gene targets of the investigated DNA binding protein.  
Reporter gene activation 
A reporter gene, for example firefly luciferase as described in Section 2.12 is 
placed under the control of the particular promoter of interest. The reporter gene 
product activity can then be quantitatively measured in the presence or absence 
of MYCN expression using a MYCN regulatable expression system.   
 Identification of indirect targets of MYCN 
An indirect gene target is one where mRNA or protein expression is altered in the 
presence of MYCN, but there is no evidence of MYCN binding. Instead, indirect 
target gene expression may be affected by downstream mechanisms or 
pathways initiated by MYCN expression. One such method of analysis is 
transcriptome profiling. Representing the transcripts present in a given cell i.e. 
mRNA, the transcriptome reflects the genes activated at a given time. Two 
methodologies are currently used, DNA microarray and RNA-seq.   
Microarray analysis 
DNA microarray technology measures the expression levels of thousands of 
genes simultaneously. A genome-wide analysis, it allows expression patterns of 
genes to be observed in response to a change in environmental conditions. To 
determine which genes are switched on or off in response to MYCN in a given 
cell, the mRNA is first collected and reverse transcribed into cDNA during which 
fluorescent nucleotides are incorporated labelling the treated and untreated cell 
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cDNA with different fluorescent dyes. The cDNA is then applied to a microarray 
chip which contains tens of thousands of pre-programmed probes, each with 
multiple single-stranded pieces of DNA attached to it which represent a specific 
gene sequence. The labelled cDNA is applied and hybridises to any 
complementary strands on the chip generating a fluorescent signal. After washing 
to remove sequences that are not specifically bound, the chip is imaged to detect 
which genes are expressed and at what level, based on the intensity of the signal 
which reflects the relative abundance of each mRNA transcript.  
RNA-Seq 
More recently RNA-Seq technology is being favoured. Using the same premise 
as microarray analysis, RNA-Seq utilises next-generation sequencing to identify 
and characterise gene expression. By the addition of sequencing adaptors onto 
the RNA-derived cDNA fragments, short sequence reads are determined which 
can be aligned with the reference genome or transcriptome (Wang et al., 2009b). 
This technique carries an advantage over hybridisation-based techniques as it 
does not rely on a pool of previously collated DNA probes, allowing for 
identification of both known and novel genomic sequences. RNA-Seq has also 
been shown to have lower background noise and a greater dynamic range of 
expression levels over DNA microarray resulting in greater sensitivity and a more 
precise assessment of the gene expression profile.       
These techniques have been used to identify MYCN target genes by observing 
their differential expression after MYCN induction, knockdown or manipulation in 
MYCN regulatable cell lines (Bell et al., 2007; Schramm et al., 2013). A whole 
genome approach, regulated genes identified using microarray analysis or RNA-
Seq often require further investigation, for example to determine whether the 
mRNAs are translated into a protein product which contribute to the oncogenic 
behaviour of MYCN, and if so, whether they directly or indirectly target genes.   
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 Aims 
Taking into consideration the correlation between MYCN and SKP2 expression 
in neuroblastoma as well as the recognition of SKP2 as a direct c-MYC target 
gene, the overall aim of the work presented in this chapter was to further 
characterise the relationship between MYCN and SKP2 in neuroblastoma cell 
lines and establish whether SKP2 is a direct transcriptional target gene of MYCN. 
These aims were addressed with the following specific objectives:        
 To investigate the relationship between MYCN and SKP2 expression in 
the conditional MYCN expression systems SHEP Tet21N and SKNAS-
Nmyc-ER.  
 To clarify the impact of SKP2 on the expression of the CDK inhibitors p27 
and p21, and cell cycle progression in the SHEP Tet21N conditional 
MYCN expression system.  
 To evaluate the relationship between MYCN and SKP2 expression in a 
panel of MYCN amplified and non-amplified neuroblastoma cell lines.  
 To determine whether SKP2 is a direct target of MYCN using chromatin 
immunoprecipitation (ChIP) analysis and a SKP2 promoter reporter gene 
assay 
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 Chapter specific material and methods 
 Chromatin immunoprecipitation (ChIP) 
Chromatin Immunoprecipitation was kindly performed by Prof. Giovanni Perini, 
Giorgio Milazzo and Dr. Samuele Gherardi (University of Bologna, Italy) as 
previously described (Chen et al., 2010b). The antibodies employed were: MYCN 
(Santa Cruz, B8.4.B, C-22), c-MYC (Santa Cruz N-262) and MAX (Santa Cruz C-
17). Mapping of the transcription factor binding was determined on the SKP2 
promoter (-3000/+2000 bp) by SYBER green qRT-PCR using the six different 
pairs of primers listed in Table 3.1. DNA primers were designed in the proximity 
of canonical and non-canonical E-boxes of the SKP2 promoter region centred 
round the transcriptional start site. The known MYCN target gene ornithine 
decarboxylase (ODC1) was used as a positive control using forward primer 5’- 
ATCACTTCCAGGTCCCTTGC-3’ and reverse primer 5’-
GAGAGCGGAAAAGGGAAATC-3’. All experiments were performed in triplicate. 
  
E Box Forward/Reverse Sequence Amplicon Size 
A1 Forward 
Reverse 
5’-GGCTTAGCCTAGGATTCTGCA-3’ 
5’-AAACCTCCCTTGTGCAGGTA-3’ 
184 bp 
A Forward 
Reverse 
5’-CGTGTTTAGCTGTTGTGCGT-3’ 
5’-CGCACCTGTTCGTCCTTTTG-3’ 
124 bp 
B Forward 
Reverse 
5’-GTGGGGATGGAACGTTGCTA-3’ 
5’-TTACCTGTGCATAGCGTCCG-3’ 
163 bp 
C Forward 
Reverse 
5’-CGGGGGTATTGTGCACTTCT-3’ 
5’-TCCTGGGGGATGTTCTCACT-3 
177 bp 
D Forward 
Reverse 
5’-AGGAGTGGGCACAACAAACA-3’ 
5’-ACAAGCCAAGAGGGAATGCA-3’ 
152 bp 
E Forward 
Reverse 
5’-AGGGTGGTCAGATTCCGGAT-3’ 
5’-TCTTCTTCGCCATCATCCCC-3’ 
128 bp 
Dist Forward 
Reverse 
5’-CCGTTTGTTCTTGCCCCAAG-3’ 
5’-CCCTTGAACAGAGCTCACCA-3’ 
139 bp 
 Table 3.1 Primer sequences for MYCN ChIP analysis of SKP2 promoter 
100 
 
 Results  
 Switching MYCN expression off in the Tet21N cell line influences 
SKP2 mRNA and protein expression  
Tet21N MYCN regulatable cells were treated with tetracycline (1 µg/ml) over 5 
days and MYCN and SKP2 expression monitored by qRT-PCR and western 
blotting. After 24 hr exposure to tetracycline the Tet21N MYCN- cells showed a 
significant reduction in both MYCN and SKP2 mRNA expression (Figure 3.1, p = 
0.009 and 0.04, respectively, paired t test).  
 
 
Figure 3.1 qRT-PCR analysis analysis of MYCN and SKP2 mRNA expression 
in the Tet21N cell line in the presence and absence of tetracycline. mRNA 
expression was normalised to the housekeeping gene GAPDH and expressed 
relative to the Tet21N-MYCN+ cells at day 1 of growth. Data are the mean and 
error bars represent the SEM of n=3 experiments. * and ** correspond to a p 
value of <0.05 and <0.01, respectively.       
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The decrease at transcript level translated to a complete loss of MYCN protein 
expression within 24 hr tetracycline exposure (Figure 3.2, day 3) with SKP2 
protein expression gradually decreasing over the 5 days in line with the 
hypothesis that SKP2 is a direct MYCN target gene. The loss of both MYCN and 
SKP2 expression was associated with an increase in protein levels of the SKP2 
targets p27 and p21, in addition to an increase in the G1 fraction of the cell cycle 
phase distribution (Figure 3.3a) and separation of the growth curves (Figure 
3.3b). Taken together these data suggest that the G1 arrest induced by switching 
off MYCN expression is in part due to stabilisation of the CDK inhibitors p27 and 
p21 resulting from the loss of SKP2.  
 
 
Figure 3.2 Western blot showing the effect of tetracycline on MYCN, SKP2, 
p27 and p21 expression in the Tet21N cell line. Cell lysates were collected at 
the time points stated. The western blot shown is a representative of 3 
independent repeats. 
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Figure 3.3 Cell cycle analysis and proliferation of Tet21N cells grown in the 
presence and absence of tetracycline. a) Percentage distribution of cell cycle 
phase populations measured by flow cytometry b) Growth curves of Tet21N 
MYCN+ and MYCN-. Cell number was determined by a Coulter counter. Data are 
the mean and error bars represent the SEM of n=3 experiments. Db = doubling 
time.    
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 Reduction of SKP2 protein expression stabilises p27 protein 
expression in the Tet21N cell line 
As MYCN overexpression promotes S phase entry, the transcript levels of p27 
and p21 were measured by qRT-PCR to determine whether the increased 
expression of the CDK inhibitors was from enhanced transcription (Figure 3.4). 
Given that the mRNA expression of p27 and p21 were found to increase 
substantially following the removal of MYCN, Tet21N cells were treated with a 
combination of tetracycline and the mRNA translation inhibitor cycloheximide (25 
µmol/L), to determine the contribution of SKP2 loss (Figure 3.5). Cycloheximide 
treatment decreased MYCN and SKP2 protein expression (lanes 3 and 4), 
mirroring the effect of tetracycline only (lanes 5-7), and reduced the level of p27 
and p21. Only p27 protein was still present, although at a reduced level, after 
combination treatment (lanes 8 and 9). Combined with the findings from the qRT-
PCR, these results suggest that the loss of SKP2 in the Tet21N MYCN- cells 
resulted in post-translational stabilisation of p27 but not p21.    
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Figure 3.4 qRT-PCR analysis of MYCN, SKP2, p27 and p21 mRNA 
expression in the Tet21N cell line in the presence and absence of 
tetracycline. mRNA expression was normalised to the housekeeping gene 
GAPDH and expressed relative to Tet21N-MYCN+ cells at day 1 of growth.  
 
 
 
Figure 3.5 Western blot of the effect of tetracycline (TET) and cycloheximide 
(CHX) treatment on the expression of MYCN, SKP2, p27 and p21 in the 
Tet21N cell line. Cell lysates were collected at timepoints stated. The western 
blot shown is a representative of 3 independent repeats   
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 Activation of MYCN transcriptional activity only influences SKP2 at 
the transcript level in the SKNAS-Nmyc-ER cell line 
The involvement of MYCN in the regulation of SKP2 expression was further 
demonstrated in the SKNAS-Nmyc-ER cell line. Expressing a hybrid N-myc-
oestrogen receptor protein (Nmyc-ER), the construct is only active when the ER 
domain is bound to 4-hydroxytamoxifen (4-OHT), due to the point mutation 
(G525R) in the receptor domain as discussed in Section 2.2.5. As shown in 
Figure 3.6a, after 48 hrs exposure to 4-OHT (100 ng/ml) SKP2 mRNA expression 
increased significantly (p = 0.02, paired t-test); however, this did not translate to 
an increase in SKP2 protein expression (Figure 3.6b), suggesting that MYCN 
only plays a partial role in regulating SKP2. Interestingly, as shown in Figure 3.7, 
the addition of 4-OHT caused a significant growth suppression of the SKNAS-
Nmyc-ER cell line (p = 0.001, paired t test) as measured by the XTT assay 
described in Section 2.15.2. This effect is consistent with recent reports where 
enhanced MYCN expression in a non-MYCN amplified setting was shown to 
reduce the viability of neuroblastoma cells through the induction of apoptosis and 
promotion of expression of favourable genes (i.e. genes whose high expression 
levels predict a favourable clinical outcome) (Tang et al., 2006b; Valentijn et al., 
2012). The SKNAS-Nmyc-ER cell line, prior to 4-OHT treatment also had a slower 
doubling time than the SKNAS parental cell line, suggesting the vector was 
affecting the cell cycle, independent of 4-OHT treatment (Figure 3.7, black line 
on both graphs) 
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Figure 3.6 qRT-PCR and protein analysis of MYCN activation in the SKNAS-
Nmyc-ER cell line. a) Fold change of mRNA level of SKP2 and ODC1 after 48 
hr exposure to 4-OHT. mRNA was normalised to the housekeeping gene GAPDH 
and expressed relative to the UT control. Data are the mean and error bars 
represent the SEM of n=3 experiments. * and ** correspond to a p value of <0.05 
and <0.01, respectively. b) Western blot showing the effect of 4’OHT on the 
expression of MYCN, SKP2, p27 and p21. Cell lysates were collected at 
timepoints stated. The western blot shown is a representative of 3 independent 
repeats.  
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Figure 3.7 Rate of proliferation of the SKNAS and SKNAS-Nmyc-ER cell line 
analysed by XTT assay. a) Growth curve for the SKNAS-Nmyc-ER cell line in 
the presence and absence of 4’OHT. Data are the mean and error bars represent 
the SEM of n=3 experiments. b) Growth curve for the SKNAS cell line. Data are 
the mean and error bars represent the SEM of 5 individual wells on a 96 well 
plate. Both SKNAS-Nmyc-ER and SKNAS cell lines were seeded at 4000 
cells/well. Db = doubling time.  
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 The relationship between MYCN, SKP2, p27 and p21 expression in 
neuroblastoma cell lines 
To further investigate the relationship between MYCN and SKP2, mRNA 
expression was analysed by qRT-PCR and protein levels by densitometry in a 
panel of MYCN amplified (MNA) and non-MYCN amplified (non-MNA) 
neuroblastoma cell lines (Figure 3.8). A significant correlation was observed 
between MYCN protein and SKP2 mRNA expression (Pearsons correlation, r = 
0.92, p = 0.01, Figure 3.9) but not with SKP2 protein levels at the 95% level 
(Pearsons correlation, r = 0.77, p = 0.07, Figure 3.10). The relationship between 
MYCN protein and SKP2 mRNA is consistent with the hypothesis that MYCN 
regulates SKP2 at the transcript level, and is further supported by the significant 
Spearman correlation between MYCN and SKP2 protein levels (Spearman 
correlation, r = 1, p = 0.003, Figure 3.10) when a rank order correlation analysis 
was performed. These cell line data are consistent with the previous report that 
SKP2 is a prognostic indicator in neuroblastoma independent of MYCN, yet is 
often found at its highest level in MYCN-amplified tumours (Westermann et al., 
2007).   
 
 
Figure 3.8 Western blot showing the basal level of MYCN, c-MYC and SKP2 
in a panel of neuroblastoma cell lines. The western blot shown is a 
representative of 2 independent repeats. 
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Figure 3.9 Comparison of MYCN protein and SKP2 transcript levels in a 
panel of neuroblastoma cell lines. a) Linear regression analysis. Each point is 
a separate cell line, r the Pearson correlation coefficient and p the significance. 
b) MYCN protein and SKP2 transcript level in each cell line. mRNA expression 
was determined by qRT-PCR and protein expression by densitometry. Both sets 
of data were first normalised to GAPDH and expressed relative to the MYCN 
amplified SK-N-BE(2c) cell line. Data are the mean and error bars represent the 
SEM of n=2 experiments.   
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Figure 3.10 Comparison of MYCN and SKP2 protein level in a panel of 
neuroblastoma cell lines. a) Linear regression analysis. Each point is a 
separate cell line and p the significance b) MYCN and SKP2 protein level in each 
cell line. Protein expression was determined by densitometry, normalised to 
GAPDH and expressed relative to the MYCN amplified SK-N-BE(2c) cell line. 
Data are the mean and error bars represent the SEM of n=2 experiments.   
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 MYCN expression sensitises Tet21N cells to cell cycle arrest.   
To further characterise the role of SKP2 and its relationship with MYCN in the 
Tet21N model, SKP2 protein was successfully knocked down using siRNA 
(Figure 3.11a). SKP2 loss resulted in a clear increase in p21 protein levels 
independent of MYCN and yet only influenced p27 levels in the Tet21N-MYCN+ 
cells, although this may be due to the higher basal expression of p27 in the 
Tet21N-MYCN- cells masking the influence of SKP2 inhibition.   
The presence or absence of MYCN did not influence the effect of SKP2 
knockdown on cell proliferation (Figure 3.11b) as significant growth inhibition, 
compared to the negative control siRNA (NCS), was observed after 72 hr 
treatment with the siRNA regardless of MYCN status (p ≤ 0.01, paired t test). 
However cell cycle arrest, measured by an increase in the G1:S ratio after 24 hr 
SKP2 siRNA exposure, was only induced in the Tet21N MYCN+ cells (p = 0.01, 
paired t test) and not in the Tet21N MYCN- cells (Figure 3.12a).  
Although the different effects on cell cycle could be the result of the enhanced 
stability of p27 and p21, as suggested by the western blot (Figure 3.11a), it may 
also reflect the role of MYCN in cell cycle regulation. Tet21N MYCN- cells have 
a markedly higher proportion of cells in G1 compared to Tet21N MYCN+ cells, 
which have a larger percentage of cells in S phase consistent with the role of 
MYCN in regulating proliferation (Figure 3.12b). The effect on the G1:S ratio in 
Tet21N MYCN+ cells may therefore reflect, in part, the lower baseline G1 
population of 50% as opposed to the Tet21N MYCN- cells where the baseline G1 
population may already be maximal at 80%. 
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Figure 3.11 The effect of SKP2 siRNA transfection on p27 and p21 protein 
expression and cell proliferation in the Tet21N cell line. a) Western blot 
showing the effect of SKP2 knockdown (SKP2) on p27 and p21 protein level. 
Knockdown is compared to negative control siRNA (NCS) and cell lysates 
collected at time points indicated. The western blot shown is a representative of 
3 independent repeats. b) Cell proliferation: An XTT assay was performed after 
72 hr exposure to siRNA. Data are normalised to non-transfected cells. Data are 
the mean and error bars represent the SEM of n=3 experiments. * and ** 
correspond to a p value of <0.05 and <0.01, respectively. 
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Figure 3.12 The effect of SKP2 siRNA transfection on the G1/S ratio and cell 
cycle phase distribution in the Tet21N cell line. a) G1/S ratio measured by flow 
cytometry after a 24 hr exposure to siRNA. b) Cell cycle phase distribution after 
24 hr exposure to SKP2 siRNA compared to negative control siRNA (NCS). Data 
are the mean and error bars represent the SEM of n=3 experiments. 
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    SKP2 knockdown induces apoptosis independently of MYCN 
expression in the Tet21N cell line 
Two techniques were used to investigate the levels of apoptosis following SKP2 
knockdown; the induction of a population of cells with a sub-G1 DNA content and 
activation of caspase-3/7. There was a significant increase in the sub-G1 
population following 48 hrs SKP2 siRNA treatment independent of the presence 
of MYCN (Figure 3.13a); however, the increase was greater in Tet21N MYCN+ 
(p = 0.007 paired t test) than in Tet21N MYCN- cells (p = 0.02 paired t test). This 
difference was confirmed by analysing caspase 3/7 activity (Figure 3.13b). 
Consistent with the sub-G1 fraction from the flow cytometry data, the Tet21N cells 
showed an increase in caspase 3/7 activity 24 hrs after exposure to SKP2 siRNA 
compared to the negative control siRNA (NCS). However, the response was only 
statistically significant in the Tet21N MYCN+ cells (p = 0.05, paired t test).   
A reduction in the G1 fraction was observed in both Tet21N MYCN+ and MYCN- 
cells following SKP2 knockdown, yet only reached significance in the Tet21N 
MYCN+ cells (Figure 3.14a, p = 0.03, paired t test). As there was no change in 
either the S phase or G2 phase population following a 48 hr exposure to SKP2 
siRNA (Figure 3.14b), the apoptotic response to SKP2 knockdown may be a 
result of replication stress.  
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Figure 3.13 The effect of SKP2 siRNA transfection on apoptosis in the 
Tet21N cell line. a) Percentage of cells in sub-G1 DNA fraction of the cell cycle 
measured by flow cytometry after 48 hr exposure to SKP2 siRNA. b) Caspase-
3/7 activity after 24 hr exposure to SKP2 siRNA. Data are normalised to the non-
transfected (NT) control and compared to negative control siRNA (NCS). Data 
are the mean and error bars represent the SEM of n=3 experiments. * and ** 
correspond to a p value of <0.05 and <0.01, respectively. 
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 Tet21N MYCN+ Tet21N MYCN- 
 NSC SKP2 NCS SKP2 
G1 Phase 47 ± 4 37 ± 2 52 ± 11 49 ± 8 
S Phase 26 ± 2 23 ± 1 22 ± 7 21 ± 4 
G2 Phase 14 ± 4 16 ± 3 12 ± 3 12 ± 4 
Sub-G1 Phase 13 ± 3 23 ± 3 14 ± 4 18 ± 4 
Figure 3.14 The effects of a 48 hr exposure to SKP2 siRNA on the cell cycle 
in the Tet21N cell line. a) G1 cell cycle phase distribution b) Cell cycle phase 
distribution. Data were analysed by flow cytometry after 48 hr exposure to SKP2 
siRNA and compared to negative control siRNA (NCS). Data are the mean and 
error bars represent the SEM of n=3 experiments. * and ** correspond to a p 
value of <0.05 and <0.01, respectively. 
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 The role of the SKP2/p27 axis in cell cycle arrest and apoptosis 
induced by Skp2 knockdown in Tet21N MYCN+ cells 
To establish the extent to which p27 stabilisation contributed to the G1 arrest in 
Tet21N MYCN+ cells, dual knockdown of p27 and SKP2 was investigated. 
Preventing p27 expression attenuated the cell cycle arrest induced by SKP2 
knockdown, implying that SKP2/p27 relationship plays a key role in the regulation 
of the G1/S transition by SKP2 in Tet21N MYCN+ cells (p = 0.04 paired t test, 
Figure 3.15a).  
Unexpectedly, a larger sub-G1 fraction, indicative of apoptotic cell death, was 
observed following the 48 hr exposure to p27 siRNA than following the 48 hr 
exposure to SKP2 siRNA (p = 0.02 paired t test, Figure 3.15b). The sub-G1 
population was reduced (p = 0.02 paired t test) following the dual knockdown 
suggesting that the accumulation of p27 plays a role in the apoptotic cell death 
induced by SKP2 knockdown.  
 
 
 
 
Figure 3.15 The effect of dual knockdown of SKP2 and p27 on G1 arrest and 
apoptosis in the Tet21N MYCN+ cells. The effect of dual knockdown on a) G1:S 
ratio and b) Sub-G1 fraction. Data was normalised to the negative control siRNA 
and the mean plotted. Error bars represent the SEM of n=3 experiments. * 
corresponds to a p value of < 0.05. 
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 MYCN directly binds to and activates the human SKP2 promoter  
MYCN ChIP was performed in the SHEP-Tet21N MYCN regulatable cells, MYCN 
amplified IMR32 and non-amplified SHSY5Y cell lines using the established 
MYCN target gene ODC1 as the positive control. MYCN was observed to bind to 
several non-canonical E-boxes in both TET21N MYCN+ (Figure 3.16, maroon 
bar) and IMR32 cells (Figure 3.17), as well as a canonical E-Box downstream of 
the transcriptional start site (TSS). The highest MYCN binding was observed at 
the TSS level (amplicon B), and was reduced to an un-detectable level after a 
week of tetracycline treatment in the Tet21N cell line (Figure 3.15, pink bar). No 
MYCN binding was observed in the SHSY5Y cells (Figure 3.18), as predicted, 
although a high intensity of c-MYC binding was observed which mirrored that of 
MYCN in the IMR32 cell line. The binding of MYCN to the SKP2 promoter was 
confirmed by ChIP-chip arrays in a second MYCN-inducible system and in the 
MYCN-amplified Kelly cell line (Figure 3.19) performed by Ray Stallings (Royal 
College of Surgeons in Ireland, Dublin, Ireland). Significant MYCN binding was 
seen in the 5' region of the SKP2 gene in SHEP cells (MYCN high expression) 
which was abrogated when the cells were treated with DOX to produce low 
MYCN expression. A high level of MYCN binding to the SKP2 promoter was also 
observed in MYCN amplified Kelly cells.   
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Figure 3.19 ChIP-chip microarray data for the SKP2 gene in the SHEP-MYCN 
regulatable cell line and MYCN amplified Kelly cells. Identification of MYCN 
binding in 5’ region of SKP2 promoter in SHEP-MYCN regulatable cells and 
MYCN amplified Kelly cells. Scale across the top of the panel indicates the base 
pair position on chromosome 5. Fluorescent intensity of probes are expressed as 
log2 ratios (green bars) and high confidence MYCN peaks (red bars) as identified 
by the NimbleScan peak finding algorithm, Position of the SKP2 transcript and 
the region tiled on the array are indicated by the two middle panels. Data provided 
by R. Stallings, Royal College of Surgeons, Dublin.   
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 MYCN functionally activates the human SKP2 promoter     
To confirm the functional regulation of the SKP2 promoter by MYCN, a SKP2 
reporter construct incorporating the 1148/+20 region from the translational start 
site was employed (Huang and Hung, 2006). Previously used to assess the 
functional regulation of the SKP2 promoter by c-MYC (Bretones et al., 2011), the 
sequence matched that used for the ChIP assay covering the oligonucleotide 
sequences for amplicon A and B. Two E-boxes were identified within the 
construct (CACCTG and CCCGTG) and targeted by site-directed mutagenesis. 
The constructs were transfected into Tet21N MYCN+/MYCN- cells (Figure 
3.20a), MYCN amplified IMR32 cells and non-MYCN amplified SHSY5Y cells 
(Figure 3.20b) and the highest promoter activity observed when MYCN was 
present; Tet21N MYCN+ (p = 0.05, paired t test) and IMR32 (p = 0.002, unpaired 
t test). Mutation of the E-box motifs significantly reduced promoter activity, to a 
level similar to that observed when MYCN was absent/not amplified (p < 0.05, 
paired t test), implying that MYCN directly activates the SKP2 promoter. Mutation 
of the two E-boxes reduced promoter activity in the Tet21N MYCN- and non-
MYCN amplified SHSY5Y cells. While this finding is consistent with the findings 
that other E-box binding factors, e.g. c-MYC, can influence SKP2 promoter 
activity (Bretones et al., 2011), it may also demonstrate SKP2 promoter regulation 
by the basal level of MYCN present in a non-amplified setting.     
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Figure 3.20 The effect of MYCN on SKP2 promoter activity analysed by a 
luciferase reporter construct. Relative luciferase activity of the SKP2 promoter 
constructs pGL3-SKP2 and pGL3-MutEB transfected into a) Tet21N-
MYCN+/MYCN cells and b) MYCN amplified IMR32 cells and non-amplified 
SHSY5Y cells. Luciferase activity was normalised to β-galactosidase activity to 
control for transfection efficiency Data are the mean and error bars represent the 
SEM of n=3 experiments. * and ** correspond to a p value of <0.05 and <0.01, 
respectively. 
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 Discussion 
MYCN has a paradoxical role in neuroblastoma as it is able to both drive 
proliferation (Lutz et al., 1996) and sensitise cells to apoptosis (van Noesel et al., 
2003). The net effect of MYCN amplification is therefore dependent on the 
interplay between these two responses. As the molecular mechanisms of MYCN-
driven neuroblastoma are not fully understood, the identification of MYCN target 
genes may help in the understanding of the mechanisms and pathways MYCN 
uses to drive tumorigenesis. 
SKP2 has been previously identified as a potential MYCN target in 
neuroblastoma (Bell et al., 2007), with SKP2 transcript levels shown to 
significantly correlate with MYCN amplification (Figure 3.20, http://r2.amc.nl), in 
addition to independently indicating a poor outcome in primary neuroblastoma 
tumours (Westermann et al., 2007). The high levels of SKP2 core promoter 
activity in MYCN amplified cells has been associated with high E2F1 activity 
combined with low abundance of repressive pRB-E2F1 complexes bound to the 
SKP2 promoter (Muth et al., 2010). SKP2 has also been shown to play a role in 
both the ubiquitin-mediated destruction of c-MYC as well as act as a 
transcriptional co-activator, a role further complicated by the identification of 
SKP2 as a direct c-MYC target gene (Kim et al., 2003; Bretones et al., 2011). 
Together, these data, in addition to the homology between MYC family members 
suggest that MYCN amplification promotes SKP2 protein expression which 
enhances neuroblastoma proliferation and aggressiveness.  
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Figure 3.21 Gene expression data from the R2 microarray analysis and 
visualisation platform (http://r2.amc.nl) showing the correlation between 
MYCN and SKP2 expression in dataset of 88 neuroblastoma tumours. 
 The interplay between MYCN and SKP2 in regulatable MYCN 
expression systems    
Switching off MYCN expression in the SHEP-Tet21N MYCN regulatable cell line 
reduced SKP2 expression at the transcript and protein level (Figure 3.1). The 
gradual decline of SKP2 protein levels over 5 days of tetracycline treatment 
(Figure 3.2), correlated with a reduction in growth in Tet21N MYCN- cells (Figure 
3.3b) and an accumulation of the CDK inhibitors p27 and p21, suggesting that 
p27/p21 stabilisation induced the observed growth inhibition. MYCN alters the 
expression of several cell cycle related targets to override the G1 checkpoint and 
has been reported to repress the expression of p21 (Iraci et al., 2011). Following 
the removal of MYCN the mRNA levels of both CDK inhibitors substantially 
increased (Figure 3.4), suggesting that the enhanced protein expression of p27 
and p21 was due to the loss of MYCN and increased transcription instead of 
enhanced stabilisation through loss of SKP2-mediated degradation. To 
determine the contribution of SKP2 loss, Tet21N cell were treated with 
cycloheximide and tetracycline which resulted in p27 stabilisation only (Figure 
3.5), suggesting that the increased p21 protein level in the Tet21N MYCN- cell 
line was controlled at the transcript level and in neuroblastoma cell lines MYCN 
regulates the SKP2/p27 axis. Previous reports show Tet21N MYCN- cells to have 
higher baseline hypo-phosphorylated pRB than the Tet21N MYCN+ cells, which 
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in association with SKP2 being recognised as a direct E2F1 target gene may 
explain the lower SKP2 expression in the Tet21N MYCN- cells as the promoter 
activity is reduced by both the lack of E2F1 activity and by hypo-pRB repression 
at the promoter level (Bell et al., 2006; Muth et al., 2010).  
Although there was an increase in SKP2 mRNA levels upon MYCN induction in 
the p53 mutant SKNAS-Nmyc-ER cell line (Figure 3.6a) increased expression 
was not reflected at the protein level (Figure 3.6b). MYCN gene overexpression 
in SKNAS cells has been shown to restore the ability to undergo retinoic acid 
activated differentiation by downregulating the expression levels of the 
microRNAs miR-20a, miR-9 and miR-92a (Guglielmi et al., 2014). Interestingly 
miR-20a negatively regulates E2F genes which may explain the increase in SKP2 
transcript levels in SKNAS-Nmyc-ER cells as the induction of MYCN 
transcriptional activity leads to a decrease in miR-20a activity which corresponds 
to an increase in E2F activity (Guglielmi et al., 2014). Conversely miR-20a, miR-
9 and miR-92a have all been previously reported to positively correlate with 
MYCN. Nonetheless a growing body of evidence suggests that MYCN has a 
predominantly repressive role in the overall miRNA signature with the 
downregulation of miRNA being the result of the deregulation of key enzymes in 
the miRNA-processing pathway (Lin et al., 2010b; Buechner and Einvik, 2012). 
Additionally, Guglielmi et al presented the downregulation of miR-20a, miR-9 and 
miR-92a as a mechanism in which MYCN could trigger the early phases of 
differentiation (Guglielmi et al., 2014). As miRNA expression patterns are known 
to correlate with neuroblastoma prognosis, differentiation and apoptosis (Chen 
and Stallings, 2007), the relationship between MYCN and a particular miRNA 
may therefore be dependent on the stage of the differentiation pathway.  
Exposure to 4’OH-Tamoxifen (4-OHT) also suppressed cell growth (Figure 3.7a) 
consistent with the literature which associates favourable prognostic 
characteristics upon forced MYCN expression in an non-amplified setting (Tang 
et al., 2006a). It would have therefore been interesting to monitor apoptotic and 
differentiation markers, in addition to genes associated with a favourable clinical 
prognosis e.g. TrkA, to confirm this. In relation to the suppression of growth, 
further investigation into cell cycle phase distribution would be of interest to 
determine whether the growth inhibition was a result of a G1 arrest, an increase 
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in the sub-G1 fraction indicating apoptosis, or a combination of the two. Treatment 
of the parental SKNAS cell line with 4-OHT would also be required to establish 
whether inhibition of growth was through mechanisms independent of activation 
of the Nmyc-ER vector.  
The discrepancies between data from the SHEP-Tet21N and SKNAS Nmyc-ER 
models at the SKP2 protein level reflects the limitations of gene expression 
systems as well as highlights differences between completely switching off the 
gene, and consequently protein expression, and manipulation of the 
transcriptional activity of MYCN. Nonetheless, the higher SKP2 transcript level in 
both the Tet21N and SKNAS-Nmyc-ER cell lines, when MYCN is present/active, 
implies that SKP2 is regulated by MYCN.   
 SKP2 and the functional MYCN signature  
The relationship between the expression of MYCN and SKP2 both at the 
transcript and protein level was reiterated in the panel of neuroblastoma cell lines 
(Figure 3.8). A significant linear relationship was seen between MYCN protein 
expression and SKP2 mRNA level, (r = 0.92, Pearsons coefficient, Figure 3.9a), 
but not with the SKP2 protein level at 95% significance level (r = 0.77, Pearsons 
coefficient, Figure 3.10a). While this followed the pattern reported by Bell et al 
(Bell et al., 2007), further statistical analysis demonstrated that there was a rank 
order relationship generated by the two oncogenes which was perfectly positively 
monotonic (rs = 1, Spearman coefficient, Figure 3.10a). This nonparametric 
measure indicates that the expression level of MYCN and SKP2 are functions of 
one another, that is any increase in one will always be paired with an increase in 
the other. These data indicates that while SKP2 expression is a shared feature in 
MYCN amplified and non-amplified neuroblastoma cell lines the level of 
expression is in part dependent on the level of MYCN expression, as previously 
reported (Westermann et al., 2007; Muth et al., 2010).  
The functional MYCN gene signature in neuroblastoma is constantly being 
redefined. The ability of MYCN to both promote and repress gene expression, 
along with its interactions with microRNAs, adds another level of complexity to its 
role in tumour progression. While many investigations into MYCN-regulated 
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genes identify sets of genes which share common cellular roles e.g. DNA repair, 
cell cycle and differentiation pathways, they do not often yield overlapping 
prognostic signatures. Some of the discrepancies from these mRNA expression 
based screens can be linked to these studies only accounting for MYCN mRNA 
levels and not protein levels as often mRNA and protein expression does not 
correlate (Ohira et al., 2005; Vermeulen et al., 2010; Valentijn et al., 2012). This 
lack of correlation between mRNA and protein expression, as demonstrated by 
SKP2 in the panel of neuroblastoma cell lines (Figure 3.8) is often observed with 
potential MYCN transcriptional targets. While on one hand this may reflect the 
complexity of the proteome, as a diverse multitude of post-transcriptional 
modifications alter both mRNA and protein expression and stability, it also 
reiterates the importance of identifying the functional MYCN signature. That is, 
genes where elevated mRNA expression in the presence of MYCN relates to 
protein levels and clinical outcome, in an attempt to identify MYCN gene targets 
which contribute to oncogenicity.    
As SKP2 has been identified as a direct c-MYC target gene (Bretones et al., 
2011), the significant homology within the Myc family may play a role in its 
expression profile in neuroblastoma. Non-MYCN amplified tumours generally 
express higher levels of c-MYC expression than MYCN and vice versa in a MYCN 
amplified setting. This inverse correlation is due to repression at the MYCN 
promoter by c-MYC and may explain the high SKP2 protein expression in the 
NMA cell lines (Breit and Schwab, 1989; Westermann et al., 2008). However, the 
highest c-MYC expression in the panel of neuroblastoma cell lines investigated 
was in the non-MNA GIMEN and Tet21N MYCN- cells which expressed the 
lowest levels of SKP2 (Figure 3.8). The presence of c-MYC also failed to 
influence the SKP2 transcript levels, suggesting that post-translational 
mechanisms which regulate SKP2 protein stability are responsible for the high 
expression in the absence of MYCN. Lower levels of p21 were seen in the MYCN 
amplified cell lines in line with the suppression of p21 transcription by MYCN (Iraci 
et al., 2011). Interestingly, the highest levels of p21 expression were associated 
with the lowest SKP2 expression suggesting that the SKP2/p21 axis may be 
dominant over the regulation of p27 by SKP2 in neuroblastoma cell lines. 
However, given the presence of MYCN amplified and p53 mutant cell lines, both 
of which have less p21 transcriptional activity, a larger panel of non-MYCN 
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amplified cell lines would have to be investigated to confirm this hypothesis 
(Figure 3.8). Contrary to the inverse relationship observed in primary tumour 
samples (Westermann et al., 2007), no clear relationship was seen between the 
protein expression of SKP2 and p27, suggesting that additional events 
associated with either SKP2 expression or p27 proteolysis may be operating in 
these cell lines.      
 MYCN expression influences the effect of SKP2 knockdown on cell 
proliferation and cell cycle progression in the Tet21N cell line  
Although SKP2 siRNA treatment significantly inhibited proliferation independent 
of MYCN expression (Figure 3.11b), a G1 arrest and increase in p27 protein level 
was only observed in Tet21N MYCN+ cells (Figure 3.12a and Figure 3.11a 
respectively). As both Tet21N MYCN+ and MYCN- cells showed an increase in 
p21 stabilisation following SKP2 knockdown, these data suggest that the 
SKP2/p27 axis plays an important role in the G1:S transition in neuroblastoma 
cell lines and that MYCN expression sensitises cells to a G1 arrest following SKP2 
inhibition. This hypothesis was supported by p27 siRNA treatment rescuing the 
cells from the cell cycle arrest induced by SKP2 inhibition (Figure 3.15a). 
Under normal growth conditions, both a higher G1:S ratio and basal levels of p27 
were observed in the Tet21N MYCN- cells in comparison to Tet21N MYCN+ cells 
(Figure 3.12b and Figure 3.11a, repectively). MYCN plays an instrumental role in 
the length of the G1 phase (Lutz et al., 1996), and as discussed in Section 3.4.2, 
when switched off in the Tet21N cell line increases the half-life of p27 (Figure 
3.5). The lack of G1 arrest following SKP2 knockdown in the Tet21N MYCN- cells 
may therefore be due to the higher proportion of cells already in G1 phase, as a 
consequence of MYCN removal, masking the effect of SKP2 inhibition. This 
observation demonstrates the dominant role of MYCN on cell cycle progression 
and questions the contribution of SKP2 to cell cycle progression in 
neuroblastoma, emphasizing the need for further investigation in a panel of non-
isogenic cell lines of differing MYCN status.  
SKP2 knockdown increased p21 levels irrespective of the presence of MYCN in 
the Tet21N cell line, although a greater effect was observed in the Tet21N 
MYCN+ cells. An increase in p21 expression has previously been identified as a 
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mechanism of inducing G1 arrest upon MYCN inhibition in neuroblastoma, 
attributing a decrease in SKP2 expression to be in part responsible for the 
stabilised expression (Bell et al., 2007). Furthermore, p21 is a well-established 
downstream effector of p53 which in turn is a known direct MYCN target gene 
(Chen et al., 2010b). As p27 stabilisation and a G1 arrest was only observed in 
the Tet21N MYCN+ cells, yet an increase in p21 expression and suppression of 
growth was induced independent of MYCN, the growth inhibition following SKP2 
knockdown may be a consequence of apoptotic cell death (Figure 3.11).  
 MYCN expression sensitises Tet21N cells to apoptosis induced by 
SKP2 knockdown  
Forty eight hour treatment with SKP2 siRNA increased the sub-G1 fraction in the 
Tet21N MYCN+ and MYCN- cells, indicating apoptotic cell death (Figure 3.13a). 
This effect was confirmed by the increase in caspase 3/7 activity compared to the 
negative control siRNA after a 24 hr siRNA exposure (Figure 3.13b). As 
discussed in Section 3.4.2, dual treatment of the Tet21N cells with tetracycline 
and cycloheximide had no effect on the half-life of p21 (Figure 3.5) implying that 
protein synthesis must be in part responsible for the increase in p21 protein 
expression following SKP2 knockdown (Figure 3.11a). Although qRT-PCR would 
have to be performed to confirm this assumption, taken together with the greater 
induction of caspase 3/7 activity observed in the Tet21N MYCN+ cells it is 
probable that SKP2 inhibition is inducing a p53 response. Both MYCN and SKP2 
have been implicated in the regulation of the p53 pathway. A recognised direct 
MYCN target gene, MYCN amplified neuroblastoma cells are reported to have 
higher basal levels of transcriptionally active p53 sensitising them to apoptosis 
(Chen et al., 2010b). In contrast, SKP2 is known to suppress p53-dependent 
apoptosis by interacting with the p53-cofactor p300, antagonizing its ability to 
acetylate and consequently activate p53 (Kitagawa et al., 2008).  
Although MYCN is reported to stimulate the transcription of p53, the MYCN-
dependent sensitisation to apoptosis would still require p53 activation. Both 
Tet21N MYCN+ and MYCN- cells undergo a prolonged period in G1 arrest be it 
due to SKP2 inhibition (MYCN+) or the loss of MYCN (MYCN-) and experience a 
shift of cells from G1 to sub-G1 at the 48 hr time-point suggesting replicative stress 
activates the p53 pathway (Figure 3.14). The higher sensitivity of the Tet21N 
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MYCN+ cells to SKP2 knockdown (Figure 3.13), albeit minor, may therefore be 
due to the higher levels of available p53. These observations on one hand may 
implicate the overexpression of SKP2 as a mechanism to evade 
chemosensitivity, while on the other identify a novel mechanism to trigger p53-
mediated apoptotic cell death in MYCN amplified neuroblastoma.  
Alternatively the difference in caspase-3/7 induction between the Tet21N MYCN+ 
and MYCN- cells may be a consequence of the level of p27 accumulation. The 
dual knockdown of SKP2 and p27 significantly reduced the sub-G1 fraction 
induced from SKP2 siRNA treatment alone (Figure 3.15b), suggesting that the 
p27 accumulation in Tet21N MYCN+ cells had a role in the apoptotic response 
from SKP2 inhibition. This assumption was supported by the significant reduction 
in the sub-G1 population following the dual knockdown of SKP2 and p27. 
Overexpression of p27 has shown to induce apoptosis in several cancer models 
(Katayose et al., 1997). Although the mechanism is not fully understood it is 
thought to be in-part associated with the p53-dependent apoptotic response, 
specifically the elevation of the BCL-2 negative regulator BAX (Fujieda et al., 
1999). Conversely knockdown of p27 alone induced the highest sub-G1 fraction 
(Figure 3.15b) implying that the stabilisation of p27 through SKP2 inhibition may 
not be beneficial for treatment of MYCN amplified neuroblastoma. However, 
further investigation into non-isogenic neuroblastoma cell lines of differing MYCN 
and p53 status would be required to further investigate the role of the SKP2/p27 
axis in cell survival. 
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Figure 3.22 Proposed interactions between MYCN, SKP2 and p53 in the 
regulation of apoptosis. In response to SKP2 inhibition, p27 and p21 
accumulate initiating a G1 arrest which induces replicative stress activating a p53 
response. The loss of SKP2 releases p300 inhibition allowing activation of p53, 
while the pRb-E2F1 complexes repress SKP2 transcription. SKP2 and p53 are 
direct target genes of MYCN resulting in higher levels in Tet21N MYCN+ cells 
increasing the sensitivity of a G1 cell cycle arrest and consequent apoptosis 
activated by replicative stress, following SKP2 inhibition.  
 MYCN directly binds to, and activates, the human SKP2 promoter  
SKP2 is a recognised direct target gene of c-MYC which binds to non-cannonical 
E-boxes on the SKP2 promoter (Bretones et al., 2011). Given the conserved 
nature of E-boxes and homology of binding between MYC family members, there 
is great potential for an interaction between MYCN and the SKP2 promoter. 
Quantitative MYCN ChIP identified a direct interaction between MYCN and non-
canonical E-box motifs within the SKP2 promoter, which correlated with ChIP-
chip array data identifying MYCN binding to the SKP2 promoter in a second 
MYCN-inducible and MYCN amplified cell line (Figure 3.19). Together these data 
provide strong evidence that SKP2 is a direct transcriptional target of MYCN.  
As already discussed c-MYC is often expressed in neuroblastoma in favour of 
MYCN in the absence of MYCN amplification. It is therefore of interest to note 
that the intensity of c-MYC binding to the promoter of the non-MYCN amplified 
SHSY5Y cell line is comparable to that of MYCN in the MYCN amplified IMR32 
cell line (Figure 3.17 and 3.18). As both cell lines have been shown to express a 
MYCN
SKP2 p53 MDM2
Apoptosis
Cell cycle arrest
p27 p21
G1 phase S phase
E2F1 pRB pRB P
p300
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similar level of SKP2 protein (Figure 3.8), this observation suggests that SKP2 is 
a dual MYCN/c-MYC target gene (Westermann et al., 2008) while again 
emphasising the role of SKP2 in neuroblastoma independent of MYCN status 
(Westermann et al., 2007).          
 MYCN expression activates the SKP2 promoter   
To confirm the functional regulation of the SKP2 promoter by MYCN, a SKP2 
luciferase reporter construct incorporating the -1148/+20 region from the 
translational start site was employed (Bretones et al., 2011). The construct 
sequence matched that used for the ChIP assay, covering the oligonucleotide 
sequences for amplicons A and B, and two E-boxes were identified (CACCTG 
and CCCGTG) and targeted by site-directed mutagenesis. The highest promoter 
activity was recorded in the presence of MYCN and was significantly decreased 
when MYCN expression was switched off/not amplified (Figure 3.20). This result 
implicates a functional role for MYCN expression in SKP2 promoter activity and 
supports the relationship between MYCN protein and SKP2 transcript level 
observed in the panel of neuroblastoma cell lines (Figure 3.9). Furthermore, 
mutation of the E-boxes significantly reduced promoter activity to a level similar 
to that seen when MYCN was not induced or amplified, suggesting that SKP2 is 
a direct MYCN target gene.  
The SKP2 promoter is regulated by a network of molecular mechanisms. 
Numerous pathways have been shown to promote SKP2 transcriptional activity 
either through direct interaction such as c-MYC (Bretones et al., 2011) and the 
IKKα subunit of the NF-кB pathway (Schneider et al., 2006), or by integrating 
signalling through the E2F1 binding sites (Zhang and Wang, 2006) e.g. PI3K/AKT 
(Reichert et al., 2007). Conversely SKP2 transcription is also suppressed by 
repressive units directly binding to the promoter, for example pRB-E2F1 
complexes in MYCN amplified neuroblastoma cells (Muth et al., 2010), FOXP3 
binding in breast cancer (Zuo et al., 2007) and STAT1 which inhibits SKP2 
expression to induce an anti-tumour function in Ras-transformed cells (Wang et 
al., 2010b).  
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These different regulatory mechanisms may explain the discrepancies observed 
between the Tet21N MYCN+ cells and MYCN amplified IMR32 cells as although 
this study shows the MYCN protein level to be comparable between the two cell 
lines (Figure 3.8), the IMR32 cells showed ~50 fold higher luciferase activity 
(Figure 3.20b). The amplicon which includes the MYCN gene is reported to vary 
in size and has been shown to vary from 100 kb to 1 Mb long. Given that the 
MYCN gene only spans ~7 kb, additional genes are often co-amplified and 
contribute to the malignant behaviour of MYCN amplified disease (Amler and 
Schwab, 1989; Scott et al., 2003). The fold difference in SKP2 promoter activity 
between Tet21N MYCN+ and IMR32 cells could therefore potentially be through 
mechanisms regulated by the genes co-amplified with MYCN. Importantly, the 
difference between the two cell lines highlights the potential limitations of 
comparing MYCN-regulatable systems with amplified/non-amplified cell lines. 
 Conclusions 
The results discussed in this chapter provide strong evidence that SKP2 is a 
direct transcriptional target of MYCN in neuroblastoma. MYCN has been shown 
to: a.) upregulate SKP2 mRNA level in two independent MYCN regulatable 
expression systems, b.) bind to non-canonical E-box motifs within the human 
SKP2 promoter in ChIP assays and c.) functionally activate a SKP2 promoter, 
luciferase-reporter construct. Furthermore functional studies of SKP2 have 
confirmed a correlation between MYCN protein and SKP2 mRNA in a panel of 
neuroblastoma cell lines with the presence of MYCN sensitising the Tet21N cells 
to a G1 arrest and apoptosis after treatment with SKP2 siRNA.    
Taken together this data suggests that the MYCN/SKP2 relationship plays an 
important role in the perpetual cell cycle entry in MYCN amplified neuroblastoma, 
and identifies a potential downstream effector of MYCN for pharmacological 
inhibition. However further investigation is required into the role of SKP2 in non-
isogenic MYCN amplified and non-amplified neuroblastoma cell lines.  
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Target validation of SKP2 in neuroblastoma cell lines 
 Introduction 
 SKP2 expression in neuroblastoma  
SKP2 has been hypothesised to play a key role in the progression of 
neuroblastoma due to its association with MYCN expression, as discussed in 
Chapter 3, in addition to its overexpression predicting a poor clinical outcome in 
primary tumours (Bell et al., 2007; Westermann et al., 2007). These reports are 
supported by the Kaplan-Meier survival curves and correlation analyses from the 
R2 microarray analysis and visualisation platform (http://r2.amc.nl) which show a 
strong correlation between MYCN and SKP2 expression (r = 0.4924, p = 1.1x10-
6, Figure 4.1a) and high levels of SKP2 relating to poor overall survival (Figure 
4.1b). The oncogenic functions of SKP2 are often related to its ability to target 
the CDK inhibitor p27 for degradation. Although SKP2 is the rate-limiting factor 
within the SCFSKP2 complex, the interaction between the E3 ligase and its primary 
target is dependent on the phosphorylation of a p27 threonine reside (Thr187) by 
the cyclin E-CDK2 complex (Montagnoli et al., 1999b) and formation of a trimeric 
complex between SKP2-cyclinA/CDK2 and the SKP2 accessory protein CKS1 
(Hao et al., 2005; Ungermannova et al., 2005; Xu et al., 2007).  
c-MYC has been shown to be promote CKS1 activity by indirect mechanisms 
which up-regulate CKS1 mRNA (Keller et al., 2007). While this observation does 
open the possibility for the regulation of CKS1 expression by MYCN due to the 
homology within the MYC family of oncoproteins, the R2 database identified no 
correlation between MYCN and CKS1B (CKS1) expression (Figure 4.2a). CKS1 
has been shown to have oncogenic roles outside of its regulation of p27 stability 
in other tumours and high levels of CKS1 were found to associate with a poor 
overall survival in neuroblastoma (Figure 4.2b). However as low levels of p27 are 
associated with the high expression of SKP2 seen in MYCN amplified tumours 
(Westermann et al., 2007), and this relationship is dependent on CKS1 activity, 
the oncogenic role of CKS1 in neuroblastoma may be primarily through its 
regulation of CDK inhibitors.    
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One transcription factor which has recently been demonstrated to regulate both 
SKP2 and CKS1 expression is the Forkhead Box M1 (FOXM1). A key modulator 
of the G1/S transition and mitotic progression, siRNA knockdown of FoxM1 
expression has been shown to significantly reduce SKP2 and CKS1  mRNA 
levels as it diminished the binding of FOXM1 to the endogenous SKP2 and 
CKS1B promoter regions (Wang et al., 2005; Kim et al., 2014). Interestingly, the 
R2 database identified a strong correlation between MYCN and FOXM1 (r = 
0.401, p = 1.1x10-4, Figure 4.3) which could contribute both to the high levels of 
SKP2 in MYCN amplified tumours and the inverse relationship with p27 as both 
high levels of SKP2 and CKS1 would be present in the MYCN amplified setting.   
Although SKP2 targets numerous proteins for degradation, the studies described 
in this chapter concentrate on the regulation of the CDK inhibitors p27 and p21. 
High levels of p27 protein expression have been shown to act as a good 
prognostic indicator, independent of MYCN amplification (Bergmann et al., 2001), 
with its accumulation contributing to a G1 arrest (Matsuo et al., 2001) and acting 
as a key mediator of neuronal differentiation in neuroblastoma cell lines (Borriello 
et al., 2000; Munoz et al., 2003; Nakamura et al., 2003). Unlike p27, p21 
expression in MYCN amplified neuroblastoma is also regulated at the transcript 
level by p53 which itself is a direct MYCN target gene. The failure of MYCN 
amplified neuroblastoma cell lines to undergo a G1 arrest following DNA damage 
has been in part associated with lower levels of p21 induction (Bell et al., 2006). 
As SKP2 has been implicated in the suppression of p53 activity (Kitagawa et al., 
2008) the high levels of SKP2 seen in MYCN amplified neuroblastoma may 
contribute to the lack of a G1 arrest.  
In summary, the high expression of SKP2 observed in neuroblastoma is 
associated with a poor outcome and could potentially be a contributing factor in 
the aggressive behaviour of MYCN amplified neuroblastoma. Given the 
challenges in targeting MYCN, it is therefore of interest to understand further the 
role of SKP2 in neuroblastoma and its potential as a therapeutic target.  
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Figure 4.1 Gene expression data from the R2 microarray analysis and 
visualisation platform (http://r2.amc.nl) showing analysis from the Versteeg 
dataset of 88 neuroblastoma tumours. a) Relationship between MYCN and 
SKP2. b) Kaplan-Meier analysis for overall survival according to SKP2 
expression. Patients with SKP2 expression greater than 511.2 (n=14) had shorter 
survival than those with lower expression (n=74).  Following probes were chosen 
for analysis, MYCN : 209757_s_at and SKP2 : 203625_x_at   
a) 
b) 
Low (74) 
High (14) 
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Figure 4.2 Gene expression data from the R2 microarray analysis and 
visualisation platform (http://r2.amc.nl) showing analysis from the Versteeg 
dataset of 88 neuroblastoma tumours. a) Relationship between MYCN and 
CKS1B. b) Kaplan-Meier analysis for overall survival according to CKS1B 
expression. Patients with CKS1B expression greater than 1450.8 (n=12) had 
shorter survival than those with lower expression (n=76). Following probes were 
chosen for analysis, CKS1B : 201897_s_and MYCN : 209757_s_at  
a) 
b) 
Low (76) 
High (12) 
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Figure 4.3 Gene expression data from the R2 microarray analysis and 
visualisation platform (http://r2.amc.nl) showing analysis from the Versteeg 
dataset of 88 neuroblastoma tumours. Relationship between MYCN and 
FOXM1. Following probes were chosen for analysis, MYCN : 209757_s_at and 
FOXM1 : 202580_x_at  
 Functional studies into the role of SKP2 in oncogenesis 
Investigations into the oncogenic role of SKP2 have largely involved the removal 
of gene function using either siRNA targeted knockdown or gene knockout mice. 
Both powerful tools, although one more absolute than the other, the removal of 
the protein provides information of the molecular function through the resultant 
phenotypic changes observed. Identification of p27 as the primary target of SKP2 
was in part through observations of SKP2 knockout mice (SKP2-/-). Although 
viable, SKP2-/- mice were smaller than their SKP2+/+ littermates and showed 
characteristics of polyploidy and multiple centrosomes, much of which was 
corrected by the additional knockout of p27 (Nakayama et al., 2000). Thus the 
ability of SKP2-/- mice to grow to adulthood indicates that the accumulation of p27 
is not sufficient on its own to arrest cell proliferation completely. This observation 
that SKP2 knockout was not embryonically lethal nor promoted any 
predisposition to cancer supported reports that SKP2 is a proto-oncogene reliant 
on additional oncogenic events to promote tumorigenesis (Nakayama et al., 
2000). In the studies described in this chapter, siRNA was employed which, 
although a more transient technique, provides a better representation of the 
effects of therapeutically inhibiting SKP2 than permanent gene deletion. Ideally 
both a small molecular inhibitors and SKP2 targeting siRNA would be used to 
investigate the functional role of the oncoprotein; however, no small molecule 
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SKP2 inhibitors which produce the same level of target-specific inhibition of SKP2 
function are currently available. As it is the overexpression of SKP2 which is 
associated with a poor prognosis, SKP2 siRNA knockdown in cancer cell lines 
will help validate any potential therapeutic benefit of targeting the oncoprotein. 
Conversely expression vectors can be employed to exogenously overexpress 
SKP2 in low level expressing cells, which may identify molecular mechanisms 
undetected in the loss-of-function analysis. The parallel approach allows 
clarification of whether SKP2 overexpression is a driving force in neuroblastoma 
or simply a bi-product of MYCN amplification. Taken together these experiments 
provide important evidence on the potential benefit of therapeutically targeting 
SKP2 in neuroblastoma.       
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 Aims 
Having identified SKP2 as a direct MYCN target gene as described in Chapter 3, 
the overall aim of the work presented in this chapter was to investigate SKP2 as 
a potential therapeutic target in neuroblastoma using cell lines and determine 
whether MYCN amplification or p53 status influenced sensitivity to SKP2 
knockdown. These aims were addressed with the following specific objectives: 
 To examine the effect of SKP2 siRNA treatment on the expression of the 
CDK inhibitors p27 and p21, cell cycle progression and cell survival in 
MYCN amplified and non-amplified neuroblastoma cell lines.  
 To clarify the relationship between SKP2 and p27 in the G1/S checkpoint 
in neuroblastoma cell lines. 
 To investigate the relationship between SKP2 and the p53 pathway by 
monitoring the effects of SKP2 siRNA knockdown on cell cycle arrest, 
apoptotic cell death and the p53 response following ionising radiation 
treatment.  
 To determine the role of the overexpression of SKP2 in driving cellular 
proliferation in the SHEP neuroblastoma cell line by transfection with a 
pcDNA-SKP2 expression vector.     
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 Chapter specific material and methods  
 SKP2 siRNA optimisation 
MYCN amplified IMR32 cells and non-MYCN amplified SHSY5Y cells were 
treated with 20, 40 and 60 nM siRNA targeting SKP2 for 24 hrs, as described in 
Section 2.5.3. Knockdown efficiency was analysed in comparison to a negative 
control siRNA (NCS) by western blotting as described in Section 2.5, and the 
optimum concentration of 40 nM chosen and subsequently applied to each cell 
line unless stated otherwise.     
 
Figure 4.4 Optimisation of a 24 hr exposure to SKP2 siRNA in non-MYCN 
amplified SHSY5Y and MYCN amplified IMR32 cells. 
 Transfection and optimisation of the pcDNA-SKP2 expression 
plasmid 
The parental cells for the Tet21N cell line, SHEP cells, were chosen for  
transfection with the pcDNA-SKP2 expression vector (kindly donated by 
Professor Neil Perkins, Newcastle University) due to their recognised tolerance 
to stable transfections and low levels of endogenous SKP2 (Figure 4.5). A range 
of plasmid concentrations were evaluated to determine an optimum level of 
plasmid. Cells were seeded at 4 x 105 cells/well into 6-well plates in RPMI 1640 
(10% (v/v) FBS), 24 hrs prior to transfection. The pcDNA-SKP2 plasmid was 
transfected into cells using Lipofectamine® 2000, in Opti-MEM® reduced serum 
medium (Invitrogen, Life Technologies, Paisley, UK). Plasmids were stored at -
20°C in stock concentrations of 0.2µg/µl, and the transfection mixture used as 
shown in Table 4.1.  
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Table 4.1 pcDNA-SKP2 plasmid transfection mixture 
DNA and Lipofectamine were diluted separately in Opti-MEM® media as shown 
in Table 4.1 and incubated for 10 minutes at room temperature. Following 
incubation, the two solutions were then mixed at a 1:1 ratio, gently inverted and 
incubated for a further 30 minutes at room temperature. The RPMI medium was 
removed from the wells, the cells rinsed with Opti-MEM® to remove any 
remaining FBS and replaced with 1.6 ml of the serum free medium. After the 
incubation, 400 µl of the transfection mixture was added to each well, briefly 
shaken, and the plate incubated at 37°C for 24 hrs. Lysates were collected and 
analysed using western blotting as describe in Section 2.5. Based on Figure 4.5 
a concentration of 0.8 µg/well was chosen for the subsequent transfections 
 
Figure 4.5 Optimisation of a 24 hr pcDNA-SKP2 plasmid transfection in 
SHEP cells 
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 SKP2 knockdown and DNA damage induction by ɣ-irradiation 
Cells were seeded at 4 x 105 cells/well into 6-well plates in RPMI 1640 (10% 
(v/v) FBS), 24 hrs prior to transfection with SKP2 siRNA as described in Section 
2.4.3. After a 24 hr exposure to siRNA the OptiMEM serum free medium was 
replaced with 2 ml RPMI 1640 medium and the plate irradiated with 4 Gy 2103 
kV X-rays from a RS320 irradiation system (Gulmay Medical, Surrey UK). The 
irradiation (IR) dose had been previously optimised (Bell et al., 2006). Cells 
were harvested at 6 and 24 hrs post irradiation for western blotting and 24 hrs 
post irradiation for cell cycle and caspase-3/7 analysis. Control lysates were 
prepared from cells treated in parallel to the IR treated samples and collected 
following a 48 hrs exposure to SKP2 siRNA to match the siRNA exposure 
length of the irradiated lysates 
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 Results  
 SKP2 knockdown inhibits cell growth independent of MYCN and p53 
status  
Based on the findings in the Tet21N cell line that MYCN sensitised cells to a G1 
arrest following SKP2 knockdown (Section 3.4.5), the functional role of SKP2 in 
the G1/S transition was examined in a panel of neuroblastoma cell lines varying 
in MYCN and p53 status. An XTT assay, performed after a 72 hr exposure to 
SKP2 siRNA showed significant growth inhibition in all cell lines compared to 
negative control siRNA (NCS), with the exception of MYCN amplified, p53 
mutant, IMR-KAT100 cells (Figure 4.6). Selected as a result of repeated-3 day 
exposure of the parental MYCN amplified IMR32 cell line to potassium antimony 
tartrate (KAT), a point mutation was identified within the DNA-binding domain of 
p53, at codon 135. This same mutation has previously been reported in the SK-
N-BE(2c) cell line which was established from a patient with relapsed disease; 
however, this cell line underwent a significant growth inhibition following SKP2 
knockdown (p < 0.01) (Goldschneider et al., 2006b; Xue et al., 2007).  
 
Figure 4.6 The effect of SKP2 siRNA transfection on cell proliferation. An 
XTT assay was performed after 72 hr exposure to siRNA. Data are normalised 
to non-transfected cells and compared to the negative control siRNA (NCS). Data 
are the mean and the error bars represent SEM of n=3. * and ** correspond to a 
p value of <0.05 and <0.01, respectively. 
P
e
r
c
e
n
ta
g
e
 m
e
ta
b
o
li
c
 a
c
ti
v
it
y
 r
e
la
ti
v
e
 t
o
n
o
n
-t
r
a
n
s
fe
c
te
d
 c
e
ll
s
 (
%
)
S H S Y 5 Y G IM E N S K N A S S K -N -
B E (2 c )
IM R -
K A T 1 0 0
IM R 3 2 L a n 5
0
2 0
4 0
6 0
8 0
1 0 0
N C S
S K P 2
n o n -M Y C N a m plified M Y C N a m plified
p53 m u t
*
* *
* *
* *
*
147 
 
 SKP2 knockdown induces G1 arrest and apoptosis in non-MYCN 
amplified neuroblastoma cells independently of the p53 pathway 
Contrary to what was observed in the MYCN regulatable Tet21N cells, only the 
non-MYCN amplified cell lines showed an increase in the G1/S ratio after a 24 hr 
SKP2 siRNA exposure, (Figure 4.7), implying that the inhibition of proliferation 
seen in the SK-N-BE(2c) cells was not a result of a G1 arrest. The non-MYCN 
amplified, p53 mutant, SKNAS cells are known to only express the C-terminal 
truncated isoform of p53 (p53β), which is reported to be unable to induce p21 
protein accumulation. Although p21 stabilisation was seen across the whole 
panel of p53 wild-type cell lines (Figure 4.8), p27 protein levels only consistently 
increased in the non-MYCN amplified cells at the 24 hr time-point (Figure 4.8a), 
suggesting that the SKP2/p27 axis plays an important role in the G1/S transition 
in non-MYCN amplified neuroblastoma cells. This lateral observation reinforces 
the findings of the protein stability experiments in Tet21N cells where only p27 
was found to be stabilised after switching off MYCN expression, as discussed in 
Section 3.4.2. 
 
 
Figure 4.7 The effect of SKP2 siRNA transfection on the G1/S ratio in a panel 
of neuroblastoma cell lines. G1:S ratio measured by flow cytometry after a 24hr 
exposure to siRNA. Data are normalised to non-transfected cells and compared 
to the negative control siRNA (NCS). Data are the mean and the error bars 
represent SEM of n=3. * and ** correspond to a p value of <0.05 and <0.01, 
respectively. 
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Figure 4.8 Western blot showing the effect of SKP2 knockdown on p27 and 
p21 protein expression in a panel of neuroblastoma cell lines. a) non- MYCN 
amplified cell lines b) MYCN amplified cell lines. Cell lysates were collected at 
the time-points stated. The western blot shown is representative of 3 independent 
repeats.    
A significant increase in the sub-G1 fraction, indicative of apoptotic cell death, was 
observed in non-MYCN amplified cell lines following a 48 hr SKP2 siRNA 
exposure (Figure 4.9a) and confirmed by the induction of caspase-3/7 activity 
24hrs after siRNA treatment (Figure 4.9b). As SKNAS cells harbour an inactive 
form of p53 (p53β) these results suggest that SKP2 knockdown initiates caspase-
dependent apoptosis, independent of the p53 pathway, but only in non-MYCN 
amplified cells.  
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Figure 4.9 The effect of SKP2 siRNA transfection on apoptosis in a panel of 
neuroblastoma cell lines. a) Percentage of cells in the sub-G1 DNA fraction of 
cell cycle measured by flow cytometry after 48 hr exposure to SKP2 siRNA. b) 
Caspase-3/7 activity after 24 hr exposure to SKP2 siRNA in non-MYCN amplified 
cell lines. All data are normalised to the non-transfected controls and compared 
to the negative control siRNA (NCS). Data are the mean and error bars represent 
the SEM of n=3 experiments, * and ** correspond to a p value of <0.05 and <0.01, 
respectively. 
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 Depletion of p27 prevents the effects of SKP2 knockdown on the cell 
cycle  
To establish the extent to which p27 accumulation was responsible for the 
induction of the G1 arrest, dual knockdown of p27 and SKP2 was investigated in 
the non-MYCN amplified cell lines (Figure 4.10a). Preventing the increase of p27 
following SKP2 knockdown attenuated the cell cycle arrest significantly in all cell 
lines investigated (p ≤ 0.05, paired t test) implying that p27 accumulation is a key 
step in the G1 arrest induced by SKP2 depletion. The importance of the SKP2/p27 
axis in the regulation of the G1/S transition in neuroblastoma is supported by the 
lack of a G1 arrest in the MYCN amplified cell lines (Figure 4.7), where the effect 
of SKP2 knockdown on p27 stabilisation was not as pronounced (Figure 4.8b). 
Alternatively, deregulated MYCN may be influencing the SKP2-independent 
degradation of p27 such as the activity of the E3 ligase KIP1 ubiquitination-
promoting complex (KPC) which promotes the degradation of cytoplasmic p27 
exported during the G0 - G1 transition (Kamura et al., 2004).    
Interestingly, preventing p27 stabilisation in GIMEN and SKNAS cell lines 
significantly decreased the apoptotic cell death induced by SKP2 knockdown in 
all cell lines investigated suggesting that p27 contributes to the apoptotic 
response from SKP2 inhibition. This effect was not observed in the SHSY5Y cells 
where the p27 knockdown alone induced a greater increase in the sub-G1 
population which was reduced upon SKP2 knockdown (Figure 4.10b). 
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Figure 4.10 The effect of dual knockdown of SKP2 and p27 on G1 arrest and 
the sub-G1 fraction in a panel of neuroblastoma cell lines. a) G1:S ratio and 
b) Sub-G1 fraction measured by flow cytometry after exposure to siRNA. Data 
was normalised to the negative control siRNA and the mean plotted. Error bars 
represent the SEM of n=3 experiments, * and ** corresponds to a p value of <0.05 
and < 0.01, respectively.    
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 SKP2 knockdown induces a p53 apoptotic response to DNA damage 
MYCN amplification is associated both with the activation and suppression of the 
MDM2-p53 apoptotic pathway. As SKP2 is a direct MYCN target gene and is 
reported to suppress p53 dependent apoptosis through inhibition of the p53 co-
factor p300 (Kitagawa et al., 2008), experiments were performed to determine 
whether SKP2 inhibition could enhance the p53 response to DNA damage 
induced by ionising radiation (IR). Cells were treated with SKP2 siRNA for 24 hr 
prior to exposure to 4Gy IR and lysates collected 24 hrs post irradiation.  
The proportion of cells in the sub-G1 population significantly increased in non-
MYCN amplified SHSY5Y cells, and MYCN amplified p53 mutant SK-N-BE(2c) 
cells, 24 hrs after DNA damage (Figure 4.11). A 24 hr treatment with SKP2 siRNA 
increased the sub-G1 fraction in the non MYCN amplified cell lines, as previously 
shown in Figure 4.9, and the response was increased in SHSY5Y cells following 
exposure to 4Gy ionising radiation (Figure 4.12a). Dual treatment with SKP2 
siRNA and IR increased the sub-G1 population in the MYCN amplified IMR32 and 
IMR-KAT100 cell lines compared to SKP2 knockdown alone, suggesting that 
SKP2 knockdown sensitises the cell lines to DNA damage (Figure 4.12b). This 
pattern of induction of apoptotic cell death was confirmed by the significant 
induction of caspase-3/7 activity (Figure 4.13), although the increase following 
dual treatment in the MYCN amplified, p53 mutant IMR-KAT100 cells did not 
reach significance at the 95% level (p = 0.06, paired t test, Figure 4.13b)   
The p53 functional response to DNA damage was investigated using western 
blotting for p53, MDM2 and p21 in the p53 wt cell lines (Figure 4.14a). Lower 
levels of MDM2 induction were seen in the MYCN amplified IMR32 cells, which 
returned to basal levels by the 24 hr time point. Both SHSY5Y and IMR32 cell 
lines demonstrated induction of p53 and p21; however, SKP2 knockdown 
maintained the p21 stability in the IMR32 cell line 24 hrs post irradiation. SKP2 
siRNA exposure had no effect on the level of p53 expression although a slight 
increase in MDM2 levels was observed in the SHSY5Y cells, which was 
associated with an increase in p21 expression 6 hrs post IR treatment. Neither 
MDM2 nor p21 induction was observed in the p53 mutant cell lines although 
combined treatment of SKP2 siRNA and 4Gy IR was associated with an increase 
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in p27 protein levels (Figure 4.14b), implying that p27 accumulation may play a 
role in the apoptotic cell death induced by combined ionising radiation treatment 
and SKP2 depletion.     
 
 
 
Figure 4.11 The effect of ionising radiation on sub-G1 population in a panel 
of neuroblastoma cell lines. Percentage of cells in the sub-G1 DNA fraction of 
the cell cycle measured by flow cytometry 24 hr after exposure to 4Gy irradiation. 
Data are the mean and error bars represent the SEM of n=3 experiments, * and 
** correspond to a p value of <0.05 and <0.01, respectively. 
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Figure 4.12 The effect of dual treatment with SKP2 siRNA and IR on the sub-
G1 population in a panel of neuroblastoma cell lines. Sub-G1 population 48 hr 
post SKP2 siRNA treatment and 24 hr post 4Gy IR treatment. a) p53 wildtype cell 
lines. b) p53 mutant cell lines. Data are normalised to the non-irradiated negative 
control siRNA (NCS). All data are the mean and error bars represent the SEM of 
n=3 experiments, * and ** correspond to a p value of <0.05 and <0.01, 
respectively. 
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Figure 4.13 The effect of dual treatment with SKP2 siRNA and IR on 
caspase-3/7 activity in a panel of neuroblastoma cell lines. Caspase-3/7 
activity 48 hr post SKP2 siRNA and 24 hr post 4Gy IR treatment. a) p53 wildtype 
cell lines. b) p53 mutant cell lines. Data are normalised to the non-irradiated 
negative control siRNA (NCS). All data are the mean and error bars represent the 
SEM of n=3 experiments, * and ** correspond to a p value of <0.05 and <0.01, 
respectively. 
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Figure 4.14 Western blot showing the effect of SKP2 knocdown and 4Gy 
ioninsing radiation on SKP2, p53, MDM2, p27 and p21 expression in a panel 
of neuroblastoma cell lines. Cell lysates were collected at the time points 
stated. a) p53 wildtype cell lines. b) p53 mutant cell lines. The western blot shown 
is a representative of 3 independent repeats. 
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 Exogenous overexpression of SKP2 induces a G2 arrest in the SHEP 
neuroblastoma cell line  
To investigate the dependence of cell cycle progression on SKP2, SHEP cells, 
which have low endogenous levels of SKP2 protein, were transfected with a 
cDNA-SKP2 expression plasmid. A transient transfection, the expression level of 
SKP2 returned back to its basal level by the 72 hr time-point indicative of the short 
half-life of the protein (Figure 4.15). The exogenous expression of SKP2 had no 
effect on the levels of p27 or p21, suggesting that other factors contribute to the 
expression profile of the CDK inhibitors.  Forced expression of SKP2 significantly 
increased the G2 population at the 48 hr time point compared to the empty vector 
control suggesting a G2 arrest (Figure 4.16). Cell cycle arrest at the G2 checkpoint 
is often associated with the p53 pathway; however, although SHEP cells do not 
harbour a p53 mutation they do have a homozygous deletion of the MDM2 
antagonist p14ARF (Carr-Wilkinson et al., 2010b). As the lack of p14 expression 
results in suppression of p53 activity, the observed G2 arrest from SKP2 induction 
may be through a p53-independent pathway. The accumulation of cells in G2 was 
associated with a decrease in the G1 population rather than S phase (Figure 
4.16b), suggesting accelerated passage through the cell cycle as seen when 
MYCN is exogenously expressed in Tet21N MYCN+ cells (Figure 4.17). These 
data support the hypothesis that SKP2 contributes to the oncogenic behaviour of 
MYCN amplification.            
 
Figure 4.15 Western blot showing the effect of pcDNA-SKP2 transfection on 
p27 and p21 expression in SHEP cells. Cell lysates were collected at the time 
points stated following transfection with the cDNA-SKP2 or empty vector.   The 
western blot shown is representative of 3 independent repeats. 
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 24hr 48hr 72hr 
% Total events Ctrl SKP2 Ctrl SKP2 Ctrl SKP2 
G1 Phase  69 ± 2 74 ± 3 41 ± 7 35 ± 7 66 ± 5 66 ± 5 
S Phase  12 ± 2 10 ± 2 22 ± 2 22 ± 3 13 ± 3 14 ± 0.5 
G2 Phase  8 ± 1 7 ± 1 33 ± 5 38 ± 5 15 ± 5 13 ± 4 
Sub-G1 Phase  11 ± 1 9 ± 1 5 ± 2 3 ± 1 6 ± 0.5 7 ± 2 
 
 
Figure 4.16 The effect of pcDNA-SKP2 transfection on cell cycle distribution 
in SHEP cells measured by flow cytometry. a). Cell cycle phase distribution 
across all time points. b) Percentage of cells in G1 and G2 after a 48 hr exposure 
to the pcDNA-SKP2 plasmid. Data are the mean and the error bars represent 
SEM of n=3, * and ** correspond to a p value of <0.05 and <0.01, respectively.     
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Figure 4.17 The effect of a 48 hr transfection with pcDNA-SKP2 on cell cycle 
distribution in SHEP cells compared to Tet21N MYCN+/MYCN- cells. Data 
are the mean and the error bars represent SEM of n=3, * and ** correspond to a 
p value of <0.05 and <0.01, respectively.     
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 Discussion 
Identified as an oncoprotein, the role of SKP2 in tumour progression is 
predominantly characterised by its ability to modulate the G1/S transition by 
targeting numerous regulatory proteins/tumour suppressors for proteasomal 
degradation. SKP2 over-expression often correlates with reduced levels of p27 
and a poor prognosis (Bloom and Pagano, 2003), with p27 knockout in SKP2-/- 
mice reversing many of the unfavourable phenotypes seen from SKP2 loss 
(Nakayama et al., 2004). However, while SKP2 is often identified as the rate 
limiting factor in the degradation of the target proteins, additional factors are 
required, namely, phosphorylation and, especially in the cases of p27 and p21, 
the presence of the SKP2 accessory protein CKS1. When analysing the role of 
SKP2 in accelerating cell proliferation and promoting tumorigeneis it is therefore 
necessary to consider these contributing factors.  
CKS1 has been identified as a potential oncogene in an array of cancers, often 
associated with the amplification of the CKS1B gene and the ability of CKS1 to 
contribute to tumour progression both dependent and independently of the 
SCFSKP2 complex (Tsai et al., 2005; Zhan et al., 2007; Wang et al., 2009a). 
Situated on chromosome 1q21.2, gains at 1q21-q25 have been linked to drug-
resistant phenotypes and aggressive growth in stage 4 neuroblastoma (Hirai et 
al., 1999), although there are currently no reports associating these gains with 
increased CKS1B expression. Alternatively the ability of MYC to induce CKS1B 
transcription (Keller et al., 2007) raises the possibility that CKS1 expression is 
regulated by MYCN, which would be an additional aspect of SKP2 biology in 
MYCN amplified neuroblastoma. Additionally, SKP2 levels fluctuate during the 
cell cycle, and SKP2 itself targeted for degradation by the anaphase promoting 
complex/cyclosome (APC/C) E3 ligase when bound to the activator CDH1 (Wei 
et al., 2004). The proteolysis of p27 is also regulated by the KIP1 ubiquitination-
promoting complex (KPC) at the G0-G1 transition, a process dependent on the 
export of p27 into the cytoplasm independent of SKP2 (Kamura et al., 2004). The 
precise role of SKP2 therefore varies depending on the phase of the cell cycle.  
In addition to its role as an E3 ligase, the oncogenic behaviour of SKP2 has been 
linked to roles independent of its F-box and interaction with the SCF complex. 
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The contribution of SKP2 to tumour progression often depends on the cancer 
type and oncogenic driver which determines initial pathway activation and how 
SKP2 participates. In neuroblastoma the role of SKP2 in tumour progression is 
mainly focussed on its relationship with p27. As shown in Chapter 3, SKP2 is a 
direct MYCN target gene and inhibition of SKP2 could potentially influence this 
aggressive oncogene by preventing MYCN-driven proliferation, tipping the 
balance towards MYCN-driven apoptosis.          
 Non-MYCN amplified cell lines are more sensitive to SKP2 
knockdown 
SKP2 siRNA treatment reduced cell proliferation across the panel of 
neuroblastoma cell lines, excluding the MYCN amplified p53 mutant IMR-KAT100 
cells (Figure 4.6), indicating a dependence on SKP2 for cell viability in 
neuroblastoma. However, only the non-MYCN amplified cell lines underwent a 
G1 arrest (Figure 4.7), which was associated with the stabilisation, albeit modest, 
of p27 at the same time point. No effect of SKP2 knockdown on p27 was observed 
in the MYCN amplified cell lines (Figure 4.8), and the absence of p27 stabilisation 
may therefore explain the lack of a G1 arrest. The requirement for p27 
accumulation was confirmed when cell cycle arrest was reversed by additional 
p27 knockdown, demonstrating the SKP2-p27 interaction plays a key role in the 
G1/S transition in non-MYCN amplified neuroblastoma (Figure 4.10a). 
Interestingly this conflicted with the effect of SKP2 knockdown in the MYCN 
regulatable Tet21N cells where a G1 arrest (Figure 3.12a) and p27 stabilisation 
(Figure 3.11a) was only observed in the presence of MYCN. However as 
discussed in Section 3.5.3 this may reflect the lower baseline G1 population in the 
Tet21N MYCN+ cells compared to Tet21N MYCN- cells. This discrepancy 
between MYCN amplification and MYCN overexpression is discussed further in 
the final discussion (Section 6.3.2).  
MYCN amplification is characterised by deregulated cell proliferation and the 
shortening of G1 phase, due to the increased activity of CDK4 and CDK2. The 
impact of SKP2-p27 on the G1/S transition may therefore not be as significant as 
in the non-MYCN driven cell lines. Although SKP2-mediated proteolysis of p27 is 
the best characterised, a multitude of pathways have been reported to regulate 
p27 degradation depending on the cell cycle phase and p27 localisation 
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(reviewed by (Chu et al., 2008)). The lack of p27 stabilisation following SKP2 
knockdown in the MYCN amplified cell lines could for instance be the result of 
degradation by the cytoplasmic KPC E3 ligase in early G1 promoted by the MYCN 
driven progression through the cell cycle (Kamura et al., 2004). Alternatively, p27 
may be protected from degradation by being sequestered into cyclin D-CDK4/6 
complexes. Implicated in the assembly and nuclear import of cyclin D-CDK4, the 
ability of p27 to inhibit the kinase activity is thought to be dependent on the 
growth-state of the cell although it is also argued that p27 has a non-inhibitory 
role in proliferating/cycling cells which is regulated by the phosphorylation of two 
tyrosine residues (Y88 and Y89) in p27’s CDK interaction domain (James et al., 
2008). Supported further by reports that p27 levels are prognostic indicators 
independent of MYCN amplification (Bergmann et al., 2001), the lack of p27 
stabilisation in the MYCN amplified cell lines exposed to SKP2 siRNA 
emphasizes the dominant role played by MYCN in tumour progression.       
SKP2 targets numerous tumour suppressor proteins for degradation which could 
potentially contribute to the suppression of growth observed in the absence of a 
G1 arrest. All the p53 wt cell lines elicited an increase in p21 expression following 
SKP2 knockdown (Figure 4.8), potentially indicating increased p53-mediated 
induction of p21 in addition to the increased stabilisation. Although the p53-p21 
axis regulates the G1/S transition, growth inhibition in the MYCN amplified cell 
lines could potentially be due to a G2/M block or increased apoptosis. Further 
investigation into the transcript and protein levels of p53 effectors, e.g. p21, 14-
3-3σ and BAX, would therefore be of interest. This hypothesis is supported by 
the ability of SKP2 to suppress p53 activity (Kitagawa et al., 2008) and the lack 
of growth inhibition in the IMR-KAT100 cells compared to the parental IMR32 
cells. Although a G1 arrest was not induced in the MYCN amplified cell lines used 
in this current study, this could be due to the increase in p21 levels only being 
high enough to slow proliferation but not cause cell cycle arrest (Bell et al., 2006). 
Nevertheless, taken together these data support the role of SKP2 in MYCN driven 
tumorigenesis whilst again reinforcing the dominance of the MYCN oncogene in 
an amplified setting.   
A significant reduction in cell proliferation was observed following SKP2 
knockdown in the p53 mutant SK-N-BE(2c) and SKNAS cell lines in the absence 
163 
 
of p21 accumulation (Figure 4.6). Although for the non-MYCN amplified SKNAS 
cells inhibition of proliferation can be attributed to p27 accumulation and a G1 
arrest, this observation does not explain the suppression of growth in the MYCN 
amplified SK-N-BE(2c) cells. IMR-KAT100 and SK-N-BE(2c) are both MYCN 
amplified and harbour the same p53 mutation which confers loss of function (Xue 
et al., 2007), yet only SK-N-BE(2c) cells undergo growth inhibition. This difference 
may be a reflection of cellular morphology as the parental IMR32 cells are N-type 
while the SK-N-BE(2c) cells are I-type. An intermediate between the neuroblastic 
N-type and non-neuronal, substrate adherent S-type, I-type neuroblastoma cells 
are reported to carry both N and S-type characteristics as well as show the 
greatest malignant potential (Ross et al., 2003). As SKP2 siRNA exposure 
induced growth inhibition in the S-type SKNAS cells it may be that in response to 
SKP2 knockdown SK-N-BE(2c) cells act more like S-type cells. Alternatively as 
IMR-KAT100 cells were developed to have a multidrug resistance (MDR) profile 
by the repeated exposure to the heavy metal compound potassium antimony 
tartrate (KAT), they could be resistant to SKP2 inhibition due to more general 
mechanisms (Xue et al., 2007). However, further investigations into possible 
mechanisms associated with the resistant phenotype compared to the parental 
IMR32 cell line would be required to confirm the reasons for resistance to SKP2 
knockdown.    
SKP2 has been shown to regulate glycolysis in cancer cells by modulating the 
function of GLUT1 (glucose transporter type 1) through non-proteolytic 
ubiquitination and subsequent activation of AKT by phosphorylation (Chan et al., 
2012). The AKT pathway is a key driver in the up-regulation of aerobic glycolysis 
in tumour cells (Warburg effect) and its activation is a common event in human 
cancers, including neuroblastoma. A poor prognostic indicator, activation of the 
PI3K/AKT pathway is reported to promote chemotherapeutic resistance in 
neuroblastoma cell lines and maintain MYCN stability through the inhibition of 
GSK3β which, when active, destabilises MYCN by phosphorylation on residue 
Thr50 (Kenney et al., 2004; Chesler et al., 2006; Opel et al., 2007). Consequently, 
MYCN amplified neuroblastomas are more sensitive to therapeutic intervention 
of the AKT pathway with small molecule inhibitors shown to downregulate cyclin 
D1 and MYCN expression, which suppresses cell growth and induces apoptosis 
(Segerstrom et al., 2011).  
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Recent findings have shown that the AKT pathway can influence SKP2 activity 
by both direct and indirect mechanisms (Figure 4.18). The phosphorylation of 
SKP2 on Ser72 by AKT both promotes the formation of the SCFSKP2 complex and 
primes SKP2 for further phosphorylation on Ser75 by casein kinase 1 (CK1). Dual 
phosphorylation protects SKP2 from degradation by the APCCDH1 complex (Gao 
et al., 2009; Lin et al., 2009), potentially creating a positive feedback loop as 
SKP2 can then target AKT for ubiquitination and activation. Alternatively, the 
AKT-mediated phosphorylation, and inactivation, of the FOXO transcription factor 
FOXO3a could influence SKP2 activity. High FOXO3a expression has been 
shown to correlate with a good prognosis in neuroblasotoma, and is able to drive 
apoptotic cell death following its re-activation by treatment with PI3K/AKT 
inhibitors (Santo et al., 2013). FOXO3a has also been identified as a negative 
regulator of SKP2 activity both at the transcript level, by directly binding and 
repressing the SKP2 promoter, and in a transcription-independent manner by 
disrupting the formation of the SCFSKP2 complex (Wu et al., 2013).  
As the XTT assay measures cell proliferation indirectly as reflected by total 
glycolytic activity (i.e. NADH production, Section 2.14) the reduction in cell 
proliferation seen in MYCN amplified cell lines following a 72 hr exposure to SKP2 
siRNA could potentially reflect their sensitivity to the inhibition of AKT regulated 
glycolysis. It would therefore be of interest to probe for MYCN protein, cyclin D1 
and phosphorylated AKT (pAKT(T308) and pAKT(S473)) to determine the effect 
of SKP2 inhibition on the AKT pathway. It would also be useful to employ a 
second cell proliferation assay to confirm the XTT assay data.   
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Figure 4.18 Interplay between SKP2 and the PI3K/AKT pathway. AKT 
phosphorylates SKP2 at Ser72 leading to cytoplasmic retention by binding to 14-
3-3β and inhibiting binding to nuclear import receptors. Ser72 phosphorylation 
enhances the formation and activation of the SCFSKP2 complex, as well as 
promotes Ser75 phosphorylation which stabilises SKP2 by disrupting the 
interaction with CDH1. The SCFSKP2 complex ubiquitinates AKT at K8 and K14 
residues promoting its membrane recruitment and EGF-triggered AKT 
phosphorylation and activation.  Activated AKT: 1. Induces GLUT1 transcription 
and protein expression promoting the glycolytic phenotype and tumour 
development, 2. Phosphorylates GSK3β preventing its phosphorylation of MYCN 
on Thr50 resulting in increased MYCN stabilisation and 3. Inactivates FOXO3a 
preventing apoptotic cell death and the negative regulation SKP2 expression.   
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 SKP2 and apoptotic cell death in neuroblastoma cell lines 
SKP2 inhibition has been shown to induce apoptotic cell death in a range of 
cancer models (Gstaiger et al., 2001), and the reduced proliferation of MYCN 
amplified cell lines following SKP2 knockdown, independent of a G1 arrest, could 
potentially be a result of apoptosis. However, as observed for the G1/S transition, 
the induction of apoptosis, represented by an increase in the sub-G1 population 
and induction of caspase-3/7 activity (Figure 4.9), was only significantly 
enhanced in the non-MYCN amplified cell lines including the p53 mutant SKNAS 
cells, suggesting that a p53-independent pathway is responsible.  
Apoptotic cell death involves two main pathways dependent on the type of cellular 
stress and the action of p53 co-activators. The extrinsic network involves the 
activation of death receptors to trigger a caspase cascade and the intrinsic 
mitochondrial pathway the activation of pro-apoptotic BCL-2 family members to 
form the apoptosome, ultimately initiating caspase-mediated apoptosis. The two 
pathways are also linked having been shown to in turn activate each other (Fulda 
and Debatin, 2006). SKNAS cells have been reported to show increased 
expression of the pro-apoptotic BH3-only protein BAD after inhibition of glycolysis 
(Chuang et al., 2013), a process SKP2 inhibition could attenuate via PI3K/AKT 
inhibition as discussed in Section 4.5.1. As both pathways culminate with the 
activation of the executioner caspases such as caspase 3 and 7, the methods 
used in this study to determine apoptosis does not distinguish between the two 
pathways. The apoptotic cell death induced by SKP2 knockdown in the p53 
mutant SKNAS cells may therefore involve the intrinsic mitochondrial pathway.  
The accumulation of p27, observed in all cells which underwent apoptosis, may 
potentially play a role in the apoptotic response. The expression of p27 has been 
shown to correlate with the pro-apoptotic regulator BAX in oropharyngeal 
carcinoma (Fujieda et al., 1999), and act as a predictor of sensitivity to apoptotic 
cell death induced by proteasome inhibitors (Drexler and Pebler, 2003) and 
chemotherapy (Taguchi et al., 2004). This role of p27 accumulation as a predictor 
of cell death is supported by the reduction in the sub-G1 population following the 
dual knockdown of SKP2 and p27 in all 3 non-MYCN amplified cell lines (Figure 
4.10b). Interestingly knockdown of p27 in SHSY5Y cells induced a greater 
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increase in sub-G1 than that observed following SKP2 siRNA treatment 
suggesting that promoting p27 stability in this cell line would be unfavourable for 
the promotion of cell death, although a second assay is required to confirm that 
apoptosis is being induced. As SHSY5Y cells did undergo apoptosis following 
SKP2 knockdown this observation suggests that p27 accumulation did not 
promote cell death in this cell line, and could potentially induce resistance to cell 
death from further therapeutic intervention.  
 SKP2 and p53 
A growing body of data has demonstrated the ability of SKP2 to alter p53 function. 
Alongside the inhibition of the p300 cofactor (Kitagawa et al., 2008), the SKP2 
isoform, SKP2B, has been observed to prevent p53-mediated apoptosis and 
transcriptional activity by promoting the degradation of the prohibitin (Chander et 
al., 2010). In addition to the ability of SKP2 deficiency to initiate oncogenic-stress 
driven senescence independent of the p19ARF-p53 pathway (Lin et al., 2010a), 
targeting SKP2 may provide a strategy to reactivate p53 or trigger cellular 
senescence.   
SKP2 is reported to promote homologous recombination by aiding Mre11-Rad50-
Nbs1 (MRN) complex-mediated recruitment and activation of the checkpoint 
kinase ATM in response to double strand DNA breaks (Wu et al., 2012a). Recent 
reports have also associated the over-expression of SKP2 with resistance to 
ionising radiation through its manipulation of the rad51 pathway (Wang et al., 
2012b). The DNA damage response in p53-wild type neuroblastoma is in part 
determined by the MYCN expression level due to the dual role of MYCN in 
regulating cellular proliferation and sensitising cells to apoptosis. Although failure 
to undergo a G1 arrest after irradiation is characteristic of MYCN amplified 
neuroblastoma, this has been shown to be associated with a lower induction of 
p21 and hypo-pRB accumulation, and a proposed switch from cell cycle arrest to 
a higher sensitivity to apoptotic cell death (Bell et al., 2006). MYCN has also been 
shown to sensitises cells to apoptosis by inducing p53 transcription (Chen et al., 
2010b) and activating the pro-apoptotic activator HIPK2, which phosphorylates 
p53 on Ser46 directing the cell towards apoptosis (Petroni et al., 2011).  
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In the current study SKP2 siRNA treatment caused a pronounced accumulation 
of p21 in all the p53 wild type cell lines independent of MYCN expression (Figure 
4.8) implying a p53 response. Although no G1 arrest or apoptosis was observed 
in the MYCN amplified cell lines, due to the involvement of SKP2 in p53 activity 
and the DNA damage response, it was of interest to investigate whether SKP2 
inhibition could strengthen the response to irradiation-induced DNA damage.  
Ionising radiation (IR) at 4Gy increased the sub-G1 fraction in non-MYCN 
amplified SHSY5Y cells and in MYCN amplified p53 mutant SK-N-BE(2c) cells 
(Figure 4.11). Interestingly, SKP2 siRNA treatment followed by 4Gy IR 
significantly increased apoptotic cell death compared to SKP2 knockdown alone 
in the SHSY5Y cells, as well as in MYCN amplified p53 mutant IMR-KAT100 cells 
and parental IMR32 cells. No further increase in apoptosis was seen in the SK-
N-BE(2c) cell line (Figure 4.12 and 4.13). Both SHSY5Y and IMR32 cells 
underwent a p53 response following ɣ-irradiation, as indicated by the increase in 
p53 and MDM2 expression (Figure 4.14). Although the response was maximal at 
6 hrs post-irradiation for the MYCN amplified IMR32 cells, SKP2 siRNA treatment 
maintained p21 stability up to 24 hrs. A slight increase in MDM2 expression 
following combined treatment was observed in SHSY5Y cells but not in IMR32 
cells. As MYCN directly regulates both SKP2 (Chapter 3) and p53 expression 
(Chen et al., 2010b) a greater induction of MDM2 was expected for the IMR32 
cells due to the larger pools of p53 being activated by the release of SKP2-
mediated inhibition of the p300 cofactor (Kitagawa et al., 2008). However, as an 
increase in cell death was also observed in the p53 mutant IMR-KAT100 cell line, 
it may be that the sensitisation to irradiation induced cell death by SKP2 
knockdown is independent of the p53 pathway.  
SKP2 knockdown was shown to induce apoptosis in the non-MYCN amplified 
p53 mutant SKNAS cell line (Figure 4.9). This apoptotic response was observed 
in the absence of p21 stabilisation yet was associated with an increase in p27 
levels (Figure 4.8). This relationship between increased p27 expression and 
apoptotic cell death was also observed in the SHSY5Y, IMR32 and IMR-KAT100 
cell lines following SKP2 siRNA/4Gy treatment, suggesting that p27 plays a role 
in the regulation of cell survival in neuroblastoma cell lines (Figure 4.14). The role 
of p27 in the regulation of apoptosis is conflicting with some reports suggesting 
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p27 overexpression protects from apoptosis (Masuda et al., 2001) whilst others 
show it induces it (Katayose et al., 1997). Although p27 knockout mice retain their 
ability to undergo a G1 arrest they do display organ hyperplasia. It is therefore 
possible that the ability of p27 to induce apoptosis plays an important role in its 
ability to maintain correct organ size (Nakayama et al., 1996). As p27 stabilisation 
was only present in IMR32 and IMR-KAT100 cells following the combination of 
SKP2 siRNA and 4Gy IR treatment (Figure 4.14), these data suggests that SKP2 
inhibition could potentially be a mechanism for promoting cell death in MYCN 
amplified neuroblastoma. However, further investigation would be required to 
confirm this using a larger panel of cell lines as well as a second mechanism of 
DNA damage, e.g. doxorubicin.  
An alternative role for p27 could involve suppression of centrosome amplification 
in MYCN amplified neuroblastoma, thereby preventing further tumour 
development and promoting stress-induced apoptosis. Centrosome duplication 
begins during the G1/S transition and although a tightly regulated aspect of the 
DNA replication cycle, these regulatory mechanisms are often abrogated in 
aggressive tumours such as MYCN amplified neuroblastoma resulting in 
amplified centrosomes and chromosomal instability. The enhanced expression of 
MYCN has been shown to lead to centrosome amplification following DNA 
damage in neuroblastoma cell lines through a mechanism involving suppression 
of p27 expression via the up-regulation of SKP2 (Sugihara et al., 2004). The 
accumulation of p27 following SKP2 siRNA could therefore trigger stress-induced 
apoptosis through a mitotic block (Sugihara et al., 2006). 
Alternatively, the increase in apoptosis observed following SKP2 knockdown in 
cells lacking a functional p53 pathway could be the result of p73 stabilisation. A 
close relative of p53, p73 is thought to mediate apoptosis in an E2F1- dependent 
manner (Irwin et al., 2000), and to rely on acetylation by the p300 co-factor for 
transcriptional activation following DNA damage (Costanzo et al., 2002). As with 
p53, SKP2 siRNA treatment could potentially promote p73-driven apoptosis by 
releasing the inhibition on the p300 co-activator.    
In the above setting, the increased p73 activity could potentiate the apoptotic 
response through the up-regulation of tumour protein p53-inducible nuclear 
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protein 1 (TP53INP1) expression. A MYCN transcriptional (Bell et al., 2007) 
target, TP53INP1 has been shown to promote apoptosis in p53-deficient cells by 
increasing the transactivation capacity of p73 (Tomasini et al., 2005). The 
increase in apoptosis following the dual treatment of SKP2 siRNA and IR in the 
p53 mutant MYCN amplified cell lines (Figure 4.12b and 4.13b), could therefore 
be though the formation of a self-amplifying loop, where SKP2 inhibition and IR 
promotes p73 activity which transactivates TP53INIP1 which, in turn, modifies 
p73 activity to stimulate pro-apoptotic functions.   
 Forced expression of exogenous SKP2 
The oncogenic role of SKP2 is primarily attributed to it targeting p27 for 
degradation, consequently promoting the G1/S transition. However in this study 
the overexpression of SKP2 in SHEP cells increased the G2 population 
suggesting cells were unable to enter mitosis. The G2 checkpoint is associated 
with DNA damage repair and progression into mitosis, and requires the 
accumulation and activation of CDK1 by its binding to cyclin B1. In the SKP2/p27 
relationship, p27 accumulation is often associated with the inhibition of CDK2 
(bound to either cyclin A or E) and potential effects on CDK1 are often overlooked 
(Toyoshima and Hunter, 1994). Alternatively, the G2/M transition is controlled by 
a p53-dependent pathway which inhibits CDK1 by the direct transcriptional 
regulation of p21, Gadd45 and 14-3-3σ (Taylor and Stark, 2001). However, as 
SHEP cells are homozygously deleted for the MDM2 suppressor p14ARF, the G2 
arrest is unlikely to be through p53-regulated pathways.   
Surprisingly, the transient overexpression of SKP2 had no effect on the protein 
levels of p27 or p21 compared to the control vector (Figure 4.15). While this 
suggests that the exogenously expressed protein is non-functional, the ability of 
SKP2 to target p27 and p21 for degradation also requires substrate 
phosphorylation and the formation of a trimeric complex between SKP2, CKS1 
and the cyclin A/E-CDK2 (Sitry et al., 2002; Bornstein et al., 2003). As SHEP cells 
are reported to express neither MYCN nor c-MYC (Chen et al., 1994) and CKS1 
has been identified as a MYC target gene (Keller et al., 2007), there is potential 
for the lack of p27/p21 degradation being due to lack of CKS1 to compensate for 
the increased levels of SKP2. It would therefore be of interest to investigate the 
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expression levels of CKS1, phosphorylated p27 and p21, as well as CDK1 and 
p53 downstream activators in this setting of SKP2 overexpression.   
Although forced expression of SKP2 did not have the anticipated effect on p27 
and p21 protein levels (Figure 4.15), it did cause a redistribution of the cells 
throughout the cell cycle, suggesting increased proliferative activity (Figure 4.16). 
Despite the minimal effects on cell cycle compared to the empty vector control, 
the enhanced G2 fraction following the transient SKP2 overexpression was 
matched by a decrease in the G1 population as expected, consistent with high 
levels of SKP2 accelerating S phase entry (Figure 4.16). Unfortunately, due to 
the transient nature of the transfection used the effect of SKP2 expression on 
overall proliferation rates could not be monitored. It would therefore be of interest 
to form stable transfectants and investigate the effects of SKP2 overexpression 
on S phase entry, via BrdU-incorporation and long term proliferation.   
Despite the lack of enhanced p27 and p21 degradation following forced SKP2 
expression, the changes to cell cycle phase distribution may still be a result of 
increased cyclin A-CDK2 activity. SKP2 is reported to compete with p27 and p21 
for binding to cyclin A in a regulatory mechanism which protects cyclin A-CDK2 
from inhibition (Ji et al., 2006). Although the authors did recognise that the molar 
concentration of SKP2 must be ~2 over that of p27 and p21, the forced 
expression of SKP2 may be physiologically relevant in the current study. 
Conversely Poon et al demonstrated that the interaction between SKP2 and 
cyclin A-CDK2 inhibited CDK2 activity (Yam et al., 1999), preventing cell cycle 
progression upon SKP2 overexpression.  
Interestingly, the 48 hr cDNA-SKP2 transfection produced a similar cell cycle 
phase distribution as the SHEP-Tet21N MYCN+ cells (Figure 4.17). As this study 
has identified SKP2 as a direct MYCN target gene (Chapter 3) this observation 
is consistent with the hypothesis that the accelerated proliferation seen in MYCN 
amplified neuroblastoma is in part due to increased SKP2 protein expression. It 
would therefore be of interest to develop stable SHEP-SKP2 transfectants for use 
in comparison with the SHEP-Tet21N MYCN+ cells to determine to what extent 
the MYCN/SKP2 relationship controls proliferation in neuroblastoma.  
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 Conclusions 
The results discussed in this chapter provide strong evidence that the inhibition 
of SKP2 would be of therapeutic benefit in non-MYCN amplified neuroblastoma. 
SKP2 siRNA treatment was shown to a.) induce a G1 arrest by stabilising the 
expression of p27 and b.) promote apoptotic cell death independent of the p53-
pathway in non-MYCN amplified cell lines. Functional studies of SKP2 have also 
identified a potential synergistic interaction between SKP2 knockdown and ɣ-
irradiation, at the level of apoptosis independent of both MYCN status and the 
p53-pathway. Lastly, the overexpression of SKP2 was found to promote 
accumulation of the G2 fraction indicative of accelerated proliferation. 
Taken together these data suggest that although the SKP2/p27 axis contributes 
to the proliferation of neuroblastoma cell lines, MYCN amplification does not 
increase sensitivity to SKP2 inhibition, yet is instead able to compensate for the 
loss of SKP2 activity. Nevertheless, targeting SKP2 may be of therapeutic benefit 
in the treatment of non-MYCN amplified disease. However given that the 
phenotypes following siRNA knockdown of a gene are not always comparable to 
those induced by small-molecule inhibition, further investigation into 
pharmacological inhibition of SKP2 in neuroblastoma is required.               
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Pharmacological targeting of SKP2 using small molecule 
inhibitors 
 Introduction 
 SKP2 as a therapeutic target 
The initial concept of targeting SKP2 therapeutically was as a mechanism to 
stabilise the expression of p27 levels, which are often found to be reduced in 
aggressive tumours and to correlate with a poor prognosis (Philipp-Staheli et al., 
2001). However, further insights into the functional role of SKP2 have resulted in 
additional protein targets being identified, and SKP2 has also been shown to 
contribute to tumorigenesis by mechanisms independent of its E3 ligase activity. 
Furthermore, SKP2 is recognised as an oncogene, and has been shown to be 
capable of promoting malignant transformation through cooperation with Ras 
(Gstaiger et al., 2001), AKT (Chan et al., 2012) and c-MYC (Bretones et al., 
2011), amongst other signalling pathways that are often deregulated during 
tumour progression. This diversity of roles results in SKP2 overexpression 
influencing a variety of cellular processes such as proliferation, apoptosis 
(Kitagawa et al., 2008) and differentiation (Pirity et al., 2006), and as a result the 
biological effects of SKP2 inhibition often depend on tumour cell-type and cellular 
biochemistry, as well as the specific activated oncogenic pathways. The complex 
biology of SKP2 was reflected in the responses of neuroblastoma cell lines to 
SKP2 siRNA knockdown, where non-MYCN amplified cell lines showed both a 
G1 arrest and apoptotic cell death independent of the p53 pathway, identifying 
SKP2 as a potential drug candidate in non-MYCN amplified disease in particular 
(Chapter 4).  
The premise of targeting SKP2 with small molecule inhibitors is strengthened by 
the observation that SKP2-/- mice are viable, suggesting a therapeutic window. 
Additionally the crystallographic 3D structures available of SKP2 and its SCF 
components, including CKS1 (Cardozo and Abagyan, 2005; Hao et al., 2005), 
have identified potential targetable pockets for small molecule inhibitors. Taken 
together these data support SKP2 as a potential cancer drug target.   
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 Targeting the SCF E3 Ubiqutin Ligases  
SKP2 is a member of the largest family of E3 ubiquitin protein ligases, and a 
range of options are available to indirectly inhibit SCFSKP2 activity. Bortezomib 
(Velcade®, Millennium Pharmaceuticals) was the first proteasome inhibitor to be 
registered as a drug, identifying a new approach to targeting the ubiquitin 
proteasome system (UPS). However, the 26S proteasome is an essential part of 
protein homeostasis responsible for the degradation of an extensive range of 
proteins involved in various intracellular regulatory roles. As a consequence, 
although bortezomib has been shown to improve the clinical outcome for some 
haematological malignancies, multiple myeloma in particular, severe side effects 
and dose-limiting toxicities restrict its effectiveness and utility (Chen et al., 2011). 
Attempts to increase the therapeutic index of proteasome inhibitors are ongoing 
with the production of second generation compounds, as reviewed by (Mattern et 
al., 2012). However, an alternative approach to enhance specificity and therefore 
reduce potential side effects is to target the proteins upstream of the proteasome, 
such as the E3 ligases, in an attempt to increase selectivity for the effector 
proteins being stabilised.  
SCF complexes are attractive anticancer targets due to their involvement in the 
regulation of tumour suppressor proteins and the deregulation found in several 
human malignancies (Nakayama and Nakayama, 2006b). Approaches to inhibit 
the activity of SCF complexes are summarised in Figure 5.1 and include; (1) 
Inhibition of substrate specific kinases, although not directly related to the E3 
ligase per se, SCF substrates require phosphorylation to be recognised by the F-
box proteins and hence, kinase inhibition will prevent substrate degradation, (2) 
Disruption of the interaction between the RBX1 RING protein and E3 ubiquitin 
conjugation enzyme (UBC), although no inhibitors have been reported (3) 
Disruption of the interaction between the SCF components such as between 
SKP2-CKS1 or SKP2-SKP1, as discussed in detail in Section 5.1.3, (4) Inhibition 
of CUL1 neddylation.         
This last approach prevents the formation of the SCF complex by locking the 
CUL1 protein in an inactive state. Acting as the scaffold holding the SCF complex 
together, prior to complex formation CUL1 requires neddylation to remove the 
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cullin binding protein CAND1, which otherwise inhibits the interactions with RBX1 
and SKP1. A pathway similar to ubiquitylation, the ubiquitin-like protein NEDD8 
is first activated by the NEDD8-activating enzyme (NAE) and then attached to 
CUL1, inducing a conformational change which displaces CAND1 allowing 
SKP1-CUL1-RBX1 formation (Duda et al., 2008). A rate limiting factor in the 
activity of SCF complexes, neddylation has been exploited by the development 
of MLN4924 (Millennium Pharmaceuticals), a potent selective inhibitor of NAE 
(Soucy et al., 2009). Binding to the NAE active site, MLN4924 induces the 
accumulation of cullin-RING ligase (CRL) substrates including those of the 
SCFSKP2 complex (Soucy et al., 2009). However, although more selective than 
bortezomib, MLN4924 still targets all CRLs in addition to other proteins reliant on 
the neddylation pathway, which potentially results in unfavourable side effects. 
Successfully increasing the therapeutic index of UPS inhibition is therefore 
dependent on the development of specific inhibitors which are highly selective 
towards a particular E3 ligase and its substrates, e.g. the F-box protein SKP2.   
 
 
 
 
Figure 5.1 Graphical representation of mechanisms to potentially inhibit an 
SCF complex. (1) Inhibition of kinases which phosphorylate F-Box substrates. 
(2)  Disruption of the interaction between the RBX1 RING protein and E3 ubiquitin 
conjugation enzyme (UBC). (3) Disruption of the interaction between the SCF 
components. (4) Inhibition of CUL1 neddylation.         
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 Direct targeting of SKP2 with small molecule inhibitors 
A primary objective in the development of small molecule inhibitors of SKP2 is to 
prevent the ubiquitylation and consequent degradation of p27. A measurable 
endpoint, this has led to the development of high-throughput screening methods 
for SCFSKP2 complex activity. One such screen led to the identification of a 
compound which was shown to inhibit p27 ubiquitylation by disrupting the SKP1-
SKP2 interaction, inducing a G1 arrest and cell death via autophagy in myeloma 
cell lines (Chen et al., 2008a). ‘Compound A’ (I), was identified using an in vitro 
screen which was based on the radioactive labelling of in vitro-transcribed and -
translated p27. Although compound A did not directly inhibit the E3 ligase activity 
of SKP2, it did act as a ‘proof of principle’ tool molecule and supported further 
development of small molecule SKP2 inhibitors. Utilising a more direct approach, 
Wu et al (2012) used an in silico structure-based tool termed virtual ligand 
screening (VLS) to search for compounds that might target the p27-binding 
interface formed by the SKP2-CKS1 interaction. A structure based approach 
exploiting the published SKP2-CKS1-p27 crystal structure, the authors first 
identified ‘hotspot’ residues that are essential for p27 binding and/or 
ubiquitination. The sub-structures containing the hotspots were then screened 
using a database of potential ligands in order to identify potential inhibitors based 
on the binding score and physico-chemical properties. Using this approach, an 
inhibitor (CI, Figure 5.7) was identified which disrupted SKP2-p27 binding and 
induced cell cycle arrest in cancer cell lines (Wu et al., 2012b), although as with 
the compound published by Chen et al, the anti-tumour activity of compound CI 
was not evaluated. Nevertheless, by disrupting the SKP2-p27 interface the 
authors increased the specificity of targeting SKP2 E3 ligase activity to the 
substrates that require CKS1 (i.e. p27, p21 and p57).  
More recently Chan et al (2012) extended previous findings by using high-
throughput in silico screening approaches to specifically target the SKP1-SKP2 
interaction based on two pockets observed in the SCF-SKP2 crystal structure 
which contribute to the SKP1-SKP2 interaction. From the high-throughput virtual 
screen 25 hits were selected and validated in an in vitro glutathione S-transferase 
(GST) pull-down assay, and an in vitro SKP1-SKP2 binding assay, resulting in 
the identification of SZL-P1-41 which showed the highest potency and most 
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significant inhibition of the SKP1-SKP2 interaction. Following conformation that 
SZL-P1-41specifically stabilised SKP2 targets (p27, p21 and AKT) but not other 
F-box substrates (FBW7), the authors investigated the therapeutic potential of 
SZL-P1-41 in cancer cell lines, identifying a potent suppressive effect on cell 
viability which was associated with the upregulation of p27 and p21 and the 
downregulation of AKT and GLUT1, presumably by the mechanism previously 
discussed in Chapter 4. Notably Chan et al also investigated the in vivo anti-
tumour activity of SZL-P1-41, showing that it restricted tumour growth in a dose-
dependent manner (Chan et al., 2012). Although further validation is required to 
determine the effects of SZL-P1-41 on other F-box complexes, and potential 
effects on SKP2 that are independent of its E3 ligase activity (Chan et al., 2013), 
the development of these small molecule inhibitors illustrates the potential of 
targeting SKP2 pharmacologically.  
 Indirect targeting of SKP2 with small molecule inhibitors  
An alternative approach to inhibiting SKP2 activity is to target its transcription or 
stability. Although the underlying mechanisms of SKP2 overexpression are not 
fully understood, SKP2 gene expression and protein stability have been shown 
to be upregulated by numerous signalling pathways, including those driven by 
oncoproteins, e.g. c-MYC/BCR-ABL. The inhibition of these pathways, for which 
small molecules have been developed, therefore offers an indirect approach to 
targeting SKP2 activity. 
SKP2 protein stability is positively regulated by several post-translational 
modifications. AKT and CDK2 have been shown to interfere with the destruction 
of SKP2 by the APCCDH1 complex, through phosphorylation of Ser72 and Ser64. 
AKT-mediated Ser72 phosphorylation has also been shown to promote SCFSKP2 
complex formation by stimulating subsequent phosphorylation at Ser75 by casein 
kinase I (Rodier et al., 2008; Lin et al., 2009). In addition to the Ser72 and Ser64 
phosphorylation sites, a third site at Thr417 is targeted by Pim-1 protein kinase, 
which is often driven by c-MYC and AKT activity (Cen et al., 2010). Small 
molecule inhibition of these SKP2 modulators may promote SKP2 degradation 
thereby reducing its activity. Alternatively, the APCCDH1 complex can be 
manipulated, for example with retinoic acid, which is currently used to treat high 
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risk neuroblastoma. Retinoic acid promotes SKP2 degradation by downregulating 
the nuclear export factor Rae1, resulting in the nuclear accumulation of CDH1 
and hence SKP2 destabilisation and p27 accumulation (Pirity et al., 2006).   
Consistent with its key role in cell cycle progression, SKP2 interacts with 
numerous cell cycle proteins. First identified in transformed cells as a component 
of the cyclin A-CDK2 complex, SKP2 interacts stoichiometrically with cyclin A and 
SKP1, suggesting that its function when bound to cyclin A is of the same 
importance in tumour progression as its E3 ligase activity when bound to SKP1 
in the SCFSKP2 complex. (Zhang et al., 1995). SKP2 has been found to interact 
with cyclin A through an alternative binding motif to the RXL-HP interaction 
observed between cyclin A and p27. Instead the direct interaction between SKP2 
and cyclin A has been found to be through a novel binding motif in the SKP2 N-
terminal domain and is therefore independent of the ability of SKP2 to mediate 
p27 ubiquitination and degradation. The literature on the effects of the SKP2-
cyclin A-CDK2 interaction on CDK2 kinase activity are conflicting, with one report 
stating the interaction is non-functional (Zhang et al., 1995) and another that 
SKP2 inhibits cyclin A-CDK2 kinase activity (Yam et al., 1999). However, by 
comparing SKP2/cyclin A and p27/cyclin A molar ratios throughout the cell cycle 
in HeLa cells with those required to reach an IC50 in an in vitro kinase assays, an 
inhibitory role has been argued to be impossible at physiological SKP2 
concentrations. Alternatively it has been suggested that when SKP2 is in excess 
over p27, it plays a protective role, preventing the p27-mediated inhibition of 
cyclin A (Ji et al., 2006). Given that the interaction of SKP2 with cyclin A-CDK2 
was found to be specific for cyclin A, and independent of the E3 ligase activity of 
SKP2, the disruption of the complex identifies an alternative route to inhibiting 
cyclin A-CDK2 activity. This hypothesis was confirmed by the introduction of a 
SKP2-cyclin A blocking peptide which facilitated the inhibition of cyclin A-CDK2 
by p27 and induced cell death specifically in cancer cells. Interestingly the 
disruption of this protective role of SKP2 induced a greater effect on cell 
proliferation and survival than SKP2 knockdown in the four cancer cell lines 
analysed (Ji et al., 2007), suggesting that targeting a specific role of SKP2 may 
be a more effective therapeutic intervention than targeting overall SKP2 activity.  
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The observations discussed above highlight the importance of investigating all of 
the biological roles of SKP2 when determining its therapeutic potential. The 
contribution of SKP2 to malignancy has been reported to be tumour specific and 
the biological effects of SKP2 knockdown shown to depend on tumour type and 
genotypic features, e.g. MYCN amplification status as discussed in Chapter 4. 
The majority of studies of SKP2 inhibition have focused on supressing SKP2 E3 
ligase activity, and the mechanisms of cancer cell death associated with the loss 
of SKP2 activity, range from apoptosis to autophagy and the induction of cellular 
senescence, depending on the method of SKP2 inhibition and cell type studied. 
Overall, when establishing the rationale for the development of SKP2 inhibitors it 
is important to acknowledge the difference between preventing protein 
expression and inhibiting its function.   
 Aims  
The overall aim of the work presented in this chapter was to identify potential 
SKP2 inhibitors through an analogue based approach. This aim was addressed 
by the following specific objectives: 
 To analyse the structure-growth inhibition relationships for compound A (I) 
analogues by determining their GI50 concentrations in HeLa cells.  
 To examine the impact of selected I analogues on SKP2-mediated p27 
degradation compared to commercially available ubiquitination pathway 
inhibitors using the p27 degradation Redistribution® assay.   
 To investigate whether MYCN sensitises the Tet21N MYCN regulatable 
neuroblastoma cell line to small molecule inhibition of SCFSKP2 activity.   
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 Chapter specific materials and methods 
 SCF-Skp2 E3 Ligase: p27 degradation Redistribution® assay  
This HeLa cell-based assay, developed by BioImage, Thermo Scientific (R04-
052-01, Thermo Scientific, Fisher Scientific, Waltham, MA, USA) uses 
Redistribution® technology to monitor a stably expressed GFP-tagged human 
p27 which contains a T187D mutation to imitate the phosphorylated state. The 
p27 protein is fused to the N-terminus of the GFP protein, and the continuous 
expression of the p27KIP1(T187D)-EGFP controlled by a standard CMV promoter 
expression of which is maintained by G418 selection.   
Due to the T187D mutation, the GFP-tagged p27 is constantly targeted for 
degradation by the SCFSKP2 complex allowing it to be used as a reporter for SKP2 
E3 ligase activity. Inhibition of SKP2 activity therefore leads to the stabilisation of 
p27 and an increase in green fluorescence which can be quantified 
fluorometrically (Figure 5.2).  
 
 
Figure 5.2 Schematic representation of the SCFSKP2: p27KIP1 degradation 
assay (Thermo Scientific) 
5.3.1.1. Propagation of the HeLa-p27KIP1(T187D)-EGFP cell line  
The HeLa-p27KIP1(T187D)-EGFP cell line was grown in DMEM growth medium, 
high glucose, without L-glutamine or sodium pyruvate (Thermo Scientific, Fisher 
Scientific  cat.#SH30081) supplemented with 10% (v/v) FBS (Sigma), 2mM (v/v) 
L-glutamine (Sigma), 1% (v/v) penicillin-streptomycin (Sigma) and 0.5 mg/ml 
G418 w/v (Calbiochem). Cells were grown at 37°C in 5% CO2 in a humidified 
incubator and passaged once 60-70% confluent.  
Non-inhibited cell:
p27KIP1(T187D)-GFP 
constantly degraded
Inhibited cell:
p27Kip1(T187D)-GFP accumulates 
mainly in nucleus
SKP2 inhibition 
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5.3.1.2. HeLa-p27KIP1(T187D)-EGFP assay protocol 
Cells were seeded at 8000 cells/well in a 96-well microplate (Thermo Scientific 
cat.#165306), 24 hrs prior to treatment, and incubated at 37°C in 5% CO2 
overnight to allow attachment. Cells were treated with the putative inhibitors 
dissolved in DMSO and diluted to 0.5% (v/v) DMSO in assay medium (culture 
medium without G418 sulphate) at concentrations ranging from 0.01 – 100 µM, 
and incubated for a further 24 hrs. After inhibitor treatment, cells were fixed by 
replacing the assay buffer with 100 µl 10% (v/v) formalin, neutral-buffered 
solution (approximately 4% (v/v) formaldehyde) and incubated for 20 minutes at 
room temperature. Cells were then washed 4 times with 200 µl PBS and 
incubated at room temperature for 30 minutes under light restricted conditions 
with 100 µl 1 µM Hoechst staining solution (1 µM Hoechst in PBS containing 0.5% 
(v/v) Triton x-100). The cells were imaged using the BMG LABTECH FLUOstar 
Omega plate reader (BMG LABTECH, Germany) with filters set at 355/460 nm 
for Hoechst and 385/520 nm for EGFP (wavelength for excitation and emission, 
respectively). The proteasome inhibitor MG132 was used to validate the assay 
and a concentration of 5 µM chosen as the positive control in each assay. For all 
compounds the GFP intensity was corrected for background fluorescence, 
normalised to Hoechst 33342 fluorescence to correct for the cell number per well, 
and the level of GFP expressed as the percentage activity relative to the 5 µM 
MG132 positive control which was defined as being 100%.   
5.3.1.3. Analysis 
GFP fluorescence intensity (% of the 5 µM MG132 positive control) was plotted 
using Graphpad Prism Version 6.0 (GraphPad Software Inc.) and the mean EC50 
values determined using Prism statistical software based on a standard point to 
point curve with 1000 segments.   
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  Results  
 Structure-growth inhibition relationship analysis of compound A (I)   
Based on the previously published compound A (I) (Chen et al., 2008a), a 
compound library was synthesised by Andrew Shouksmith (NICR, School of 
Chemistry, Newcastle) by systematically modifying the chemical structure of I 
(Figure 5.3a). The GI50 values of the analogues were determined in HeLa cells 
as described in Section 2.15 (Figure 5.3b/c) and ranged from 5.8 µM (Id) to ˃100 
µM (Ik), the maximum concentration investigated, indicating structure-growth 
inhibition relationships (Figure 5.3c). Importantly, a significant relationship was 
observed between the GI50 and cLogP values (Figure 5.3d), indicating that the 
lipophilicity of the compounds may play a significant role in their cellular toxicity 
(Spearman correlation, rs = -0.76, p < 0.0001, Figure 5.3d).  
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Figure 5.3 Growth inhibition induced by compound I and its analogues in 
HeLa cells analysed by SRB assay a) Structure of compound I and the dimethyl 
group removed for the des-dimethylpryan substituents. Other derivatives 
included replacement of the tetrahydropyran with a methyl group b) 
Representative graph of the growth inhibition curves generated for each 
analogue. HeLa cells were treated with indicated concentrations for 72 hrs and 
analysed using an SRB assay. Data are the mean and error bars represent the 
SEM of individual wells. c) GI50 values of analogues of compound I grouped 
according to the structural modification. Each point is the mean GI50. d) 
Relationship between the mean GI50 value and cLogP value for each compound. 
Each point is the mean GI50 for a separate analogue and cLogP values were 
calculated using ChemDraw, ACS format.    
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Modification or removal of the 4-dimethyl amino group from the benzylamino ring 
had no effect on compound potency suggesting it was not required for growth 
inhibition (Figure 5.4, Ia, Ib and Ic). Furthermore, replacement of the 4-NMe2 with 
a N-isopropyl group resulted in the most potent compound, as well as the most 
lipophilic (Id) suggesting the increased toxicity may have been a result of 
enhanced membrane permeability.  
Removal of the dimethyl group from the tetrahydropyran ring (Ie) reduced potency 
compared to the gem-dimethyl analogue (I), although this was associated with a 
decrease in lipophilicity. In the des-dimethyl series, growth inhibitory activity was 
improved following the substitution of the 4-NMe2 with 4-chloro (If), 4-methylthio 
(Ig) or 4-trifluoromethyl groups (Ih), with the most potent of this series being the 
4-pyrolidinyl derivative (Ii), which again had a low cLogP value. Replacement of 
the tetrahydropyran ring in If with a methyl group (Ij) had no effect on the GI50 
concentration, although additional removal of the phenyl ring inactivated the 
structure (Ik), implying that while the tetrahydropyran ring is not required for 
growth inhibitory activity, the phenyl ring is (Figure 5.4).  
 
  
185 
 
 
 
 
 
Figure 5.4 Structures of compound A (I) analogues, cLogP and HeLa cell 
GI50 values. GI50 data are the mean of 3 individual repeats ± standard deviation. 
Compounds were drawn and the cLogP values calculated using ChemDraw 
(ACS format).  
  
Ib
Mwt: 351.52
cLogP = 5.67
GI50 = 17 ± 3 µM
Ic
Mwt: 394.59
cLogP = 5.84
GI50 = 18 ± 2 µM
Ia
Mwt: 385.97
cLogP = 6.39
GI50 = 11 ± 4 µM
I
Mwt: 394.59
cLogP = 5.84
GI50 = 16 ± 1 µM
Id
Mwt: 393.60
cLogP = 7.10
GI50 = 5.8 ± 1.1 µM
Ie
Mwt: 366.54
cLogP = 4.80
GI50 = 27 ± 4 µM
Ih
Mwt: 391.47
cLogP = 5.52
GI50 = 16 ± 1 µM
Ii
Mwt: 392.58
cLogP = 4.92
GI50 = 7 ± 1 µM
If
Mwt: 357.92
cLogP = 5.35
GI50 = 18 ± 1 µM
Ig
Mwt: 369.56
cLogP = 5.20
GI50 = 17 ± 1 µM
Ij
Mwt: 287.83
cLogP = 5.63
GI50 = 16 ± 1 µM
Ik
Mwt: 211.73
cLogP = 4.21
GI50 = ≥ 100 µM
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 Impact of compounds I and Id on p27 stability in HeLa cells  
Based on their growth inhibitory activity, the effect of I and Id on SKP2 activity as 
measured by p27 levels was investigated using western blotting. Both 
compounds were shown to induce a rapid cellular response, inducing cell death 
after 30 minutes exposure. Neither I nor Id influenced SKP2 protein levels (Figure 
5.5), consistent with the findings of Chen et al and the predicted mechanism of 
action, namely disruption of the SKP1-SKP2 interaction (Chen et al., 2008a). 
However, an increase in p27 protein level was observed after 24 hr exposure to 
either compound at their GI50 concentrations, suggesting that SKP2-mediated 
p27 degradation was inhibited (Figure 5.5). Due to the cytotoxic nature of the 
compounds longer time points could not be investigated.   
 
 
 
 
Figure 5.5 Western blot showing the effect of I and Id on SKP2 and p27 
levels in HeLa cells. Cell lysates were collected at time points stated. The 
western blot shown is a representative of 2 independent repeats. Uneven protein 
loading was observed at the 6 hr timepoint for x5 GI50 compound Id in both 
repeats.   
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 Impact of compound I and structural analogues on p27 stability in the 
HeLa-p27(T187D)-EGFP cell line 
To confirm the accumulation of p27 following treatment with I and Id, presumed 
to be due to the inhibition of the SCFSKP2 complex, the compounds were 
investigated using the HeLa-p27(T187D)-EGFP cell line. Due to limited 
compound supply no further studies could be carried out on Id which was 
replaced with a compound with similar potency (Ii, GI50 8 ± 1 µM), a des-methyl 
derivative with the benzyl 4-NMe2 substituent replaced with a 4-pyrolidinyl group. 
Additional analogues were selected including the 2 enantiomers of Ie, Ie-(S) and 
Ie-(R) (Figure 5.6). The proteasome inhibitor bortezomib (Velcade®), the NAE 
inhibitor MLN4924 (both Millennium Pharmaceuticals) and the Merck Millipore 
SKP2 inhibitor (CI) were all also studied (Figure 5.7).   
Due to the genetic modifications made to the HeLa-p27 cells the GI50 values of 
the selected compounds were re-assessed using the SRB assay. Interestingly, 
the gem-dimethyl analogues (I and Il) were less toxic compared to the unmodified 
HeLa cells, suggesting that the constitutively degraded GFP-tagged mutant of 
p27 (p27T187D), the transfection process or G418 selection influenced drug 
potency. However, the enantiomers Ie-(S) and Ie-(R) which are des-dimethyl 
analogues, were found to induce greater growth inhibition than in the unmodified 
HeLa cells, while no change in potency was observed for Ij. Overall these data 
are consistent with the previous structure-growth inhibition relationships, which 
showed the removal of the tetrahydropyran ring had little influence of potency 
(Table 5.1).  
In this small series of compounds no relationship was observed between the GI50 
and EC50 concentrations. The most toxic compound, Ii, showed similar potency 
for p27 accumulation to I, which had a ~6 fold greater GI50 concentration, 
suggesting that off-target effects may influence Ii induced growth inhibition. For 
the enantiomers of Ie, while equipotent in growth inhibition studies, the (S) 
configuration gave a 2-fold greater potency in the p27 accumulation assay. The 
most potent analogue in the p27 accumulation assay was Ij, indicating that the 
tetrahydropyran ring is not required for inhibition of SKP2-mediated p27 
degradation. 
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Figure 5.6 Structures, GI50 and EC50 values and concentration response 
curves for compound I and analogues in the HeLa-p27(T187)-EGFP cell line. 
GI50 data are the mean of 3 replica wells as determined using an SRB assay. 
EC50 data  refers to the concentration at 50% GFP change and are the mean of 
3 independent experiments ± standard deviation, excluding compound  Il which 
is n=2. Concentration-response curves shown are representative and data are 
the mean of 3 replica wells. cLogP values were determined using ChemDraw, 
ACS format.     
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A concentration response was observed for p27-GFP accumulation for all the 
analogues of I, excluding Il (Figure 5.7). The least toxic compound (GI50 71 ± 13 
µM), Il did not produce p27-GFP accumulation to 50% of the level induced by 5 
µM MG132, suggesting that the growth inhibitory effect was not due to inhibition 
of the SCFSKP2 complex. However, unexpectedly, a similar observation was made 
for the NAE inhibitor MLN4924, although in contrast to Il a concentration 
response was observed with the highest level of GFP-p27 being reached at 10 
µM (Figure 5.7). As expected, the most effective compound was the proteasome 
inhibitor bortezomib (EC50 200 ± 8 nM) followed by the Merck Millipore SKP2 
inhibitor CI (SKPin), which is reported to disrupt specifically the SKP2-p27 
interaction and hence is potentially the most selective small molecule assayed 
with regards to the inhibition of SKP2-mediated p27 degradation (Wu et al., 
2012b).  
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Figure 5.7 Structures, GI50 and EC50 values and concentration response 
curves of commercially available compounds in the HeLa-p27(T187)-EGFP 
cell line. GI50 data are the mean of 3 replica wells as determined using an SRB 
assay. EC50 data  refers to the concentration at 50% GFP change and are the 
mean of 3 independent experiments ± standard deviation, excluding the EC50 
data for CI which in n=2. Concentration-response curves shown are 
representative and data are the mean of 3 replica wells.  
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Table 5.1 Mechanism of action, HeLa cell GI50 and HeLa-p27(T187D)-EGFP 
(HeLa-p27) cell GI50 and EC50 values for molecules targeting SKP2. GI50 
concentration in unmodified HeLa cells and EC50 data in HeLa-p27 cells are the 
mean ± standard deviated of n=3 excluding EC50 data of CI and Il which is n=2. 
GI50 concentrations in the HeLa-p27 cell line are the mean of 3 replica wells 
determined using the SRB assay.  
  
Inhibitor Mechanism of Action HeLa GI50 HeLa-p27 GI50 EC50 
Bortezomib Proteasome Inhibitor - 20 ± 2 nM 200 ± 2 nM 
MLN4924 NAE Inhibitor - 1.6 ± 0.3 µM - 
SKP2 E3 
ligase 
Inhibitor I (CI) 
SKP2-CKS1 mediated 
substrate recruitment 
inhibitor (SKPins) 
-  
22 ± 0.6 µM 
 
1.9 and 2.5 
µM 
I Putative SKP1/SKP2 
inhibitor 
16 ± 1 µM 37 ± 0.6 µM 20 ± 5 µM 
Ii Putative SKP1/SKP2 
inhibitor 
7 ± 1 µM 5.1 and 5.4 µM 21 ± 3 µM 
Ij Putative SKP1/SKP2 
inhibitor 
16 ± 1 µM 18 and 17 µM 15 ± 4 µM 
Ie-(S) Putative SKP1/SKP2 
inhibitor 
31 ± 3 µM 17 and 14 µM 61 ± 7 µM 
Ie-(R) Putative SKP1/SKP2 
inhibitor 
28 ± 4 µM 15 and 16 µM 36 ± 3 µM 
Il Putative SKP1/SKP2 
inhibitor 
51 ± 10 µM 80 and 61 µM - 
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 Pharmacological targeting of SKP2 in the SHEP-Tet21N cell line 
As SKP2 has been reported to be overexpressed in MYCN amplified 
neuroblastoma (Westermann et al., 2007) and identified as a direct MYCN target 
gene (Chapter 3), the influence of MYCN expression on SKP2 inhibition was 
investigated using the Tet21N MYCN regulatable cell line. In addition to the 
putative SKP2 inhibitors investigated in the HeLa-p27(T187D)-EGFP cell assay, 
the BET bromodomain inhibitor JQ1 and all-trans retinoic acid (ATRA) were also 
investigated due to their reported effects on MYCN regulated transcription 
(Puissant et al., 2013) and SKP2 degradation (Dow et al., 2001), respectively. 
Although expression of MYCN sensitised the cells to all of the compounds 
investigated, a significant increase in sensitivity was only observed following 
treatment with MLN4924 and CI (Table 5.2, p = 0.027 and 0.037, respectively, 
paired t test).   
Western blotting analysis demonstrated a MYCN-dependent increase in SKP2 
expression following exposure of MLN4924 to Tet21N MYCN- cells. However, 
this was not associated with a decrease in p27 stabilisation. Interestingly 
MLN4924 was observed to have no effect on SKP2 levels in Tet21N MYCN+ 
cells. Conversely, JQ1 induced a loss of SKP2 protein independently of MYCN 
expression at both concentrations tested; however, this did not have a marked 
effect on p27 levels (Figure 5.9). 
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Inhibitor Mechanism of Action Tet21N MYCN+ Tet21N MYCN- 
Bortezomib Proteasome Inhibitor 7 ± 0.6 nM  13 ± 4 nM 
MLN4924 NAE Inhibitor 9 ± 1nM * 80 ± 20nM 
CI SKP2-CKS1 mediated substrate 
recruitment inhibitor (SKPins) 
26 ± 2 µM * 40 ± 4 µM 
NCL-
00018545 
Putative SKP1/SKP2 inhibitor  21 ± 0.6 µM 24 ± 0.6 µM 
NCL-
00018645 
Putative SKP1/SKP2 inhibitor 4.4 ± 0.5 µM 7.6 ± 0.3 µM 
Roscovitine CDK2, CDK7 and CDK9 inhibitor 14 ± 2 µM 18 ± 1 µM 
NU6102 CDK2 inhibitor 8.6 ± 5 µM 12 ± 3 µM 
ATRA Promotes neuronal differentiation, 
represses MYCN expression 
75 ± 0.5 µM 88 ± 11 µM 
JQ1 BET bromodomain inhibitor, 
down-regulates MYCN mRNA  
170 ± 70 nM 210 ± 60 nM 
Table 5.2 GI50 concentrations of small molecule inhibitors analysed by the 
XTT assay in Tet21N neuroblastoma cell line. Data are the mean and standard 
deviation of n=3. * Corresponds to p values of ≤ 0.05 for GI50 values in the two 
cell lines. ATRA: All trans-retinoic acid  
 
 
Figure 5.8 Western blot showing the effect of the BET inhibitor JQ1 and 
NAE inhibitor MLN4924 on SKP2 and p27 levels in the Tet21N 
neuroblastoma cell line. Cell lysates were collected following 24 hr treatment at 
the concentrations indicated. The western blot shown is a representative of 2 
independent repeats. 
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 Discussion   
F-box proteins act as the substrate recognition subunits for the SCF E3 ligases 
and represent a class of potential therapeutic targets which would provide a 
higher selectivity, and less associated toxicity than proteasome inhibitors, as their 
inhibition should only stabilise a specific set of cellular proteins. However, unlike 
protein kinases where inhibitors can bind in the ATP catalytic pocket or peptide 
substrate binding sites, targeting E3 ubiquitin ligases is challenging as it requires 
the disruption of a protein-protein interaction. As a result it is only recently that 
compounds capable of directly targeting SKP2 have been described (Chen et al., 
2008a; Wu et al., 2012b; Chan et al., 2013).    
Protein-protein interactions present a challenging target for pharmaceutical 
intervention as often lack the small pockets that accommodate natural substrates 
and ligands in enzymes and receptors. Additionally, binding sites on protein 
surfaces are often not conserved, although ‘hot spot’ residues can be identified, 
for example by alanine-scanning mutagenesis as reviewed by Moreira (Moreira 
et al., 2007). Due to these challenges many of the small molecules targeting p27 
degradation have been discovered using screening and end-point analysis (Chen 
et al., 2008a), rather than rational design approaches. However, advances in 
computational methods, structural bioinformatics and fragment-based lead 
discovery have both increased the ability to predict binding pockets on a protein 
surface, and allowed for rapid probing of the surfaces for small molecule binding 
sites.       
The studies described in chapter 4 investigated the potential of targeting SKP2 in 
neuroblastoma by using siRNA knockdown and in the current chapter small 
molecule inhibition of SKP2 activity was studied.     
 Growth inhibition and physiochemical properties of analogues of 
compound I  
Based on the chemical structure of I (compound A), a putative inhibitor of the 
SKP1-SKP2 interaction (Chen et al., 2008a), 32 analogues were synthesised and 
HeLa cell GI50 concentrations determined to explore structure-growth inhibition 
relationships. A strong relationship was observed between the GI50 and cLogP 
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values, with the more lipophilic compounds inducing greater toxicity (Figure 5.3d), 
suggesting that cell membrane permeability is a determining factor in the growth 
inhibitory response. 
The cLogP or partition coefficient is related to the distribution of drugs within the 
body. Often measured by determining the ratio of the distribution of a compound 
between octanol and water, a higher value reflects preferential distribution to 
hydrophobic compartments such as lipid bilayers and a low value to more 
aqueous environments such as extracellular fluid. In designing small molecule 
drugs a clogP value no greater than 5 is often sought in accordance with Lipinski’s 
rule of five (Lipinski et al., 2001). A measure of the ‘drug-like’ qualities of a 
substance 4 parameters are associated with the solubility and permeability of 
orally active drugs, and the ‘rule’ states that poor absorption/permeation is more 
likely when: (1) there are more than 5 H-bond donors (expressed as the sum of 
OH and NH groups), (2) the molecular weight is over 500, (3) the LogP is over 5 
and (4) there are more than 10 H-bond acceptors (expressed as the sum of N 
and O atoms) (Lipinski et al., 2001).  
For the putative SKP2 inhibitors, lipophilicity could theoretically result in 
increased binding to SKP1 improving disruption of the SKP1-SKP2 interaction. 
Alternatively, the hydrophobic nature of the compounds could result in non-
specific disruption of membrane integrity which would induce cell death, as 
observed by compounds I and Id. Taken with the strong monotonic relationship 
between the partition coefficient and GI50 values it may be that the decrease in 
cell viability observed in HeLa cells is the result of non-specific cell death rather 
than selective growth inhibition.  
Regardless of the mechanism of cellular toxicity, variations in GI50 concentrations 
were observed following the systematic alterations of the structure I (Figure 5.4). 
Modifications to the dimethyl amino group on the benzyl ring had little effect on 
toxicity, e.g. compounds I, Ia - Id, although alkylation of the aromatic ring led to 
the most toxic and lipophilic analogue Id. Removal of the dimethyl group from the 
tetrahydropyran ring increased the GI50 concentrations of the series, despite 
reducing the cLogP value to within Lipinski’s ‘rule of 5’ (Lipinski et al., 2001). 
Toxicity was maintained when the 4-NMe2 on Ie was replaced with the 4-
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pyrrolidinyl group (Ii) without increasing lipophilicity. Collectively these data 
suggest that the tetrahydropyran ring contributes to the lipophilic nature of the 
compound yet is not required for cellular toxicity. In contrast, both phenyl rings 
are required for activity and attachment of a para electron withdrawing group 
(propyl or pyrrolidinyl) increases toxicity which may be a product of the electron-
withdrawing substituents stabilising the phenyl ring.       
 Targeting SKP2-mediated degradation of p27  
Compounds I and Id induced rapid toxicity and cells began to display 
characteristics of cell death, such as detachment from the tissue culture flask and 
cell rupture, after a 30 minute exposure. Nevertheless, both compounds induced 
p27 accumulation following 24 hr exposure to the GI50 concentration, indicating 
that SKP2 activity had been inhibited (Figure 5.5).  
For the limited number of compounds studied in the HeLa-p27(T187D)-EGFP 
cell-based assay there was no relationship between the GI50 concentration and 
that required to induce p27-GFP accumulation to 50% of the level observed with 
5 µM MG132. Interestingly, a higher concentration of I was required to suppress 
growth in the HeLa-p27(T187D)-EGFP cell line compared to the unmodified HeLa 
cells, while the opposite was observed for the enantiomers Ie-(S) and Ie-(R). 
Differing in the dimethyl group attached to the tetrahydropyran ring, this 
observation is consistent with the structure-growth inhibitory relationship 
observed in the unmodified HeLa cells.  
As expected, the most effective small molecule in stabilising GFP-p27 was the 
proteasome inhibitor bortezomib (Velcade®, Millennium Pharmaceuticals), which 
along with MG132 validated the cell based assay. The ‘SKPin’ CI was the most 
specific compound investigated, and is reported to be highly selective in 
stabilising SKP2-CKS1 targets (i.e. p27, p21 and p57). As with bortezomib, a 10-
fold difference was observed between the concentrations of CI required for 
growth inhibition (GI50 22 µM ± 0.6) and GFP-p27 stabilisation (EC50 2.2 µM ± 
0.4). Initially this may suggest that p27 accumulation only partly contributes to the 
observed growth inhibition.  
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The lack of p27 accumulation in the HeLa-p27(T187D)-EGFP cell line following 
treatment with the NAE inhibitor MLN4924 was unexpected as the compound is 
a well-established inhibitor of SCF complex formation. However, unlike Il which 
also failed to induce GFP-p27 accumulation to 50% of the level produced by 5 
µM MG132, a concentration response effect was induced by MLN4924, indicating 
that SKP2-mediated degradation of p27 was being inhibited. However, p27 
stabilisation was not to the level achieved by the proteasome inhibitor. Although 
the assay was optimised to analyse inhibition of SKP2 activity, low levels of GFP-
p27 accumulation were also found following siRNA knockdown of the E3 ligase 
E6AP which can also target p27 for degradation (ThermoScientific, 2004; Mishra 
et al., 2009). As MG132 prevents the turnover of all proteins reliant on the 26S 
proteasome, it may potentially be inhibiting alternative pathways which regulate 
p27 stability, including E6AP and the ubiquitin ligase KPC (Kamura et al., 2004). 
The inability of MLN4924 to produce an EC50 value may therefore be a reflection 
of its higher specificity towards the SCFSKP2 complex compared to MG132.  
MLN4924 is structurally related to adenosine 5’-monophosphate (AMP) and upon 
binding to the NEDD9-activating enzyme (NAE) forms a tight MLN4924-NEDD8 
adduct which blocks the NAE active site (Soucy et al., 2009). The HeLa-
p27(T187D)-EGFP cell line has been modified to express a constitutively 
degraded mutant p27 protein and consequently the SCF pathway should be more 
active than in unmodified HeLa cells. Neddylation of CUL1 is regulated in part by 
the availability of the F-box protein and its substrate, i.e. SKP2 and p27, with 
increased levels of p27 being reported to lock the SCFSKP2 complex in the 
neddylated and assembled state by preventing deneddylation (Bornstein et al., 
2006). The CMV-driven p27 expression in the HeLa-p27(T187D)-EGFP cell line 
may therefore be reducing the contribution of the neddylation pathway towards 
the SKP2-p27 axis, and thereby abrogating the MLN4924 response. It would 
therefore be informative to determine the basal levels of the SCFSKP2 components 
(e.g. NAE, CUL1, SKP1-SKP2, CKS1, p27) in the HeLa-p27(T187D)-EGFP cell 
line compared to unmodified HeLa cells.  
The HeLa-p27(T187D)-EGFP cell line was employed as a cell-based screen to 
evaluate the novel analogues of compound I studied, and validation by secondary 
assays would be required to confirm proposed mechanisms of action. For 
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example, given the unknown selectivity of the analogues, determination of the 
EC50 values in comparison to and after SKP2 siRNA knockdown would help 
determine the proportion of p27 stabilisation from SKP2-specific inhibition versus 
off-target effects. As I analogues are proposed to target the SKP1-SKP2 
interaction, active compounds would be expected to stabilise all SKP2 
substrates. Western analysis could therefore be performed to investigate the 
influence of the inhibitors on the accumulation of additional SKP2 targets, for 
example p21, E2F1 and c-MYC, followed by the analysis of substrate half-lives 
to confirm that any increase in protein level is due to stabilisation.  
Although not all analogues synthesised were assessed in the HeLa-p27(T187D)-
EGFP assay, for the sub-set that were tested a structure activity relationship was 
suggested. While the enantiomers of Ie were equipotent in the growth inhibition 
assay, Ie-(S) showed greater activity for SKP2 inhibition than Ie-(R), 
demonstrating stereo-specificity for GFP-p27 stabilisation. Addition of the 
dimethyl substituent to the tetrahydropyran ring increased potency, decreasing 
the EC50 from 36 µM ± 3 (Ie-(S)) to 20 µM ± 5 (I); whereas in contrast the GI50 
concentration increased ~2 fold suggesting that growth inhibition is not solely a 
function of p27 stabilisation. Similar p27 stabilisation was observed with 
compounds I and Ii (EC50: 20 µM ± 5 and 21 µM ± 3, respectively), although Ii 
was ~7x more potent in the growth inhibition assay (I GI50: 37 µM ± 0.6 and Ii 
GI50: 5.1 and 5.4 µM). Overall, no relationship was identified between the GI50 
concentrations and the EC50 values for GFP-p27 stabilisation; however, in both 
assays removal of the tetrahyropyran ring increased potency (I to Ij), suggesting 
that this moiety is not required for activity.   
In extending these studies further analysis of the novel analogues is required. 
Firstly, all of the compounds synthesised should be tested using the HeLa-
p27(T187D)-EGFP cell line, and any GFP-p27 stabilisation observed confirmed 
by western blotting. The relationship between growth inhibition and GFP-p27 
accumulation should be further evaluated and additional mechanistic studies 
performed, such as co-immunoprecipitation or pull down assays, to establish 
whether the SKP1-SKP2 interaction has been disrupted. In addition, structural 
biology studies could be performed such as in silico analysis and experimental x-
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ray crystallography to confirm compound binding and predict modifications which 
may increase SKP2-inhibtion potency and selectivity.   
 Targeting SKP2 activity in neuroblastoma  
As demonstrated in Chapter 3, SKP2 is a direct MYCN target gene and MYCN 
was shown to sensitise the Tet21N cell line to G1 arrest and apoptotic cell death 
following SKP2 siRNA knockdown. Based on these findings a selection of small 
molecule inhibitors were investigated which are reported to target pathways 
associated with SKP2 activity and MYCN expression, in order to determine 
whether MYCN sensitises neuroblastoma cells to SKP2 inhibition. Although 
Tet21N MYCN+ cells were more sensitive to all of the inhibitors tested, a 
significant increase in growth inhibition compared to Tet21N MYCN- cells was 
only demonstrated for the NAE inhibitor MLN4924 and the SKPin CI (Table 5.2). 
Encouragingly, these two compounds are the more specific SKP2 inhibitors, in 
contrast to the CDK inhibitors, ATRA and compound I analogues, with the 
mechanism of activity yet to be established for the latter. Overall, the greater 
sensitivity of the Tet21N MYCN+ cells to MLN4924 and CI supports SKP2 
inhibition as a potential therapeutic strategy in MYCN amplified neuroblastoma.  
Analysis of the functional effects of MLN4924 on SKP2-mediated p27 
degradation by western blotting (Figure 5.8), showed an increase in SKP2 protein 
expression in Tet21N MYCN- cells, although this had no influence on p27 levels 
most probably due to the SCF complex being inactive. All cullin RING ligases 
(CRLs) require neddylation for full activation and thus, as an inhibitor of NEDD8 
modification, MLN4924 can influence the stability of a broad spectrum of 
substrates. SKP2 is targeted for degradation primarily though the APC/CCDH1 
complex and although the APC2 protein, which forms the APC/C scaffold, is 
related to the cullin protein it does not require neddylation for activation (Tateishi 
et al., 2001). Alternatively, SKP2 can undergo auto-ubiquitination when linked to 
the SCF complex in a mechanism that is dependent on the SKP2-binding of CUL1 
(Galan and Peter, 1999; Wirbelauer et al., 2000). The prevention of CUL1-RBX1-
SKP1 complex formation, by locking CUL1 in its inactive conformation, could 
therefore prevent the auto-ubiquitination of SKP2 resulting in its stabilisation. As 
SKP2 is a direct MYCN transcriptional target, this effect may be masked by the 
higher basal levels of SKP2 in the Tet21N-MYCN+ cells. Interestingly MLN4924 
200 
 
induced no further increase in SKP2 protein expression most probably due to 
already high basal levels.  
Bromodomain and extra-terminal (BET) proteins regulate gene expression by 
binding to ɛ-N-acetylated lysine residues in chromatin to promote gene 
expression. One BET family member, BRD4, has been identified as a crucial 
mediator of RNA polymerase II-driven transcription (Yang et al., 2008) and has 
been identified as a promising therapeutic target in hematologic malignancies 
(Ott et al., 2012; Stewart et al., 2013). JQ1 is a selective and potent inhibitor which 
competitively binds to the acetyl-lysine recognition pockets in chromatin, 
displacing BRD4 (Filippakopoulos et al., 2010). Recently MYCN amplification has 
been identified as a marker for sensitivity to JQ1 and has been shown to 
downregulate MYCN-dependent transcription in the MYCN amplified 
neuroblastoma cell lines SK-N-BE(2c) and Kelly by displacing BRD4 from the 
MYCN promoter (Puissant et al., 2013). The decrease in SKP2 protein 
expression seen in Tet21N MYCN+ cells is consistent with this observation, and 
the direct regulation of SKP2 by MYCN as discussed in Chapter 3. Interestingly 
JQ1 exposure decreased SKP2 protein levels in Tet21N MYCN- cells, although 
the effect was partly masked by the removal of MYCN. However, as SKP2 is a c-
MYC target gene (Bretones et al., 2011), this loss of SKP2 protein may be due to 
the JQ1-downregulation of c-MYC transcription (Delmore et al., 2011). No 
convincing increase in p27 expression stabilisation was observed following the 
decrease in SKP2 protein levels, although this may reflect the short time interval 
investigated.  
The lack of marked effects on p27 protein levels questions the therapeutic 
potential of targeting the SKP2/p27 axis in neuroblastoma; however, MLN4924 
and JQ1 are selective inhibitors of neddylation and bromodomains, respectively, 
and do not directly target the SKP2/p27 axis. SKP2 knockdown studies (Chapter 
4) identified SKP2 targeting in non-MYCN amplified neuroblastoma cell lines as 
a therapeutic approach, and knockdown was associated with an increase in p27 
protein expression, albeit modest. Given that MLN4924 also failed to induce GFP-
p27 accumulation to 50% of the level produced by 5 µM MG132 (Figure 5.7) the 
lack of p27 stabilisation in the Tet21N cells following treatment with JQ1 and 
MLN4924 may be a reflection of their indirect targeting of the SKP2/p27 axis. 
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Apart from bortezomib, a non-specific proteasome inhibitor, the ‘SKPin’ CI was 
the most potent inhibitor of GFP-p27 degradation. The higher potency of CI in 
Tet21N MYCN+ cells is further evidence of the contribution of the SKP2/p27 axis 
in neuroblastoma and its upregulation in MYCN amplified tumours; further 
investigation of CI is therefore warranted.        
 Conclusions      
This chapter describes the evaluation of a small compound library based on the 
published putative inhibitor, (I), of the SKP1-SKP2 interaction of the SCFSKP2 
complex (Chen et al., 2008a). For the analogues of I studied, there was a 
relationship between the GI50 concentration and lipophilicity, with the more 
lipophilic compounds being more potent. Some overlap was observed in the 
structural determinants of growth inhibition and GFP-p27 stabilisation; however, 
further studies are required to determine the contribution of p27 stabilisation to 
the growth inhibitory properties of I and its analogues. Investigation into the 
potential of inhibiting SKP2 in neuroblastoma suggested that MYCN expression 
sensitised the Tet21N MYCN regulatable cell line to growth inhibition induced by 
both direct and indirect inhibition of SKP2 activity. These observations are 
consistent with the previous finding that MYCN promotes SKP2 expression 
(Chapter 3), and that SKP2 knockdown promotes a G1 arrest and cell death 
(Chapter 4).   
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General Discussion 
First identified ~30 years ago, MYCN amplification remains the best-
characterised genetic marker of high risk neuroblastoma. A member of the MYC 
family of transcription factors, MYCN regulates a plethora of genes by forming 
heterodimers with MAX at consensus E-box sequences. The MYCN gene is 
amplified in 20-25% of cases and creates a stem-like state by driving the 
expression of genes involved in cellular proliferation (e.g. CDK4) (Westermann 
et al., 2008) and apoptosis (e.g. TP53) (Chen et al., 2010b), whilst supressing 
the activity of genes which promote differentiation (e.g. TG2) (Liu et al., 2007). 
Given the frequency of MYCN amplification, and the resistance of high-risk 
relapsed neuroblastoma to conventional chemotherapeutic options, targeting 
MYCN therapeutically represents an important approach in the treatment of 
neuroblastoma. However, while advances are being made in the development of 
direct inhibitors, predominantly by targeting the MYC/MAX binding domain 
(reviewed by (Prochownik and Vogt, 2010)), inhibiting MYCN activity still 
represents a formidable challenge. Given that MYCN overexpression is 
associated with driving proliferation and sensitising cells to apoptosis, some 
studies have suggested an alternative approach of targeting downstream of 
MYCN, to tip the balance in favour of apoptosis (Bell et al., 2010).  
SKP2 has been previously identified as a MYCN candidate gene in 
neuroblastoma by gene expression microarray analysis where SKP2 expression 
was downregulated following MYCN siRNA knockdown, and a relationship was 
observed between SKP2 transcript levels and MYCN amplification in tumours 
(Bell et al., 2007; Westermann et al., 2007). Interestingly, although SKP2 mRNA 
was found to correlate with aggressiveness of disease, there was no correlation 
with MYCN expression in non-amplified tumours. Accordingly, this pattern of 
expression was found at the protein level, where SKP2 was more prevalent in 
MYCN amplified tumours and inversely correlated with p27 protein levels 
(Westermann et al., 2007). Nevertheless, the identification of E-box motifs within 
the SKP2 promoter (Bretones et al., 2011) strengthened the hypothesis that 
SKP2 is a direct MYCN transcriptional target, and may therefore contribute to the 
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enhanced proliferation and aggressiveness seen in MYCN amplified 
neuroblastoma.  
 SKP2 is a direct transcriptional target of MYCN 
This study confirmed the positive association between MYCN and SKP2 in 
investigations in neuroblastoma cell lines (Chapter 3). Switching off MYCN 
expression in the SHEP-Tet21N MYCN regulatable cell line, and activating 
MYCN activity in the SKNAS-NMyc-ER cell line, resulted in opposing effects on 
SKP2 mRNA expression levels as expected for a MYCN candidate gene. The 
hypothesis of direct transcriptional regulation of SKP2 by MYCN was also 
supported by the positive linear relationship observed between MYCN protein 
and SKP2 mRNA expression in MYCN amplified and non-amplified cell lines. 
Prior to the studies described in this thesis the hypothesis was that low level of 
SKP2 transcript in a cell with low MYCN levels is a combined effect of reduced 
E2F1 activity, due to the absence of MYCN driving the CDK4-mediated 
phosphorylation of pRB, and increased SKP2 promoter repression, resultant from 
the direct binding of hypo-phosphorylated pRB complexes (Muth et al., 2010). 
However, following the detection of E-box motifs within the SKP2 promoter and 
demonstration of direct transcriptional regulation by c-MYC (Bretones et al., 
2011), ChIP and SKP2-reporter gene assays were performed to explore a more 
direct mechanism (Figure 3.16, 3.17, 3.18 and 3.20). MYCN was found to directly 
bind to non-canonical E-box motifs within the SKP2 promoter and upregulate 
transcriptional activity, which was confirmed by the significant reduction in 
promoter activity following mutation of the E-boxes in the reporter construct. 
Taken together with the ChIP-chip array data (Figure 3.19) showing MYCN 
binding to the SKP2 promoter in a second MYCN-inducible and MYCN amplified 
cell line, these results provide strong evidence that SKP2 is a direct 
transcriptional target of MYCN.  
 MYCN expression does not correlate with SKP2 protein level 
Although SKP2 protein expression gradually decreased following the removal of 
MYCN in the Tet21N cell line, no association was observed between MYCN and 
SKP2 protein levels in SKNAS-Nmyc-ER cells or across the panel of MYCN 
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amplified and non-amplified cell lines, where high levels of SKP2 were observed 
in the absence of MYCN expression (Figure 3.6, 3.8, 3.9 and 3.10).  
The inverse relationship between MYCN and c-MYC in neuroblastoma is well 
documented (Breit and Schwab, 1989), with c-MYC reported to drive malignancy 
in non MYCN amplified tumours (Westermann et al., 2008). Downstream targets 
of c-MYC are grouped by their binding affinity, with the genes with lower affinity 
sites more likely to be influenced by MYCN expression (Fernandez et al., 2003). 
As c-MYC was shown to bind to two high affinity E-boxes in the SKP2 promoter 
(Bretones et al., 2011), the interplay between MYCN and c-MYC could potentially 
play a significant role in driving SKP2 gene expression. However, as higher c-
MYC expression in the non-MYCN amplified cell lines did not alter the relationship 
between MYCN and SKP2 mRNA levels (Figure 3.9), or explain the low levels of 
SKP2 protein in the non-MYCN amplified c-MYC expressing GIMEN cells (Figure 
3.8), it is hypothesised that the high levels of SKP2 protein observed are the result 
of post-translational mechanisms that regulate SKP2 stability. One such 
mechanism is activation of the PI3K/AKT pathway which has been found to be a 
frequent event in neuroblastoma with activated AKT, i.e. phosphorylated in the 
regulatory (S473) and/or catalytic domains (T308), and identified as a prognostic 
indicator of poor outcome. An established regulating factor for SKP2 stability, as 
discussed in Section 1.9.6, activated AKT has been shown to be present in 
neuroblastoma cell lines independent of MYCN status (Opel et al., 2007) and 
could therefore be contributing to the high levels of SKP2 protein in the absence 
of MYCN.  
 Induction of cell cycle arrest and apoptosis by SKP2 knockdown is 
dependent on the stabilisation of p27  
 SHEP-Tet21N cell line data 
SKP2 protein expression gradually decreased in Tet21N MYCN- cells following 
treatment with tetracycline, and was associated with accumulation of the CDK 
inhibitors p27 and p21, and the suppression of cell proliferation (Figure 3.2 and 
3.3). MYCN is closely associated with p21 expression and has been shown to 
regulate several components of the p53-p21 axis including the p53 inhibitor 
MDM2, resulting in the suppression of p21 transcription (Slack et al., 2005; Bell 
et al., 2007; Chen et al., 2010b). Knockdown of MYCN has been shown to 
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promote the accumulation of p21 and increase the G1 phase population, 
suggesting that the increased p21 expression in Tet21N MYCN- cells was a 
reflection of released transcriptional repression as opposed to p21 protein 
stabilisation (Bell et al., 2006). This hypothesis was supported by the lack of p21 
observed after dual treatment with tetracycline and the translation inhibitor 
cycloheximide. The persistence of p27 protein, although at a lower level, following 
dual MYCN suppression and cycloheximide treatment, supported the current 
view that the oncogenic role of SKP2 overexpression in neuroblastoma is 
associated with accelerated p27 proteolysis (Westermann et al., 2007). However 
the difference in p27 protein level between tetracycline only and dual 
tetracycline/cycloheximide treatment suggests that MYCN is also regulating p27 
expression by alternative mechanisms either at a transcriptional or post-
translational level (Figure 3.5).  
MYCN sensitised Tet21N cells to a G1 arrest following SKP2 siRNA treatment 
(Figure 3.12), an effect which was reversed upon dual knockdown of p27 and 
SKP2 (Figure 3.15), emphasising further the role of the SKP2/p27 axis in 
neuroblastoma, and consistent with the lack of p27 stabilisation and cell cycle 
arrest in the Tet21N MYCN- cells. However, when MYCN expression is absent 
the effects of SKP2 inhibition may be masked by release from MYCN-induced 
shortening of the G1 phase (Lutz et al., 1996).  
SKP2 knockdown had a greater effect on the level of p21 protein over p27 
independent of MYCN expression, although a higher sensitivity was observed in 
Tet21N MYCN+ cells (Figure 3.11a). As SKP2 is reported to suppress p53 activity 
by sequestering the p53 acetyltransferase p300, SKP2 inhibition may potentially 
be influencing p21 protein expression by both increasing p53-mediated 
transcription and decreasing the SKP2-mediated degradation. As p53 (Chen et 
al., 2010b) and SKP2 (Chapter 3) are direct MYCN transcriptional targets, the 
greater increase in p21 protein levels following SKP2 siRNA treatment in Tet21N 
MYCN+ cells, may therefore be the result of the higher basal levels of the p53 
and SKP2.  
The increase in p21 levels seen in Tet21N cells suggests that SKP2 inhibition 
induces a p53 response. However, SKP2 knockdown increased the sub-G1 
population independently of MYCN expression, whereas enhanced caspase-3/7 
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activity was only detected in Tet21N MYCN+ cells (Figure 3.13b). The lack of 
consistency between the two apoptosis assays may reflect the different 
endpoints. Caspase-3/7 cleavage is a sensitive measure of cells committed to 
apoptotic cell death, while the sub-G1 fraction reflects fragmented DNA and thus 
gives no information on whether the cells are later stage apoptotic, necrotic or at 
an early stage of apoptosis from which they can recover. SKP2 inhibition has also 
been reported to induce caspase-independent cell death through the induction of 
autophagy (Chen et al., 2008a), and autophagy may explain the SKP2 siRNA 
knockdown induced decrease in cell viability observed in the Tet21N cells. 
Further clarification of the mechanisms and pathways of cell death induced by 
SKP2 knockdown is required.  
Overexpression of p27 has also been reported to cause apoptotic cell death 
(Wang et al., 1997). Taken together, the data from the Tet21N MYCN regulatable 
cell line model emphasises the importance of the SKP2/p27 axis in 
neuroblastoma and suggests that MYCN expression sensitises cells to G1 arrest 
and apoptotic cell death following SKP2 inhibition. However, when MYCN is 
expressed, the effects of SKP2 knockdown may still be dominated by MYCN and 
its paradoxical role in cell cycle progression and apoptosis.       
6.3.2 MYCN amplified and non-MYCN amplified cell line data 
In contrast to the effect of SKP2 siRNA treatment in Tet21N cells, MYCN 
amplification did not sensitise a panel of non-isogenic cell lines to the growth 
inhibitory effects of SKP2 knockdown. However, in non-MYCN amplified cells 
SKP2 knockdown did induce a G1 arrest and apoptotic cell death (Figure 4.7 and 
4.9). Importantly, following SKP2 knockdown, a significant reduction in cell 
viability was observed in all cell lines, with the exception of the MYCN amplified 
p53 mutant IMR-KAT100 cells (Figure 4.6). This difference between Tet21N cells 
and non-isogenic neuroblastoma cell lines in the effect of MYCN on SKP2 
knockdown-induced cell cycle phase distribution and apoptosis may reflect the 
difference between MYCN overexpression and amplification. Although the level 
of MYCN expression in Tet21N cells has been reported to be comparable to that 
in MYCN amplified cells, at both the mRNA and protein level (Bell et al., 2006), 
the difference in response to SKP2 knockdown may reflect the higher MYCN copy 
number in the amplified setting. This hypothesis is supported by the greater level 
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of MYCN binding and SKP2 promoter activity seen in the ChIP and luciferase 
reporter assays in MYCN amplified IMR32 cells compared to Tet21N MYCN+ 
cells.  
The structure and size of the amplicon that includes the MYCN gene can vary 
between 100 kb and 1 Mb, with MYCN occupying a central position yet only 
spanning 100-200 kb (Amler and Schwab, 1989; Scott et al., 2003). Other genetic 
aberrations that can coexist with MYCN amplification, e.g. 1p loss and 17q gain, 
may therefore be responsible for the failure of cells to arrest in the G1 phase and 
undergo apoptotic cell death following SKP2 inhibition. Alternatively, the co-
amplification of genes on the MYCN amplicon in the MYCN amplified cell lines 
may influence the response to SKP2 knockdown. For example NCYM, the cis-
antisense gene of MYCN, has been reported to be co-amplified with MYCN and 
to both stabilise MYCN protein and promote metastatic tumour development in 
MYCN/NCYM transgenic mice (Suenaga et al., 2014). Comparison of the 
doubling times of Tet21N MYCN+ cells (42 hr, Figure 3.3) and IMR32 cells (20 
hr, www.atcc.org), highlights further the non-MYCN amplified background of the 
Tet21N cell line, emphasizing again the importance of recognising the difference 
between MYCN overexpression and amplification, and how this can affect tumour 
cell biology. 
As with Tet21N MYCN+ cells, the G1 arrest observed in the non-MYCN amplified 
cell lines (Figure 4.7), was associated with an increase in p27 protein expression 
following a 24 hr exposure to SKP2 siRNA (Figure 4.8), an effect which was 
reversed by additional p27 knockdown (Figure 4.10a). These findings provide 
proof of principal data that targeting the SKP2/p27 axis has potential therapeutic 
benefits in neuroblastoma, and are consistent with previous reports of high levels 
of p27 expression being associated with a favourable outcome independent of 
MYCN status (Bergmann et al., 2001).   
Although p21 stabilisation was observed in all of the p53 wild-type cells (Figure 
4.8), the G1 arrest and apoptosis induced by SKP2 loss in p53 mutant SKNAS 
cells (Figure 4.7 and 4.9), independent of p21 expression, suggests that p27 
accumulation is the primary factor in coordinating apoptotic cell death (Wang et 
al., 1997). This suggestion is supported by the observation that the sub-G1 
population in neuroblastoma cells is reduced following dual p27/SKP2 
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knockdown. However, a greater response was observed following knockdown of 
p27 as opposed to SKP2 in SHSY5Y cells, suggesting that the apoptotic 
response observed in this cell line involves mechanisms that are independent of 
the E3 ligase activity of SKP2 (Figure 4.10b). The potential pro-apoptotic role of 
p27 accumulation in neuroblastoma cells was emphasised by the increased 
sensitivity of MYCN amplified cells to irradiation following SKP2 knockdown and 
associated p27 accumulation.   
Based on the SKP2 knockdown studies, the data presented in this thesis suggest 
that although MYCN amplification does not sensitise neuroblastoma cells to the 
effects of SKP2 knockdown as first hypothesised, the SKP2/p27 axis does 
nevertheless play an important role in regulating the G1/S cell cycle transition, 
and potentially in cell survival in a non-MYCN amplified setting.   
 Novel small molecules show potential as SKP2 inhibitors 
Putative SKP2 inhibitors were synthesised based on a published structure 
(compound A, (I), (Chen et al., 2008a)), and a strong association was observed 
between the lipophilicity of the novel compounds and their GI50 concentrations in 
HeLa cells (Figure 5.3d), implying that membrane permeability may be a 
contributing factor to their toxicity. Systematic alterations of I, identified a 
structure-growth inhibition relationship suggesting that while the tetrahydropyran 
ring was not required for growth inhibition both phenyl rings were, with toxicity 
being increased by substitution with electron-withdrawing groups at the 
benzylamine para position (Figure 5.4).  
No relationship was observed between growth inhibition (GI50) and p27 
stabilisation (EC50) across a sub-set of compounds assayed in the HeLa-
p27(T187D)-EGFP cell line (Figure 5.6, Table 5.1). Enantiomers of Ie, i.e. Ie-R 
and Ie-S, demonstrated that p27 stabilisation was greater for the compound with 
an (R) configuration, whilst the (S) and (R) enantiomers were equipotent in the 
growth inhibition assay. The most active compound tested lacked the 
tetryhydropyran ring suggesting that this group does not contribute to the activity 
of the compound as inhibitors of SKP2-mediated p27 degradation.    
Although MYCN expression did not sensitise Tet21N cells to growth inhibitory 
activity of the I derivatives, MYCN expression did increase sensitivity to the NAE 
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inhibitor MLN4924 and the SKPin CI, consistent with the rational of targeting the 
SKP2/p27 axis in MYCN overexpressing neuroblastoma (Table 5.2). However, 
due to the differences between amplification and overexpression as discussed 
previously, and the functional studies showing that non-MYCN amplified cell lines 
are in fact more responsive towards SKP2 knockdown, further analysis in a larger 
panel of neuroblastoma cell lines is required.  
 Final Conclusions 
In conclusion, the data presented in this thesis demonstrates that SKP2 is a direct 
transcriptional target of MYCN in neuroblastoma and is likely to contribute to 
perpetual cell cycle entry in MYCN-amplified cells. Based on the siRNA 
knockdown studies, SKP2 is a potential therapeutic target in neuroblastoma with 
the response to SKP2 inhibition primarily involving the SKP2/p27 axis, 
independent of the p53 pathway. Although MYCN was found able to compensate 
for the loss of SKP2, Tet21N MYCN+ cells showed a greater sensitivity towards 
both direct and indirect inhibition of SKP2-mediated p27 degradation, suggesting 
that pharmacological inhibition of SKP2 may be beneficial in neuroblastoma; both 
p53 wt and mutant disease.  
 Further Directions  
Although SKP2 knockdown was consistent throughout the study and produces 
repeatable biological effects, it would be beneficial to confirm this data using a 
second method of protein inhibition such as a different siRNA olig sequence or 
shRNA constructs. This would highlight any off target effects and verify the 
observed phenotypes.    
The effects of SKP2 knockdown and of putative SKP2 inhibitors e.g. CI, in 
neuroblastoma cell lines confirm SKP2 as a potential therapeutic target in 
neuroblastoma, although further investigation of the effects of SKP2 siRNA 
knockdown and inhibition are warranted. Additionally, given the involvement of 
SKP2 in AKT activation and glycolysis, it would be of interest to determine 
whether SKP2 inhibition acts synergistically with AKT and glycolysis inhibitors.  
With regards to the novel inhibitors, additional systematic structure-activity 
analysis is required to identify drug candidates with mechanism of action studies 
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in both cell-free assays and a panel of neuroblastoma cell lines. Such studies 
would also benefit from structural biology insights.   
SKP2-mediated p27 degradation is dependent on phosphorylation and 
presentation of p27 by cyclin E-CDK2, in addition to the formation of the binding 
pocket between SKP2 and CKS1. Elevated CDK4 expression is a common 
characteristic of MYCN amplified disease and CDK4 inhibition has been shown 
to partly restore G1 arrest and reduce SKP2 activity (Muth et al., 2010; Gogolin et 
al., 2013). CDK4 inactivates p27 and p21 by sequestering the CDK inhibitors, 
lowering the inhibitory threshold and activating the cyclin E-CDK2 complexes, 
while CDK2 inhibition has been shown to be a potential MYCN disease-selective 
therapy in neuroblastoma (Molenaar et al., 2009). It would therefore be of interest 
to evaluate the effects of inhibiting both SKP2 and cyclin E-CDK2 in MYCN 
amplified neuroblastoma. Furthermore, CKS1 has been identified as a c-MYC 
transcriptional target (Keller et al., 2007), which has p27-independent oncogenic 
roles, and hence further investigations are warranted into the contribution of 
CKS1 to neuroblastoma malignancy.  
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Appendix I 
Western blotting buffers:  
10x Electrophoresis buffer 
30.3g Tris-Base (Sigma) 
144.1g Glycine (Sigma) 
10g SDS (Sigma) 
Transfer buffer 
3.03g Tris-Base 
14.14g Glycine 
200 ml Methanol 
Made up to 1 litre with ddH20 
10x TBS Tween 
90g NaCl (Sigma) 
60g Tris-Base 
1 litre ddH20 
pH 7.5 with HCl 
5ml Tween 20 (Sigma) 
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